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Falsified or substandard medicines can present a health hazard to us. We have been 
attempting to clarify how often we might encounter such medicines and also to identify 
the specific features of defects to find clues for improvement. Despite of our results, 
much remains to be studied. Therefore, we reviewed the quality of medicines for 
lifestyle diseases in Cambodia for three years, and the quality of antimicrobial 
medicines in Cambodia for four years. In addition, we surveyed counterfeit or 
substandard medicines in Yangon, Myanmar survey in 2014 for collecting more data. 
We conducted a four-year and three-year study to evaluate the quality of selected 
antimicrobials and lifesaving medicines and to examine the prevalence of falsified or 
substandard antimicrobial and lifesaving medicines in Cambodia, aiming to promote 
efforts to improve the quality of medicines. We collected samples of clarithromycin, 
sulfamethoxazole/trimethoprim, ceftriaxone, cefuroxime, levofloxacin, gentamicin, 
ciprofloxacin, fluconazole, nalidixic acid, ofloxacin, phenoxymethyl penicillin and 
roxithromycin medicines as well as cimetidine, amlodipine, esomeprazole, rabeprazole, 
glibenclamide and metformin from pharmacies, Depot-A, Depot-B, wholesalers and 
non-licenced drug outlets in five provinces (rural areas) and Phnom Penh (an urban 
area), during 2011 to 2014 (antimicrobial) and 2011 to 2013 (lifesaving). The 
authenticity of the collected medicines was investigated, and the medicines were 
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analyzed to determine whether they met the appropriate pharmacopoeial standards. We 
collected 647 samples, produced by 179 manufacturers, from 353 outlets. Only 51 
(15%) of the outlets were air-conditioned. We found different-coloured packaging of 
the same brand (different lots) of products from some manufacturers. The insert 
information of one sample was different from the package information. Twelve (1.9%) 
samples were not officially registered with DDF. In authenticity investigation, 43 of 
179 manufacturers replied and confirmed the authenticity of 154 samples (out of 647); 
also, 18 out of 54 MRAs replied to enquiries about whether products were licensed or 
not (one was not). Among the samples, 84 (16.5%), 58 (12.5%) and 47 (8.1%) failed in 
dissolution, content uniformity and quality tests, respectively. Samples of cefuroxime 
and roxithromycin that failed were significantly cheaper than those that passed. Poor-
quality antimicrobial medicines were found in Cambodian markets, though no falsified 
medicines were detected. Manufacturers should be encouraged to improve GMP 
implementation. Storage conditions in the distribution chain may also need to be 
improved. Continuous efforts by MRAs are needed to ensure that medicines are 
properly licensed. 
In the case of three-year survey, we found 342 samples (223 from Phnom Penh) 
were collected from 263 outlets; among them, 32 (9.4%) had no inserts, and 14 (4.1%) 
were not registered with DDF. 38 (11.1%) were domestically produced. The containers 
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of one amlodipine and three cimetidine samples were different from those of authentic 
samples. Nonstandard inserts were found in two samples (amlodipine and metformin). 
Only 21/81 manufacturers and 16/35 MRAs replied during authenticity investigation. 
In quality evaluation, 38 (11.1%), 52 (15.2%) and 48 (14%) samples failed dissolution, 
content uniformity and quantity tests, respectively. The failure rate in quality tests was 
significantly associated with the results of visual analysis of samples. Poor-quality 
medicines were prevalent in Cambodia in 2011-2013. Further surveys should be 
conducted to monitor the situation. Measures are desirable to improve the quality of 
domestically manufactured products.  
We also investigate the current situation of substandard or counterfeit medicines 
in Myanmar. Samples of oral medicines, cefuroxime axetil (CXM), donepezil 
hydrochloride (DN) and omeprazole (OM), and injections, ceftriaxone sodium (CTRX) 
and gentamicin sulfate (GM), were collected from pharmacies, hospitals and 
wholesalers in Yangon, Myanmar in 2014. Authenticity and registration were verified. 
Quality tests of samples were performed according to the pharmacopeia indicated on 
the label. There were 221 (94%) foreign medicines among 235 samples collected from 
75 locations. Five samples of GM and 1DN sample were not registered with Myanmar 
Food and Drug Administration (MFDA). In quality analysis, 36 samples out of 177 
(20.3%) did not pass quantity tests, 27 samples out of 176 (15.3%) did not pass content 
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uniformity tests, and 23 out of 128 samples (18.0%) did not pass dissolution tests. Three 
of the unregistered GM samples failed in both identification and microbial assay tests. 
Counterfeit GM is being sold in Yangon. Also, the quality of OM is a matter of concern, 
and requires follow-up. Poor-quality medicines were frequently found among the 
products of a few manufacturers. Regular surveys to monitor counterfeit and 
substandard medicines in Myanmar are recommended.  
We found that poor-quality medicines are the urgent problems in Cambodia and 
Myanmar, even though the medicines were not counterfeit. Serious dissolution failure 
is the dominant problem in these countries.  It is necessary to collect more information 
of such medicines, and to analyze the characteristics of the data for preventing health 
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Medicine is one of the most essential elements especially for human being to 
survive in the in the world. People used different types of plants for their treatments before 
5000 years [1] however, now in modern world patients are using biotech medicines like 
as insulin, interferon, interleukin and so on [2]. Sir Alexander Fleming discovered the 
benzylpenicillin (Penicillin G) from the mould Penicillium notatum in 1928 [3], since 
then patients in the world wants to use particular elements (active ingredient) for their 
treatments. From the historical reason and requirement in the world manufacturers are 
producing lot of medicines and supplying to the markets. Some manufacturers are taking 
a chance and preparing counterfeit or falsified or poor quality medicines and supply to 
the markets. These types of medicines are accessed in both developed and developing 
countries [4-6]. One investigation was occurred and found around 1% and 10% in 
developed and developing countries, respectively [7]. People are suffering and even died 
due to effect of counterfeit / falsified / substandard / poor quality medicines which 
evidences were already established in the world [8-10]. Perception from the above of 
story the governments of Myanmar and Cambodian were started more than one 
collaborative projects with Kanazawa University investigated to observe their own 
situations and evaluate the quality of selected medicines through different surveys.   
                                                                                                            Chapter One: 
An investigation into the quality of medicines in Yangon, 
Myanmar survey in 2014 
3 
 
1.1 Introduction  
Medicines are the most essential elements especially for human beings for 
surviving their lives in this world. It is almost impossible to imagine the remedy of human 
body from various diseases without taking good quality of medicines. Deliberately, many 
pharmaceuticals have been producing counterfeit medicines and supply to the patients as 
well as they are taking a chance to earn more money by producing such detrimental 
counterfeit medicines and even extending their imposture day by day. This is also 
happening in both developed and developing countries [4-6]. In this vast sector it is very 
difficult to optimize the counterfeit medicines. Depending on geographic region the range 
of counterfeit drugs supply to the developed countries as well as the rising countries are 
about 1% and 10%, respectively [7]. Another investigation from the World Health 
Organization (WHO) about 20%-90% falsified medicines were found in several Africa 
countries [11, 12]. The incidence due to counterfeit medicines were estimated in 
Cambodia with the range of 4%- 90% from 2001 to 2010 [13-16]. Furthermore, owing to 
fake medicines around 200 children were died in Bangladesh in 1990–1993 ingesting 
counterfeit paracetamol that contained diethylene glycol [17].   
In Myanmar, a massive investigation occurred by World Health Organization 
(WHO) in 1999 and caught counterfeit medicines [18]. It is very difficult to identify such 
4 
 
counterfeit medicines however it is also possible to buy good quality medicines. The 
problem is that the sellers demand extra money for good quality medicines which is illegal 
and unethical. For this reason, an emergency cases, people suffer or may die for the 
prevalence of counterfeit drugs [17, 19]. In most cases the patients from developing 
counties do not want or cannot fulfill antibiotic courses due to their economic crisis. Thus 
the misuses or inadequate doses of antibiotics may guide them to the advance of resistance 
[20] while support the extra food demands of the rising population of the world antibiotics 
are using in husbandry sectors specially in poultry industry as a growth promoter and 
transmitted to the human that is occurred resistance by several types of microorganisms 
particularly in bacteria [21, 22].  
Counterfeiting or poor quality antibiotic is Worldwide spreading that is one of the 
biggest and vital factors and is making sub-inhibitory concentrations naturally and 
enhance the selection of resistant strains from various types of microorganisms [23, 24].  
1.2 Aim of This Work 
People in low income countries are suffering in counterfeit or poor quality 
medicines in their daily life. People in this type of country are almost depending on 
foreign country medicines. In 1999, a massive investigation occurred by WHO to evaluate 
the quality of medicines and found counterfeit medicines in Myanmar. Since then there 
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were no systematic survey conducted on medicines in Myanmar. We want to investigate 
the quality of medicines which associate outlet condition, outlet types, price of medicine, 
type of medicines (domestically produced or not) and medicines entered in to Myanmar 
that is needed to fulfil Myanmar government policies. Finally, we suggested to the 
government of Myanmar how to remove counterfeit or poor quality medicines from 
Myanmar markets.   
1.3 Sample Collection 
 From the suggestions of Myanmar FDA (MFDA), we selected a populated region 
as well as from the MFDA essential drugs list, we selected five types of medicines.  
Samples of oral medicines, cefuroxime axetil (CXM) [25], donepezil hydrochloride (DN) 
and omeprazole (OM) [26] and injections, ceftriaxone sodium (CTRX) and gentamicin 
sulfate (GM) [27] were purchased during 27 September- 4 October 2014 by two teams 
from Yangon, Myanmar (Annex 1.1). Each team consisted of one supervisor from MFDA, 
one local assistant and one or two Japanese researcher (s). All team members received 
training before starting the sampling work. During the sampling period, we maintain a 
sampling form for each number of samples (Annex 1.2). We collected samples from the 
governmental hospital and private hospital as well as community pharmacies, clinical 
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pharmacies and wholesalers. Obtained samples were stored at 20-25ºC before analyzed 
in Kanazawa University, Japan. 
1.3.1 Observation Analysis  
 During the sampling we observed room conditions like as temperature, humidity 
and also observed in both internal and external environmental conditions around the 
surrounding of the retail shops. After sampling, the obtained samples were checked 
physical shape, size of sample volume or shape, uniform colour, insert, spelling, 
registration number from MFDA, manufacturing date, expire date, lot no., name of active 
ingredient, doses form etc. that were utilized in the form of the “Tool for Visual Inspection 
of Medicines” (Annex 1.3) [28]. For establishing the evidences, photographs were taken 
for each samples with scanned insert and the sample box.   
1.3.2 Sample Authenticity Investigation 
 The authenticity investigation and registration verification was performed 
according to the modification method of World Health Organization (WHO) [16].  We 
asked some questions to the responsible manufacturers by using a form (annex 1.4) with 
sent scan copy of the samples box, samples photographs and insert of the sample by E-
mail (annex 1.5). At the same time, we asked to the Medicine Regulatory Authority 
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(MRA) of each country regarding the medicines were registered or not (annex 1.6). While, 
we asked to the MFDA about obtaining medicines were registered or not.  
1.3.3 Samples for Chemical Analysis 
 Samples were evaluated according to the pharmacopeia that mentioned on the 
package of the samples. In the following method we used and evaluated our collected 
samples. Our collected cefuroxime samples 250 mg tablets were performed dissolution, 
content uniformity and quantity test. To determine the amount of cefuroxime 
(C16H16N4O8S) dissolved by employing UV absorption at the wavelength of maximum 
absorbance at 278 nm on filtered portions of the solution under test, suitably diluted with 
dissolution medium 0.07N Hydrochloric Acid; 900 ml, if necessary, in comparison with 
a standard solution having a known concentration of UPS cefuroxime axetil RS, 
equivalent to about 0.01 to 0.02 mg of cefuroxime (C16H16N4O8S) per ml, in the same 
medium. 55 rpm (for test 1) and 100 rpm (for test 2) were used during the dissolution test, 
while samples considered at 15 and 45 minutes not less than 60%, 75% for 1st stage and 
50% ,70% for 2nd stage gradually. 0.2 M monobasic ammonium phosphate (purchased 
from Nakalai Tesque Kyoto, Japan) dissolve 23.0 gm of monobasic ammonium 
phosphate in water to preparer 1000 ml of solution. 620 ml solution were taken from 1000 
ml and added 380 ml methanol (Wako, Japan) to make 1000 ml mobile phase. 5.4 mg 
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acetanilide dissolved in per ml methanol to preparer internal standard solution. For 
Resolution Solution, mix 10.0 ml of a solution of USP cefuroxime axetil RS in methanol 
containing 1.2 mg per ml then transfer in a 50 ml volumetric flask and including of 5.0 
ml of internal standard solution with 3.8 ml of a solution of cefuroxime axetil Delta-3 
Isomers RS in a methanol containing 0.16 mg per ml. Finally, to fill with dilute with 0.2M 
monobasic ammonium phosphate to make the target the volume, and well mix. For 
standard preparation, transfer 30 mg of USP cefuroxime axetil RS to a 25 ml volumetric 
flask dissolve dilute to make the volume. Promptly transferred 10.0 ml of this solution to 
another 50 ml volumetric flask then added 5.0 ml of internal standard solution and 3.8 ml 
of methanol, finally added dilute to make the volume. In assay preparation, fine powder 
not fewer than 10 tablets were accurately counted. Transfer the powder, with the aid of 
methanol, to a volumetric flask of such capacity that when filled to volume, the solution 
will contain the equivalent of about 2 mg of cefuroxime (C16H16N4O8S) per ml. Added 
methanol to fill the volumetric flask to about half of its capacity, and shake by mechanical 
means for about 10 min. Dilute with methanol to volume, and mix. Filter a portion of this 
stock mixture, and transfer 5.0 ml of the filtrate to a 50 ml volumetric flask. Add 5.0 ml 
of internal standard solution and 8.8 ml of methanol dilute with 0.2 M monobasic 
ammonium phosphate to the volume, and mix. The HPLC system from JASCO (Tokyo, 
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Japan) were maintained 278 nm UV detector, 4.6 mm x 25 cm; 5µm packing L13 column, 
400 C column oven temperature, flow rate 1.2 ml/min and injection volume 10 µl. In 
quantity analysis 90.0≦mean≦110.0 and content uniformity AV≦15.0 were followed 
[29], cefuroxime peak observed (Figure 1.1). The linearity of the standard cefuroxime/diluent 
solution was maintained and analyzed between 0.025 and 0.5 mg/ml and the 0.6 to 0.5 
(Figure 1.2). 
 
Figure 1.1 Chromatogram of cefuroxime (standard) 
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Figure 1.2 Linearity of cefuroxime solution, using acetanilide as an 
internal standard. 
For content uniformity test of ceftriaxone for injection (1 gm vial) at first we 
prepared PH 7.0 buffer, dissolve 17.415gm of dibasic potassium phosphate in 500 ml of 
water and dissolve 13.605 gm of monobasic potassium phosphate in 1000 ml of water. 
Control the pH of dibasic potassium phosphate solution to pH 7.0 by using monobasic 
potassium phosphate solution. pH 5.0 buffer, dissolved 12.9 gm of sodium citrate in 250 
ml of water and dissolved 9.6 gm of citric acid in 500 ml of water. Control the pH of 
sodium citrate solution to pH 5.0 by using citric acid solution. Dissolved 3.2 gm of 
tetraheptyl ammonium bromide were taken in 400 ml of acetonitrile, added 44 ml of pH 
7.0 buffer and 4 ml of pH 5.0 buffer, and added water to make 1000 ml to make the mobile 
phase. 0.5 µm membrane filter was used then allow to degas. 450 ml Acetonitrile were 
taken into the 1000 ml volumetric flask then added water up to the volume for diluents as 
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well as IS preparation 5 mg of diethyl terephthalate were taken to dissolve in diluents and 
make up to the volume 50 ml. Regarding the standard solution preparation, 5 mg of 
ceftriaxone sodium RS were transferred to 50 ml volumetric flask, and dilute with diluents 
to the volume (0.1 mg/ml) then 2 ml of these solutions were transferred into 10 ml 
volumetric flask (20µg/ml) to make 200%. Mixed 3 ml of 20µg/ml solution and 1ml of 
diluents (15 µg/ml) to make150%. Mixed 2 ml of 20µg/ml solution with solution 2 ml 
diluents (10 µg/ml) for 100%. Again mixed 2 ml of 10 µg/ml solution with 2 ml of 
diluents (5 µg/ml) to make 50% of the solution. While, mixed 2 ml of 5 µg/ml solution 
and 2 ml of diluents then prepared (2.5 µg/ml) 25% of the samples. Mixed 1 ml of each 
(200%, 150%, 100%, 50% & 25%) of this solution with 1 ml of IS solution for linier 
carve. During the assay preparation, 1 gm ceftriaxone sodium were transferred to a 100 
ml volumetric flask then added diluents to the volume. Transferred 1 ml of this solution 
to 50 ml volumetric flask and added with diluents to the volume. Mix 0.5 ml of this 
solution and 2.5 ml of diluents. Mix 1 ml of this solution and 1 ml of IS solution. In 
chromatographic system 270 nm detector, 4.0 x 10 cm column, 2.0 ml/min flow rate, 
injection volume and 400C oven temperature were maintained. In quantity analysis 
90.0≦mean≦115.0 and content uniformity AV≦15.0 were followed [30].   
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Donepezil samples were investigated according to the Japanese Pharmacopoeia 
16th edition (JP 16). 2.5 gm of sodium-1 decane sulfonate were dissolved in 650 ml of 
water, and added 350 ml of acetonitrile, 1 ml of per chloric acid to make mobile phase, 
then to prepare standard solution and weighed accurately about 50 mg of JP donepezil 
hydrochloride RS, and dissolved in diluent-1 (Methanol and 0.1 mol/L hydrochloride 3:1) 
to make exactly 25 ml. Transfer 5 ml of this solution to a suitable test tube, added diluent-
1 to make exactly 50 ml. For assay preparation, one tablet of donepezil hydrochloride 
with added diluent-1 so that it contained the concentration about 0.2 mg per ml then 
sonicate and properly mix until a tablet is disintegrated for 10 min. After sonicate then 
centrifuge for 4000 rpm for 15 min with continued 25℃ and supernatant solution were 
taken. For dissolution test was performed at 50 revolutions per minute according to the 
puddling method as directed under the dissolution test in JP16, using 900 ml of the 
dissolution medium. After the dissolution, performed the test with 50 µl each of the 
sample solution and standard solution as directed under Liquid Chromatography in JP16 
followed and calculate the ratios of AT and AS, of the peak area of donepezil 
hydrochloride. 3.4 gm Potassium dihydrogen phosphate and 3.55 gm of sodium 
dihydrogen phosphate were taken in 1000 ml water to make the phosphate buffer. 
Phosphate buffer (pH 6.8) and water (1:1) were used as a dissolution medium. Mightysil 
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RP 18GP 150×4.6 mm (5 µm) column, wavelength 271 nm, 35℃ in column temperature, 
1.0 ml/min flow rate, 50 µl injection volume, mobile phase: water, acetonitrile and per 
chloric acid (650:350:1) were used in this test. To make the standard solution we weighed 
accurately about 20 mg of JP donepezil hydrochloride RS with dissolve in diluent-1 to 
make exactly 20 ml. 1 ml of this solution were transferred to a suitable test tube then 
added with the dissolution medium to make exactly 100 ml. In addition, transferred 5 ml 
of this solution to a suitable test tube and added the dissolution medium to make exactly 
10 ml solution. The sample solution was withdrawal not less than 20 ml of the medium 
at 15 min, after starting the test and filtered with a membrane filter which contained the 
pore size of 0.45 µm. Discard the first 10 ml filtrate of the sample then transfer the 
subsequent filtrate to a suitable test tube. Not less than 80 % of the labeled amount of 
donepezil hydrochloride (C24H29NO3・HCl) is dissolved in 15 min were considered 
[31].  
Identification was performed on the gentamicin samples. 1gm of o-
phthalaldehyde in 5 ml of methanol and added 95ml of 0.4 M boric acid that previously 
adjusted with 8 N potassium hydroxide to a pH of 10.4 and 2 ml of thioglycolic acid. 
Adjust, obtained of the solution with 8 N potassium hydroxide to a pH of 10.4. To prepare 
the mobile phase and maintained the ratio of methanol, water and glacial acetic acid 
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(68:27:5) as well as 5gm of sodium 1-heptanesulfonate were added per liter to this 
solution. Then standard solution was prepared to use of USP gentamicin sulfate RS in 
water to make the concentration of 0.65mg per ml. 10 ml of this solution were transferred 
to a suitable test tube and added of 5ml of isopropyl alcohol with 4 ml of o-phthalaldehyde 
solution then properly mix and finally isopropyl alcohol were added to obtain 25 ml of 
solution. At 60°C tempereture were maintained in a water bath for 15 minutes then cool. 
In the case of sample solution preparation, 1ml of the sample were taken and mix with 
60.5 ml of water. Taken 10 ml from the mixture transfer to a suitable test tube with added 
5ml of isopropyl alcohol as well as 4 ml of o-phthalaldehyde solution then properly mix 
and finally added isopropyl alcohol to obtain 25 ml of solution. At 60°C tempereture were 
maintained in a water bath for 15 minutes then cool. Phenomenex Luna C18 L1 150×4.6 
(mm) column, 1.0 ml/min flow rate, 330 nm UV detector and 20 μl injection volume were 
used in the chromatographic system. In analysis part, we compared the peak of the sample 
with that of the RS to quantitate GM, and determine whether any impurity peaks appear 
in the chromatogram [32].  
Content uniformity test in omeprazole at first to make for the solution A (1L) 
10.454 gm tri-sodium phosphate 12-water and 15.616 gm disodium hydrogen phosphate 
were taken in a 1000 ml volumetric flask. Suitable amount of distill water were added 
15 
 
and sonicate to dissolve it. Adjust the volume with distill water then adjust the pH to 11.0 
± 0.05 with 10 M sodium hydroxide or orthophosphoric acid were used. For solution B 
(500 ml) 5 ml of 10 M NaOH were taken in 500 ml volumetric flask. To make the volume 
of 500 ml with 0.05 M phosphate buffer solution pH 4.5 and well mix. In 1 L phosphate 
6.8 gm potassium dihydrogen were taken in a 1000 ml volumetric flask and added suitable 
amount of distill water to dissolve and used a sonicate, adjust the volume and then filter 
by a vacuum filter and degas it. 210 ml of 0.05 M phosphate buffer solution (pH 4.5) with 
60 ml of solution B were mixed, from it 200 ml solution were taken in a 1000 ml 
volumetric flask and make volume with solution A. Finally, this solution used for diluent. 
Regarding the mobile phase, 1.17 gm of sodium dihydrogen phosphate dihydrate 
(NaH2PO4.2H2O) were taken in a 500 ml volumetric flask, allow to the sonicator for 
dissolved and added with dilute to the volume. In another 500 ml volumetric flask was 
taken and transferred 1.06 gm of disodium hydrogen phosphate (Na2HPO4) dissolve in 
diluent and make sure the volume. Transferred the NaH2PO4.2H2O solution to a 1000 ml 
beaker and adjust the pH to 7.6 ± 0.05 with Na2HPO4 solution in a p
H meter.  For 1 Liter 
of mobile phase 600 ml of this solution were taken in a 1000 ml volumetric flask and 
added 400 ml of acetonitrile (60:40 ratio). Filtered the solution in a suction filter and then 
degas the mixture in a sonicator for 30 minute. For standard solution preparation 10 mg 
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of omeprazole RS were weighted and dissolve to a 50 ml volumetric flask with medium 
in a sonicator than sure to make the final volume and properly mix which was 200% 
(solution concentration 0.2mg / ml). From this concentration of the solution with medium 
to make 150%, 100%, 50% and 25% of solution. while weighted accurately about 10 mg 
of lansoprazole were dissolved to a 100 ml volumetric flask with medium in a sonicator, 
make final volume and mix for IS preparation (0.1 mg/ml). Transferred 1 ml of 200% ~ 
25% to each test tube with 1 ml IS added to each mix then allow to filter and put it in 1 
ml vial. For assay preparation in content uniformity, 10 capsules granules were 
transferred in 50 ml volumetric flask. Dissolved the capsules with diluent in a sonicator 
and continue sonication until it dissolves. Transferred 1 ml from each to 10 test tube and 
added 3 ml of diluent and mix then filtered of the sample by 0.45 μm filter paper, 1 ml of 
this solution was taken and added 1 ml of IS solution with well mix and transferred to 1 
ml vial. 4.6 mm × 150 mm column (C18) column, 302 nm wavelength, 300 C column 
oven temperature, 0.5 ml/min flow rate and 10 μl injection volume were maintained in 
chromatographic system. In quantity analysis 95.0≦mean≦105.0 for BP as well as 
90.0≦mean≦110.0 for USP and content uniformity were followed in AV≦15.0 [33-35]. 
In dissolution test for omeprazole samples were performed according to BP and USP that 
were mentioned on the package label. Regarding the dissolution test in BP, solution A 
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and solution B were used as well as to prepare solution C with 1.170 gm Sodium 
dihydrogen phosphate dihydrate and 1.061 gm disodium hydrogen phosphate were taken 
in a separate 500 ml volumetric flask. Suitable amount of distil water were used then 
allow for sonicate to dissolve and then adjust volume. Added 400 ml of disodium 
hydrogen phosphate to 500 ml of sodium dihydrogen phosphate dihydrate and adjust pH 
to 7.6±0.05. We prepared the mobile phase and 400 ml acetonitrile with 600 ml of 
solution C were properly mixed (pH 7.6±0.05) then filter it in a vacuum filter and degas 
it for 30 minute in a sonicator. At that time, we prepared this solvent, 13.6 gm potassium 
dihydrogen phosphate were taken in a 2000 ml volumetric flask with added distil water 
to dissolve in a sonicator (about 10 min), adjust the volume and allow for filter by a 
vacuum filter then degas it. For the first stage, 0.05 M phosphate buffer solution pH 4.5 
and solution A (1:4, v/v) as well as in the final stage, 0.05 M phosphate buffer solution 
pH 7.6 and solution A (1:4, v/v) were mixed to make the diluent. In the dissolution tester 
water were transferred before test, to keep warmed to 37 ± 0.5 ℃. Measure the degassed 
solvent 700 ml in a graduated cylinder and put it in the vessel. Filled all the six vessels 
following the first one. Mount the paddle up, then lower it to the original position when 
temperature reaches to the desired level, set rotational speed to 100 rpm. Put the weighed 
samples, in each vessel in 1 min interval. In acid stage (pH 4.5), after 45-minute elution, 
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5ml medium were withdrawal and filter the aliquot of dilute to 25 ml with solution A in 
a 25 ml volumetric flask then transferred 1 ml of this test solution to a test tube with added 
1 ml IS solution to it and properly mixed. Proceed immediately to the final stage. 
Preparation of standard we used, 1) 40 ml of 0.05 M phosphate buffer solution (pH 4.5) 
were taken in a 200 ml volumetric flask and fill it up to the mark with solution A (Solution 
D). 2) Accurately weigh 5 mg of lansoprazole IS were put in 50 ml a volumetric flask, 
added a suitable amount of Solution D, sonicate for 10 minutes to dissolve and then make 
it up to 50 ml with solution D (0.1mg/ml). Taken 1 ml of this solution to place it in a 
volumetric flask of 10 ml and filled up with Solution D (IS solution with 10 μg / ml). 3) 
Accurately weigh 5 mg of Omeprazole RS and put in a volumetric flask of 50ml, add an 
appropriate amount of Solution D, sonicate for 10 minutes to dissolve, and make volume 
(0.1mg/ml). 2 ml of this solution were transferred to 10 ml volumetric flask and dilute it 
up to the mark with solution D 200% solution (concentration of 20 μg/ml). From this 
concentration of this solution with diluent to make 150%, 100%, 50% and 25% of the 
solution. Transferred 1 ml from solution 200% ~ 25% to each test tube and added 1 mL 
IS to each with mix then filter and put it in 1ml vial. For the buffer stage (pH 6.8), within 
5 minutes of the 200 ml of solution B at 37±0.50 C were added to each vessel. The rotation 
speed at 100 revolutions per minute was controlled and continue to operate the apparatus 
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for 45 minutes as well as again 5 ml of the dissolution medium were withdrawn 45 
minutes, after starting the test and transferred to a 25 ml volumetric flask, make sure to 
the volume with dilute then 1 ml of above test solution were transferred to a test tube and 
added 1 ml of IS solution with well mix. Regarding the buffer stage again we prepared 
for standard, 1) 21 ml of 0.05M phosphate buffer solution (pH 4.5) were mixed with 6 ml 
of Solution B, from this solution 20 ml were transferred in a 100 ml volumetric flask and 
make volume with solution A (Solution E). 2) 5 mg Lansoprazole were transferred in a 
50 ml volumetric flask with added the suitable amount of solution E and sonicate for 10 
minutes to dissolve then actual make the volume (0.1mg/ml). Taken 1 ml from it to a 10 
ml volumetric flask then make volume with solution E that was IS solution. 3) 5 mg 
omeprazole RS were put in a 50 ml volumetric flask, added a suitable amount of solution 
E and sonicate for 10 minutes to dissolve then make volume (0.1mg/ml). From this 
volume 2 ml were placed in a 10 ml volumetric flask and filled it up with Solution E 
(20μg / ml) and obtained 200% solution. From 200% solution with diluent used to make 
150%, 100%, 50% and 25% of the solution. Transferred 1 ml from solution 200% ~ 25% 
to each test tube and added 1 ml of IS to each with mix then allow to filter and put it in 
1ml vial. In chromatographic system 302 nm detector, Gemini-NX column, 0.5 ml/min 
flow rate, 30℃ temperature and 10μl injection were used. In acid stage, no individual 
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unit exceeds 10% dissolved and buffer stage no unit is less than Q+5% (Q= 65%) were 
considered. According to the USP dissolution method, for the mobile phase we used 340 
ml of Acetonitrile to a 1000 ml volumetric flask, dilute with pH 7.6 phosphate buffer to 
the volume then allow for filtration through membrane filter then degas for 30 minutes. 
1) For Acid Resistance Stage, 40 ml of 5N HCl were measured exactly and placed it in a 
2000 ml volumetric flask dilute were used to make the volume (0.1NHCl). 2) pH 10.4, 
0.235M disodium hydrogen phosphate (For 1L) 2.4 L for Buffer Stage 33.36 g of 
disodium hydrogen phosphate were dissolved in 1000 ml of water and adjust with 2N 
sodium hydroxide for pH of 10.4 ± 0.1. 3) pH 6.8 phosphate buffer (900mL), 500 ml of 
0.1N hydrochloric acid were added with 400 ml of disodium hydrogen phosphate pH 10.4. 
0.235 M dibasic sodium phosphate (Na2HPO4.7H2O) were used to adjust with 2N 
hydrochloric acid or 2N sodium hydroxide, if necessary to the contain of pH of 6.8 ± 0.05. 
4) pH 7.6 phosphate buffer (1L) for the mobile phase, 0.178 gm sodium dihydrogen 
phosphate and 1.12 gm disodium hydrogen phosphate were transferred in a 250 ml 
volumetric flask and dissolve it with distilled water. If necessary, adjust to pH 7.6 ± 0.1 
with utilized 2N sodium hydroxide or 2N hydrochloric acid. Total solution was 
transferred to 1000 ml volumetric flask and make the volume with dilute. 5) For 0.01M 
sodium borate solution (1L), 3.8137 gm of Sodium tetra-borate decahydrate (Borax) were 
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taken in a 1000 ml volumetric flask and make the volume with distilled water. Regarding 
the dissolution of the Sample, water was pre-fill to the dissolution tester and to keep warm 
to 37.0 ± 0.5 ℃. 500 ml of media (0.1 N HCl) were placed in each of the six dissolution 
vessels. The apparatus was assembled and warm the media to 37o ± 0.5oC. Weigh and 
place pellets equivalent to 20 mg omeprazole were maintaining one-minute interval in 
each vessel and immerse paddle in media to a distance of 2.5 ± 0.2 cm between the paddle 
and bottom of the vessel. Analyze the sample by the following HPLC method. For the 
acid resistance stage in standard solution, 40 ml methanol were transferred in 200 ml 
volumetric flask than added with 160 ml of 0.01 M sodium borate solution for diluent 
preparation. To prepare the IS solution, 5 mg Lansoprazole RS were used and put it in a 
50 ml volumetric flask as well as added a suitable amount of diluent allow to sonicate for 
10 minutes for dissolving and then make it up to 50 ml with diluent (0.1mg/ml). From 
this solution 1 ml were taken and placed in a10 ml volumetric flask with filled up with 
solution D. To make the WS solution, put 5 mg of accurately weighed omeprazole RS 
into 50 ml volumetric flask with added an appropriate amount of diluent to allow sonicate 
for 10 minutes then filled the volume with diluent. 4 ml solution were put in a10 ml 
volumetric flask of and make up to volume with diluent for 200%) Solution. From 200% 
solution with diluent to make 150%, 100%, 50% and 25% of the solution. Transferred 1 
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ml from solution 200% ~ 25% to each test tube and added 1 ml IS to each as well as mix 
to allow filter and put it in 1ml vial. In the case of test solution, after 2 hours filtered the 
dissolution medium which were containing the pellets through a sieve with an aperture 
not more than 0.2 mm. Collected the pellets on the sieve and rinse them with water and 
were using approximately 60 ml of 0.01M sodium borate solutions with carefully transfer 
the pellets quantitatively to a 100 ml volumetric flask then sonicate for about 20 minute 
until the pellets are broken up. Added 20 ml of methanol to the flask with dilute of 0.01M 
sodium borate solution to volume and properly mix. Dilute an appropriate amount of this 
solution with 0.01M sodium borate solutions were obtained a solution which having a 
concentration of about 0.02 mg per ml. Filter the solution through Whatman No. 42 or 
equivalent omeprazole filter paper were used. Then filter the filtrate again done through 
syringe filter of 0.20 micron. During the buffer stage, proceed as directed for Acid 
resistance stage with accurately weighed fresh pellets from the same batch. After 2 hours 
400 ml of 0.235M dibasic sodium phosphate were added to the 500 ml of 0.1N 
hydrochloric acid medium in the vessel as well as of adjust, if necessary, with 2N 
hydrochloric acid or 2N sodium hydroxide to a pH of 6.8 ± 0.05 were used. At the end of 
30 minutes, determine the amount of omeprazole dissolved in pH 6.8-phosphate buffer. 
Regarding the test solution (for 20 mg display of capsule), after dissolution for 30 
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minutes, immediately transferred 5 ml of the solution under test to a test tube which 
containing 1 ml of 0.25 M sodium hydroxide, well mix well and filter the solution through 
Whatman No. 42 or equivalent filter paper. Then filter the filtrate again through syringe 
filter of 0.20 micron. To prepare the standard solution, 200 ml pH 6.8 phosphate buffer 
with 40 ml 0.25 M sodium hydroxide were used for diluent as well as in the IS solution, 
accurately 5 mg Lansoprazole RS were weighed and put it in a volumetric flask of 50 ml 
with added a suitable amount of the diluent then sonicate for 10 minutes to dissolve with 
the making for 50 ml which containing of the diluent, from this solution taken for 1 ml 
and placed it in a volumetric flask of 10 ml fill up with solution D. Then we were making 
the WS solution and put 5 mg of accurately weighed omeprazole RS into 50 mL 
volumetric flask with added an appropriate amount of diluent then allow for sonicate for 
10 minutes finally to prepare the volume with diluent. Transferred 4 ml solution in a 
volumetric flask of 10ml and filled the volume with diluent which was 200% solution. 
From this solution (200%) with diluent to make 150%, 100%, 50% and 25% of the 
solution. Transferred 1 ml from the solution of 200%~ 25% to each test tube and were 
added 1 ml of the IS solution to each and well mix allow to filter and put it in 1ml vial. 
In chromatographic system 280 nm detector, 4.0 mm×12.5 cm including packing L7 of 
5μm of column, 1.0 ml/min flow rate and 10 μl injection volume were used. In acid 
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resistance stage tolerance, level L1 individual data will not exceed 15% of the omeprazole 
dissolved, for the level L2 of 12 average units within 20% dissolved omeprazole in 
individual data will not exceed 35% omeprazole dissolved. Regarding the level L3of 24 
within 20% of the average dissolution omeprazole units, greater than 35% of the 
maximum in also dissolved within 2 units is omeprazole, individual units is not greater 
than 45% of omeprazole dissolved. While in the case of buffer stage, level B1 Each unit 
is not less than Q+5% (Q=75%) and the level B2 average of 12 units was equal to or 
greater than Q and no individual unit were less than Q-15%, finally the level B3 average 
of 24 units is equal to or greater than Q and not more than 2 units were less than Q-15% 
and no unit was then Q-25%. 
In our investigation, we caught counterfeit gentamicin samples. For this reason, 
we further investigation in this way to use fluorescence spectrophotometer and observed 
and compare in pass and counterfeit samples. In fluorescence spectrometry both an 
excitation spectrum (the light that is absorbed by the sample) and/or an emission spectrum 
(the light emitted by the sample) can be measured.  The concentration of the analyte is 




1.3.4 Samples for Biological Analysis 
 Our collected gentamicin samples (injection) which were performed in microbial 
assay according to the analysis of USP. Regarding this test, Staphylococcus epidermidis 
ATCC 12228 strain were performed during this test. We used Base layer media which 
consists of peptone, pancreatic digest of casein, yeast extract, beef extract, dextrose, agar 
and water (12:8:6:3:2:32:2000) and controlled the pH 6.6±0.1. culture organisms were 
transferred in this media. 16.73 gm/l of diabasic potassium phosphate and 0.523g/L of 
monobasic potassium phosphate were mixed to make 0.1 M buffer with adjust the pH to 
8.0±0.1 with 18 N phosphoric acid or 10 N potassium hydroxide. Microorganisms were 
suspend in 10 ml saline and adjust the solution to give a transmittance of around 1.0% at 
580 nm as a solution. For the standard solution, we weighted 10 mg of gentamicin RS 
and dissolve in 10 ml of the buffer solution. From the serial dilution we prepared the 
standard solution 5 (4.0 gm/ml), solution 4 (3.0 gm/ml), solution 3 (2.286 gm/ml), 
solution 2 (1.0 gm/ml) and solution 1 (0.5 gm/ml). Also, prepared a control solution which 
were containing 2.0 gm/ml (＝590 ug/mg as potency) of gentamicin RS. To make the 
sample solution,1ml of the solution from the ampoule (sample) were taken and added to 
a flask with  adjust to 17576 fold dilution of buffer (= 2.2758 gm/ml) then transferred the 
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solution to a clean bench, allow for filter and place it a  2 ml tube. In this method we 
maintain the following procedure, at first we injected 100 ml of microrganism solution 
on the base layer, and spread with a turn table and spreader. At least five test plates are 
needed to make the standard curve. Second, place  four cylinder-cups on each plate. Third, 
injected 250 ml of one of the standard solutions 1 to 5 and control solution on each plate. 
Put control solution in one cylinder on each plate and fill the remaining cylinders as 
follows. 1) Plate 1 has one control and three cylinders of solution1. 2) Plate 2 has one 
control and three cylinders of solution 2. 3) Plate 3 has one control and three cylinders of 
solution 3. 4) Plate4 has one control and three cylinders of solution 4. 5) Plate 5 has one 
control and three cylinders of solution 5. 6) Plate 6 has one control and three cylinders of 
sample (1). 7) Plate 7 has one control and three cylinders of sample (2). Fourth, place all 
the test plates were in an incubator at 35°C and cultivate for twenty hours [36]. 
 According to the USP (our collected samples) the endotoxin and sterility tests 
were applicable in both cefteriaxone (for injection) and gentamicin (injection) samples. 
For endotoxin test were performed in two ways one for gel-clot thecnique and another 
was  chromogenic technique. In gel-clot technique, at first 5 ml pure water were injected 
into the Limulus Ambocyte Lysate (LAL) vial. For another 10 ml pure water were 
injected into the standard endotoxin which concentration 1000 EU/ml and then vortex. 
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From this concentration to prepare 100, 10, 1, 0.1, 0.6 (2λ), 0.03 (λ), 0.015 (0.5λ) and 
0.0075 (0.25λ) (Table 1.1). Each step was done for vortex in one minute and solutions 
were keep into an ice box. 10 ml pure water were used with sample and vortex for 1 
minute, to make the sample solution. 0.6 ml were taken from the stoke solution with 5.4 
ml pure water then vortex for 1 minute to make for dilute stoke solution. For the positive 
control, 1 ml from stoke solution with 1 ml from 100 EU/ml solution and then added 8 
ml pure water to allow for vortex to make 10 EU/ml solution 1. 1 ml from the solution 1 
with 9 ml pure water were used for 1 EU/ml solution 2. 0.3 ml solution 2 were taken and 
added 4.7 ml pure water for 2 λ solution 3. 1 ml from solution 3 with 7 ml of pure water 
were used to make 0.25 λ solution 4. A total 44 bottles were taken and transferred 0.1 ml 
of LAL reagent. Three bottles were used in each of the sample solution, positive control 
10 EU/ml, standard endotoxin concentration 10 EU/ml and pure water as well as 1 battle 
was used for normal water. For an another case four bottle were used in each of the sample 
solution, positive control 10 EU/ml, 1 EU/ml, 2 λ and 0.25 λ. While two battles were used 
in each of the standard concentration 10 EU/ml, 1 EU/ml, 2 λ, 0.25 λ and pure water. 
After one an hour incubation and we observed about the positive control of 10 EU/ml and 
1 EU/ ml, standard concentration 10 EU/ml and 1 EU/ml solution with normal water 
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containing were solid in the bottles and rest of the bottles were liquid (Fig 1.3a & 1.3b) 
[37]. 










Concentration taken from the amount Pure water Concentration 
From 1000 to 2 ml 18 ml 100 
From 100 to 1 ml 9 ml 10 
From 10 to 1 ml 9 ml 1 
From 1 to 1 ml 9 ml 0.1 
From 0.1 to 9 ml 6 ml 0.06 (2λ) 
From 2 λ to 4 ml 4 ml 0.03 (λ) 
From λ to 4 ml 4 ml 0.015 (0.5λ) 
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Figure 1.3 Outline of endotoxin gel test 
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1 ml DS + 1 ml 100 
EU/ml 1 ml (1) 
8 ml PW 9 ml PW 
Dilute Sample 10 EU/ml (1) 1 EU/ml (2)  
1 ml from (3)    
4.7 ml PW 0.3 ml from (2)  
7 ml PW 
Vortex were done 
each step for 1 min. 
0.25 λ EU/ ml 2 λ EU/ml (3) 
0.1 ml of LAL Transfer 
A total 44 bottles were taken. Three bottles were 
used in each of the sample solution, positive 
control 10 EU/ml, standard endotoxin 
concentration 10 EU/ml and pure water as well 
as 1 battle was used for normal water. For an 
another case four bottle were used in each of the 
sample solution, positive control 10 EU/ml, 1 
EU/ml, 2 λ and 0.25 λ. While two battles were 
used in each of the standard concentration 10 
EU/ml, 1 EU/ml, 2 λ, 0.25 λ and pure water. 
PW= Pure Water, DS= Dilute Sample   





In colorimetric methods, 5 ml were taken from 1000 EU/ml and 5 ml PW were 
added to make the concentration 500 EU/ml then to prepare 100 EU/ml, 50 EU/ml, 10 
EU/ml, 5 EU/ml, 1 EU/ml, 0.5 EU/ml, 0.1 EU/ml, 0.05 EU/ml, 0.025 EU/ml and 0.00625 
EU/ml of the solution for calibration curve. 10 ml PW were injected into the sample for 
the sample stock solution (SS). For the making of sample solution, 0.1 ml were taken 
from the sample stock solution and added 9.9 ml PW were added as well as for the positive 
control of the solution, 0.1 ml taken from the stock solution and 0.5 ml were from standard 
concentration 0.1 EU/ml solution then 9.4 ml PW were added in a test tube. While PW 
were used as a negative control. 7 LAL bottles were taken and keep into the ice box with 
aluminum cap then marking for sample, positive control, negative control, standard 
concentration 0.1 EU/ml, 0.05 EU/ml, 0.025 EU/ml and 0.0065 EU/ml. 0.2 ml of buffer 
solution were added into each LAL battle (pipetting with no bubble). Each of 0.2 ml of 
the solutions sample, positive control, negative control, standard concentration 0.1 EU/ml, 
0.05 EU/ml, 0.025 EU/ml and 0.0065 EU/ml were transferred into the representative LAL 
bottles and keep into the water bath for 30 minutes. During the bath preparation we were 
taken Pyrocolour MP which were containing 1, 1A, 2, 3, 3A kits. Just, solutions of the kit 
1A were transferred into the kit 1 (sodium nitrite) as well as solutions of the kit 3A (N-
Methyl- 2- pyrrolidone) were transferred into the kit 3 (N- (1-Napthyl) ethylenediamine 
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dihydrochloride). 4 ml Water were added into the kit 2 which containing Ammonium 
sulfamate. 7 LAL bottle were picked up from the water bath and put into the ice box. 
Each 0.5 ml solutions were taken from the prepared solutions 1, 2 and 3 and added of the 
seven bottles then allow for measuring spectrophotometer with 545 nm wavelength. After 
the measurement calculates the average concentration of endotoxin based on the 
calibration curve. Expected the absolute value of the correlation coefficient of the 
calibration curve is 0.98 or more (Figure 1.4a & 1.4b). Whether the measurement results 
of the water for injection (negative control) does not exceed the limit of the blank test, 
which is set in the lysate reagent, bellow the detection limit of endotoxin. For positive 
control and is based on the difference between the endotoxin concentration of the sample 
solution that, the recovery rate is calculated and it is in the range of 50% to 200% (Figure 
1.4b). Based on the average endotoxin concentration of the sample solution to determine 
the endotoxin concentration of the sample, when meeting the endotoxin standards that 






Figure 1.4 Outline of endotoxin test in colorimetric method 
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Regarding the sterility test were performed in both ceftriaxone and gentamicin 
samples. In this types of samples (injectable) must be contained in sterile condition. 
According to the pharmacopeia we were investigated on these types of samples. At first 
10 ml pure water were injected into the samples. Steritest EZ Devices were clamped on 
the stand and tubes were properly griped in the Fluid Transfer Pump (FTP). Dehydration 
tubes were attached with the bottom side of the both kits. Fluid A were transferred into 
the both kits. Red caps were attached at the top side of the kites then the fluids were 
dehydrated by the using of dehydration tubes then red caps were leaved from the kites. 
Prepared samples were transferred in both kits and dehydration with red caps. Again fluid 
A were transferred into the both kits for washing and dehydration with red caps. The 
dehydration tubes and red caps were removed and yellow caps were attached with the 
bottom side of the kits. The tubes of the kits which were griped in the FTP, among one 
tube was blocked by the clip and other was open and tryptic soy broth medium transferred 
into the one kit. Similarly, other tube which was used to blocked and one tube opened, 
then fluid Thioglycollate medium were transferred to the kit. Both kits were picked from 
the stand. Tryptic soy broth medium containing kit was transferred an incubator which 
maintained at 21-250C as well as fluid Thioglycollate medium containing kit was 
transferred another incubator which was maintaining at 370C (Figure 1.5). Finally, we 
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observed both kits under 14 days for visible any particles, if the samples were 
contaminated by microorganisms [39].     















Dehydration tubes were attached bottom side of the kits and 
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 Steritest EZ Devices were clamped on the stand and the tubes 
of Steritest EZ Devices were properly griped by the FTP 
Dehydration with red caps 
Again at a time fluid- A were transferred  into the both kits for 
washing and dehydration with red caps  
Dehydration tubes were rem-oved and attached yellow caps 
One by one medium was transferred by one jar and another kit 




1.4.1 Sample collection:  
Outline of the samples collected in this study was summarized in Table 1.2. In our 
survey we collected 235 samples from 63 manufacturers with 71 different brand products. 
14 (6%) samples were produced domestically. 49 (20.9%) Samples were ceftriaxone (1 
gm/vial), 60 (25.5%) samples were cefuroxime (250 mg) [25], 58 (42.7%) samples were 
gentamicin (80 mg/ml) [27], 65 (27.7%) samples were omeprazole (20 mg) [26] and 3 
(1.3%) samples were donepezil hydrochloride (5 mg) collected from Yangon, Myanmar. 
1.4.2 Drug outlets and registration status in Myanmar FDA  
   We sampled 103 samples from community Pharmacy, 47 samples were 
governmental hospital, 42 samples were private hospital, 28 samples were clinic and 15 
samples obtained from five different wholesalers as well as 6 (2.6%) samples were not 






















No. of samples 
registered in 
Myanmar FDA 
No. of samples 
unregistered in 
Myanmar FDA 
Ceftriaxone(49) 9 11 18 7 4 49 0 
Cefuroxime(60) 14 12 22 9 3 60 0 
Donepezil 
Hydrochloride(3) 
- - 2 - 1 2 1 
Gentamicin(58) 11 7 31 6 3 53 5 
Omeprazole(65) 13 12 30 6 4 65 0 
Total  (235) 47 (20%) 42 (17.9%) 103 (43.8%) 28 (11.9%) 15 (6.4%) 229 (97.4%) 6 (2.6%) 




In our observation 71 manufacturers were participated in this survey. While 8 
manufacturers were repeated in more than one item of the medicines. We observed 41 
manufacturers which were Indian originated (Figure 1.6). A total 235 samples were 
collected from Myanmar. Among of 149 samples out of 235 were found from Indian 
manufacturers (Figure 1.7). Mentioned on the label of each sample should be stored at ≤ 
25-30°C with dry place. Only twenty-nine out of 74 retail shops (39.2%) are air-
conditioning. 36 (15.5%) Out of 235 samples did not contain package inserts. We had 
collected two samples which did not found box (loos samples). While one sample of 
address was showing different in the label and insert. One cefuroxime sample of blister 
was torn in a hole and another manufacturer from Indian origin and their one sample was 
existed two different types of colour of the tablet in a strip. All ceftriaxone, cefuroxime 
and omeprazole samples were registered but one donepezil hydrochloride sample out of 
3 (33 %) which was Indian origin and 5 gentamicin samples out of 58 (8.6 %) from two 
Chinese companies were not registered in Myanmar FDA (Table 1.3). 11 CXM and 2 
GM samples were found which showing error spelling (Figure 1.8a & 1.8b). One GM 










Figure 1.6 Number of Manufacturers found in the program  
 
            









Authenticity investigation with the response from the manufacturers side were 
quite low. We received, 6 Manufacturers replied out of 19 that were represented of 8 
samples out of 235 with agree as a genuine product (Table 1.3a & 1.3b), while 3 MRAs 
out of 12 MRAs in manufacturing countries informed about manufacturers licenses 
(Table 1.4). We obtained information from Myanmar, Switzerland and Bangladesh 




Figure 1.8a Spelling error in CXM samples A-030, 057, 068, 079, 085, 099, B-023, 
047, 067, 093, 111 
 
Figure 1.9 Low volume with 
different  colour (yellow)    
 
































Aristo Pharma Ltd.  ✓ 2 1 0 0   
Jayson Pharmaceutical Ltd.  1 1 0 0   
Renata Limited  1 1 0 0   
Square Pharmaceutical Ltd.  6 3 0 0   









Shenzhen Zhijun Pharmaceutical Co. Ltd  1 1 0 0   
Beverly Henan Pharmaceutical Co. Ltd  1 1 0 0   
Henan Dekang Pharma Actual Co; Ltd   2 1 0 0   
Kunming Pharmaceutical Corp  2 1 0 0   
Shanghai Modern Hasan   Pharmaceutical Co. 
Ltd 
 2 1 0 0   
Tianjin Pharmaceutical Group Xinzheng Co. 
Ltd  
 4 1 0 0   
Zhanfeng Pharma. Factory, Long Chuan, 
Yunnan 
 4 1 0 0   
河南龙源药业股份有限公司   1 1 0 0   
Subtotal  17 8 0 0   
 
Japan 
Eisai Co. Ltd ✓ 2 1 0 0   
Subtotal  2 1 0 0   
 
Korea 
Korea Pharma Co. Ltd  2 1 0 0   
Shin Poong Pharm. Co. Ltd  4 1 0 0   




Myanmar Pharmaceutical Factory  6 2 0 0   
No.(1)Pharmaceutical Factory  2 1 0 0   
No.(2) Pharmaceutical Factory  6 1 0 0   
Subtotal  14 4 0 0   
 
Pakistan 
CCL Pharmaceuticals(Pvt) Ltd.  2 2 0 0   
Subtotal  2 2 0 0   
 
Singapore Golden Kabaw Pte. Ltd  1 1 0 0   
Subtotal  1 1 0 0   
 
Switzerland F.Hoffmann-LaRoche Ltd.  1 1 0 0   
Subtotal  1 1 0 0   
 
Taiwan Siu Guan Chem, Ind. Co. Ltd  14 1 0 0   
Subtotal  14 1 0 0   
 
Thailand The United Drug Co., Ltd.  3 1 0 0   
Subtotal  3 1 0 0   
 
UK 
Glaxo Smith Kline  11 1 0 0   




Domesco Medical Import Export Joint Stock 
Corp 
 1 1 0 0   
Fresenlus Kabi Bidiphar Jolnt - Stock 
Company 
✓ 3 1 3 0 3  
Pharbaco Central Pharmaceuticals J.S.C No1  1 1 0 0   








































































Alkem Laboratories Ltd  20 1 0 0   
AMN Life Science Pvt. Ltd  2 1 0 0   
Asmoh Laboratories Ltd.   1 1 0 0   
Belco Pharma  1 1 0 0   
Blue Cross Laboratories Ltd  2 1 0 0   
Brawn Laboratories Ltd  2 1 0 0   
Cadila Health Limited  12 2 0 0   
Cipla Ltd.  4 1 0 0   
Dr. Reddy`s Laboratories Ltd  18 1 0 0   
Eisai Pharmatechnology and Manufacturing Pvt  ✓ 1 1 1 0 1  
Emcure Pharmaceuticals   4 2 0 0   
Fourrts Laboratories Pvt. Ltd  2 1 0 0   
Galpha Laboratories Ltd  2 1 0 0   
Global Pharma Healthcare Pvt. Ltd  13 2 0 0   
Great Himalayan Pte. Ltd  1 1 0 0   
Intas Pharmaceuticals Ltd ✓ 2 1 2 0 2  
Lupin Ltd   5 2 0 0   
Lyka Labs Limited  5 1 0 0   
MDC Pharmaceuticals (P) Ltd  6 1 0 0   
Mercury Laboratories Ltd  3 1 0 0   
M. J. Biopharm Private Limited    2 1 0 0   
Nectar Lifescience Ltd   8 1 0 0   
Orchid Healthcare  4 1 0 0   
Rainbow Life Sciences Pvt. Ltd  1 1 0 0   
Ranbaxy Laboratories Limited  11 1 0 0   
Regain Laboratories ✓ 2 1 0 0   
Rhydburg Pharmaceuticals Ltd  1 1 0 0   
Saviour Pharmaceuticals  2 1 0 0   
Stallina Laboratories Pvt. Ltd  1 1 0 0   
SRS Pharmaceutical Pvt. Ltd  1 1 0 0   
Toqure Pharmaceutical  1 1 0 0   
Umedica Laboratories Ltd  3 1 0 0   
Universal Pharmaceuticals  Limited  1 1 0 0   
Virchow Healthcare Private Limited  1 1 0 0   
Wockhard Limited  2 1 0 0   
XL Laboratories Pvt. Ltd.  2 1 0 0   




















Bangladesh (n=4,  
10 samples) 
The Directorate General of Drug Administration 
Ministry of Health & Family Welfare 
 
YES uk uk uk uk 
China (n=8, 17 
sample) 
Department of Drug Registration State Food and Drug 












India (n=36, 149 
sample) 
Drugs Controller General of India  Central Drugs 
Standard Control  Organization,  Directorate 
General of Health Services,  Ministry of Health and 








































Pakistan (n=1,  
2 samples) 
Director General Health| Drug Control Organization| 











Singapore (n=1,  
1 samples) 
 











Switzerland (n=1,  
1 samples) 
 











Taiwan (n=1,  
13 sample) 
 











Thailand (n=1,  
3 sample) 
 









































*We found two samples from a Japanese manufacturer. We confirmed about the license 
of the Japanese manufacture’s   from online.        
1.4.5 Quality evaluate of samples 
  The results of the samples are showing in Annex 1.7 and Annex 1.8 as well as the 
summary of the results of quantity test is shown in Table 1.5. In the quality test 36 samples 
were unacceptable out of 177 samples. Among 176 samples were analyzed that finally 
confirmed, 27 samples were unacceptable in content uniformity tests as well as in the case 
for dissolution tests 23 samples were unacceptable out of 128 samples. In the case of 
omeprazole 23 (35.4%), 9 (13.8%) and 17 (26.2%) samples were unacceptable in 
quantity, content uniformity and dissolution test respectively [26]. In our investigation, 
we found 149 samples out of 235 from Indian origin. Among of the Indian 49 samples 
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were failed in any test out of 149 samples (Figure 1.10). Particularly, any fail of the all 
cefuroxime and omeprazole (except one from Bangladesh) samples came from India [25-
26], while three counterfeit gentamicin samples were found from China (Figure 1.11, 
1.12, 1.13, 1.14 & 1.15). We had collected 12 cefuroxime samples which manufacturer 
was Global Pharma Healthcare Pvt. Ltd, India. Among of them 10 samples were failed 
out of 12 [25]. Both endotoxin and sterility tests in ceftriaxone and gentamicin were 
satisfactory but in this case of unregistered three gentamicin samples out of 58 were failed 
in identification and during the analysis there were no peak appeared against standard 
solution at that moment (Fig. 1.16 & 1.17). While in the case of microbial assay test these 
three counterfeit gentamicin samples were not showing the zone of inhibition (Fig. 1.18). 
Myanmar Government announced three gentamicin samples from two Chinese 










Table 1.5 Summary of quality test of samples 
 
*Result  pending due to insufficient of samples






Sterility test Identification Microbial 
Assay 
 Pass Fail Pass Fail Pass Fail Pass Fail Pass Fail Pass Fail Pass Fail 
Ceftriaxone (49) 47 2 46 3 - - 49 0 49 0 49 0 - - 
Cefuroxime (60*) 49 11 44 15 54 6 - - - - 60 0 - - 
Donepezil 
Hydrochloride (3) 
3 0 3 0 3 0 - - - - 3 0 - - 
Gentamicin (58) - - - - - - 58 0 58 0 55 3 55 3 
Omeprazole (65) 42 23 56 9 48 17 - - - - 65 0 - - 




Figure 1.10 Comparison between pass and fail samples of origin 
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A-020 & A-077                                         A-069 
 
 
Figure 1.19 Zone of inhibition (microbial assay) are showing between standard 
concentration and counterfeit GM samples 
  
Control:590㎍/mg 
10 fold of A-069: 
1277㎍/mg 
Counterfeit GM 





1.4.6 Factors influencing the outcome of the price 
There was significant difference in the average price of passed and failed samples 
of cefuroxime (Student’s t-test, p<0.05). In the samples of gentamicin, failed sample 
(identification, microbial assay) were significantly cheaper than passed samples 
(Student’s t-test, p<0.05) and falsified ones were cheaper than other samples (Table 1.6).  
1.4.7 Effect of air-conditioning  
In the table 1.7, we also observed in significance that associated between air 
conditioning and temperature (t-test, p<0.01).  
Table 1.6 Association between price and medical quality (CXM, GM, OM and CTRX)  
*Fail includes first, second and permanent fails. 
** Counterfeit 
**Excluded B-008 (free gift) 
*** 1 Kyat ⇔0.00076$ 
 
Table 1.7 Association between air conditioning and temperature /humidity 
  
Air-conditioning n Average temperature (℃) ±SD. p (t-test) 
yes 29 28.6±2.6 
 
P＜0.01 
no 44 30.8 ± 2.2 
 Average Humidity(％) ±SD.  
yes 29 67.9 ± 12.4 n.s. 
no 44 69.3 ± 8.7 
 n Mean(Kyat****) ±SD. p (t-test) 
CXM 













38.3± 10.4 P＜0.05 
OM 






      













1.4.8 To observe again of the unacceptable samples by using new judge which is 
wider than original (pharmacopeial criteria)   
In Myanmar some samples were unacceptable, according to pharmacopeial test. 
We want to see, if the restricted value considers than original value how many samples 
are pass or fail. In dissolution test, we considered and calculated 80% of Q value of 
cefuroxime 75%, donepezil hydrochloride 80%, omeprazole 10% acid stage and 65% for 
buffer stage. For example, if Q value 75% so that, consider new value is 75*0.8= 60. In 
this case, the samples are containing ≤ 60 consider as a pass samples. In the case of content 
uniformity test the acceptance value (AV) is 15. In this case we consider 120%. Our new 
value is 15*1.2= 18. The samples which are containing AV bellow 18 consider as a pass 
samples in regarding this test. While quantity tests we multiply 0.8 with lower limit and 
upper value with 1.2 (80%-120%). The following tables 1.6 and 1.7 are showing the 
summary of comparisons between original and new value on pass and fail samples. While 
annex 1.8 are showing broadly of the results.    
Table 1.8 Showing the comparisons of the pharmacopeial quality test between original 
and newly considered value.    












Pass Fail Pass Fail Pass Fail Pass Fail Pass Fail Pass Fail 
Cefuroxime(60*) 54 6 60 0 49 11 51 9 44 15 48 11 
Omeprazole(65) 48 17 51 14 42 23 64 1 56 9 59 6 
Ceftriaxone(49) - - - - 47 2 49 0 46 3 46 3 
 
Table 1.9 are showing the comparisons between original all and new all tests.  
 
 
Name of sample Original all New all 
Pass Fail Pass Fail 
Cefuroxime(60) 44 16 49 11 
Omeprazole(65) 33 32 45 20 
Ceftriaxone(49) 46 3 46 3 
54 
 
Cefuroxime samples were analyzed in dissolution and 4 samples were finally 
failed. But when it was done 1st stage 12 sample were fail. To consider and apply new 
judge in cefuroxime samples (75*0.8= 60%) all sample pass in this test in first stage and 
need not to go for 2nd stage. Insert new judge for quantity test 80%-132% were considered. 
To apply new judge on 11 fail samples which were in 1st stage and all samples are pass 
in this stage and need not to go for 2nd stage in quantity test. In content uniformity to use 
new AV =18, 4 samples pass in this stage and need not to go for 2nd stage. Though all 
cefuroxime samples are not pass in content uniformity but we can say the results of 
dissolution and quantity test are satisfactory by using new judge.    
In omeprazole samples in dissolution acid first stage to use new judge (12%) 2 
fail samples and buffer stage (Q=57%) 18 samples pass in this stage and need not to go 
for 2nd stage. In the case of USP consider Q=65% pass 2 sample. In the same way when 
we judge in 2nd stage finally 14 samples are fail which were smaller than the original 
number. In quantity test all sample is pass except one when we use the new judge in 1st 
stage. In content uniformity 7 samples are fail when we use new judge that is lower than 
the actual number.  In this case we can say quantity test of this samples are all most 
satisfactory but not in dissolution and content uniformity.  
In ceftriaxone injection samples all samples are pass in quantity in 1st stage when 
use wider interval 72-138 and need not to go for 2nd stage. But in content uniformity test 
3 fail samples are not changed if we apply new judge AV=18. Though all samples are not 
pass in CU but the result of quantity test are satisfactory. Summary of the results are 





Table 1.10 Compare the results between pharmacopeial guideline and considered new 
judge   
 
 
* Gentamicin three samples were failed in both identification and microbial assay which 
were not applicable for considered new judge, while all of Donepezil Hydrochloride were 
pass and need not to new judge.  
 
1.4.9 Results of fluorescence spectrophotometer 
  We analyzed the excipient of gentamicin samples. We did not get any peak for 
samples of gentamicin and low peak observed of the samples which were showing in 
yellow colour of the samples as well as the samples which were pass found peak in the 
following figures.  
Figure 1.20 counterfeit samples A-020 (China) 
 
 
Name of sample Original all New all 
Pass Fail Pass Fail 
Cefuroxime (60) 44 16 49 11 
Omeprazole (65) 33 32 45 20 
Ceftriaxone (49) 46 3 46 3 

































Figure 1.25 pass sample A-024 (Myanmar) 
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1.5 Discussion  
We selected Yangon the commercial city of Myanmar, considered of population 
density and number of drug outlets. In this city, our survey and 235 samples were 
collected from pharmacy, governmental hospital, private hospital, clinic and also 15 
(6.4%) samples were taken from wholesalers. Medicines must be stored at optimum 
temperature that mentioned on the label. Temperature is the most critical factors for 
degrading medicines not only in shop but also it can affect medicines during the 
distribution time [40-42]. Our all sampled medicines that mentioned on the label and 
should be keeping in ≤ 25-30°C with dry place, but air conditioner was set in fewer than 
half the number of retail shops visited. Under such situation in Myanmar good pharmacy 
practice, distribution practice and storage practice are not having satisfactory. 
Temperature and humidity parameters can be affected and decline the quality of product 
during the storage or distribution time. To obtain the better quality medicines it will be 
needed to develop the storage condition at the drug outlets. Most of the omeprazole 
samples were failed in quantity test as well as dissolution test. These products might be 
quality and eventually lead to adverse effect of health. This is similar to the high 
unacceptable ratio in dissolution of omeprazole samples collected in the Cambodian 
pharmaceutical markets [43]. 
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Antibiotics have been prescribing against infectious diseases that are occurring by 
microorganisms. The roles of antibiotics in the world are able to kill or inhibit the growth 
of different types of infectious microorganisms and finally overcome from diseases by its 
proper uses. Unfortunately, misusing of antibiotic or counterfeiting from manufacturers 
end side that are increasing to resistance by microorganisms. Resistance to third 
generation cephalosporin series and aminoglycoside series have been established 
worldwide. Especially, resistance to third generation cephalosporin by Klebsiella 
pneumoniae and Neisseria gonorrhoeae were documented at 60% and 18% respectively 
in Myanmar [44, 45]. Sixty percent of Acinetobacter species, 60% of E. coli, 55% of 
Klebsiella species, 60% of Pseudomonas and 36 % of Staphlococcal species were 
resistance to gentamicin at North Okkalapa General Hospital in Myanmar [46]. Better 
qualities of antimicrobials drugs are key issue to prevent microbial resistance. We 
analyzed and observed in gentamicin samples but three samples out of 58 did not get the 
zone or low potency from the samples which were counterfeiting (Fig.1.19) as well as did 
not have peaks during the identification investigation (Fig. 1.17). In fluorescence 
spectrophotometer we farther investigate about the excipient of GM samples, we did not 
get any peak for the excipient during the investigation (Fig. 1.20-1.22). We found GM 
samples (injection) in vial which were low volume and some were yellow colour. During 
this investigation we observed the low peak for excipient which were yellow colour than 
61 
 
the white colour of the samples (Fig. 1.24). In our survey, we observed a strategy that was 
associated for spreading counterfeit samples. They made a plan and counterfeit samples 
were placed only to the community pharmacy. Though, we collected samples from 
community pharmacy, private hospital, government hospital and clinical pharmacy but 
the counterfeit samples of gentamicin that were collected from only community pharmacy 
and these counterfeit medicines produced by Chinese manufacturers who were not 
registered in Myanmar FDA. In the case of two nonregistered Chinese manufacturers 
were produced gentamicin, Myanmar government announced their products were 
counterfeited. Obviously it is compulsory to include antibiotic after any surgical operation 
to tackle infection from microorganisms.  
In our studied, though analytical tests were satisfactory except five gentamicin 
samples while in the case of cefuroxime and ceftriaxone some samples were not 
satisfactory in pharmacopeias test. Even we observed one cefuroxime sample was 
showing torn in a hole of blister and another cefuroxime sample from Indian origin 
showing different colour in a same strip which were unexpected. Though ceftriaxone and 
gentamicin all samples were acceptable both sterility and endotoxin tests. Unacceptable 
cefuroxime tended to cost almost a half price of the pass products. Gentamicin belongs to 
the class of aminoglycoside antibiotics medicines which is killed or inhibits the growth 
of bacteria. The price of counterfeit gentamicin is one fourth cheaper than that of good-
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quality products, even though no clear relation between unacceptable and price were 
observed in omeprazole and ceftriaxone products; we should be carefully to buy very 
cheap products compared to normal price of the domestic markets. Though the counterfeit 
medicines were very cheaper than the pass samples but other fail samples which were 
also cheaper as a poor quality not counterfeit. Thus, if cheaper medicines will import in 
future it must confirm the quality from manufacturers. Deliberately, the manufacturers 
were not only producing counterfeit medicines but also in manufacturing purpose they 
were using inexperienced manpower for more money saving. In this case we found 
spelling errors, different volume in the ampoule were not uniform of the solution (Fig. 
1.8a, 1.8b & 1.9). Probably, this is the first report of counterfeit gentamicin in Myanmar. 
During the critical period the patients have been suffering these types of mistake and 
cannot separate from the authentic drugs. More overdue to lack of awareness general 
customers were confused these types of messages usually in the crucial time and entered 
to the danger zone. Spreading the drugs which are unregistered and distributed by 
unknown wholesaler or company is increasing the percentage of counterfeit to the 
markets. In this survey we found counterfeit gentamicin samples were unregistered in 
Myanmar FDA that above mentioned. 
Investigation of this survey may not indicate the overall situation of Myanmar 
because we had several limitations like as region of sample collection, inadequate sample 
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size, random sampling and budgetary limitations. In authenticity investigation, we tried 
to communicate to the manufacturers and medicine regulatory authority of each country 
over telephone or by email which were involved in this program but, the response from 
the manufacturers side were quite low and there were no manufacturers to reply who were 
produced counterfeit drugs.  
In Myanmar counterfeit medicines have been existing because survey was not 
conducted for long time. In our survey, we found counterfeit gentamicin which is a matter 
of serious concern, while chipper samples were more problematic than high price of the 
samples. For this reason, it is needed to evaluate the quality of medicines regularly in 
future. Any kind of medicine must be registered in country FDA with maintain actual 
protocol for storages and distribution time.  
1.6 Conclusion  
Counterfeit GM is being sold in Yangon. The quality of OM is a matter of concern, 
and requires follow-up. We found that a few specific manufacturers tend to produce poor-
quality medicines. Regular surveys to monitor counterfeit and substandard medicines in 






























                                                                                    Chapter two 





Poor quality or falsified medicines are a serious problem which introduce the global 
issue especially in low-income countries from a public health point of view [4, 5, 47]. In 
particular, poor-quality antibiotics and antiparasitic agents may lead not only to treatment 
failure, but also to development of drug resistance [12,18,48,49,50]. For example, low 
concentrations of antibiotics accelerated the acquisition of resistance by Salmonella 
typhimurium LT2 strain, and the effect lasted for over 700 generations in vitro [51]. This 
problem is exacerbated by the use of antibiotics in the livestock sector as a growth 
promoter, with resistant strains being passed to humans [22]. The quality problem is not 
confined to antibiotics, however; in a study of 104 samples of anti-malarials in Southeast 
Asia in 2001, 38% were found to be substandard or falsified [52]. In Cambodia in 1999, 
substandard or falsified artesunate containing sulfadoxine-pyrimethamine caused the 
death of at least 30 people [53]. Falsified paracetamol that contained diethylene glycol 
killed more than 200 children in Bangladesh in 1990-1993 [17].   
In Cambodia, the prevalence of falsified and substandard antibiotics has been reported 
to range from 4% to 90 %, according to the Ministry of Health and our earlier surveys 
[13-16, 43]. In this paper, we describe a 4-year consecutive investigation of medicines 
distributed in Cambodia, designed to investigate the quality of antimicrobial medicines 
in Cambodia, as well as to promote efforts to improve the quality of medicines on sale 
there in the future.  
2.2 Objective 
  In Cambodia, the prevalence of falsified and substandard medicines has been 
reported to range from 4% to 90 %, according to the Ministry of Health and our earlier 
surveys. As a part of Cambodia’s continuing efforts to eliminate falsified medicines, the 
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Ministry of Health of Cambodia in collaboration with Kanazawa University carried out a 
further survey designed to evaluate the quality of selected key medicines in the country 
as well as to promote efforts to improve the quality of both antimicrobial and lifesaving 
medicines on sale there in the future.   
2.3 Materials and Methods 
2.3.1 Selection of sampling areas  
In consultation with the Department of Drugs and Food (DDF), Cambodia, we 
selected six sampling areas in the provinces of Battambang, Kandal, Kampong Speu and 
Takeo (rural areas) and in Phnom Penh, the capital of Cambodia (urban area) (Annex 2.1). 
2.3.2 Sample collection  
Samples of clarithromycin [54] and sulfamethoxazole/trimethoprim (June 2011) [55]; 
ceftriaxone (June 2012) [56]; cefuroxime [25], levofloxacin, gentamicin (August 2013) 
[57]; ciprofloxacin [58], fluconazole, nalidixic acid, ofloxacin, phenoxymethyl penicillin 
and roxithromycin (August2014) [59] were collected by two teams, each containing one 
or two Japanese researcher(s), one local assistant and one supervisor from DDF. Samples 
were collected from pharmacies, Depot-A, Depot-B, non-licenced drug outlets and 
wholesalers.  Depot-A was defined as a site having a pharmacist with at least three years’ 
pharmacy training, while Depot-B was defined as a site having a doctor or retired nurse 
in attendance.  
2.3.3 Observation 
The obtained samples were checked with reference to “Tool for Visual Inspection 
of Medicines” [28]. Packages, tablets and blisters of collected samples were observed 
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carefully for package data, packaging condition, Cambodian registration number on the 
label, and insert of each sample. Photographs were taken of each sample. During sampling, 
we also observed the environment of the drug outlets.  
2.3.4 Authenticity  
Authenticity investigation and registration verification were adopted from the 
World Health Organization procedures [16, 18, 48, 60, 61]. E-mail, contact address and 
telephone numbers were collected from each manufacturer with Medicine Regulatory 
Authority (MRA) from their web site. We sent photographs of samples with short 
questionnaires to the manufacturers to check authenticity and asked MRAs whether 
manufacturers were licensed or not. We also asked the DDF about sample registration in 
Cambodia.  
2.3.5 Sample chemical analysis    
The quality of samples was evaluated according to the pharmacopeia indicated on 
the sample package. For the quantity test, an HPLC method was adopted. A Shim-pack 
CLC-ODS (M) 15 cm column (Shimadzu, Kyoto, Japan) was used for clarithromycin, 
ceftriaxone, ciprofloxacin, fluconazole, nalidixic acid, ofloxacin, roxithromycin and 
gentamicin samples. A Shim-pack CLC-ODS (M) 25 cm column (Shimadzu, Kyoto, 
Japan) column was used for cefuroxime and levofloxacin samples, while a 30 cm column 
was used for sulfamethoxazole/trimethoprim samples. An NTR-VS6P dissolution tester 
(Toyama, Osaka, Japan) was used in dissolution test for all samples except in the cases 
of ceftriaxone for injection and gentamicin injection. All tests followed on pharmacopeial 
(according to the package information).  
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*Ceftriaxone and gentamicin samples were analyzed previous way.   
Items Brand name of 
HPLC system 






Q value for 
30 min. in 
dissolution 





4.6 mmX30 cm 254 nm 40˚C 15 90-110 ≥70% 
Levofloxacin Shimadzu, 
Japan 
4.6 mmX25 cm 260 nm 45˚C 15 90-110 ≥75% 
Ciprofloxacin Waters, USA 4.6 mmX15 cm 278 nm 30˚C 15 90-110 ≥75% 
Fluconazole Shimadzu, 
Japan 
3.9 mmX15 cm 261 nm 40˚C 15 90-110 ≥75% 
Nalidixic Acid Shimadzu, 
Japan 
4.6 mmX15 cm 254 nm 25˚C 15 90-110 ≥80% 















4.6 mmX15 cm 205 nm 30˚C 15 90-110 ≥75% 
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2.3.6 Statistical analysis 
Data analysis was performed using SPSS 19.0.0 (SPSS Inc, Chicago, IL, USA). 
Student’s t-test was used to determine the significance of differences in scale data. 
Statistical significance was assessed at 5% level.  
 
2.4 Results  
 
Collected samples are summarized in table 2.2. During the four-year survey, we 
collected 647 samples, produced by 179 manufacturers, involving 247 different brand 
products: 50 clarithromycin (n=24 500 mg, n=26 250 mg tablet) (7.7%) [54], 72 
sulfamethoxazole/trimethoprim (n=24 800/160 mg, n=48 400/80 mg tablet) (11.1%) [55], 
61 ceftriaxone (1gm vial) (9.4%) [56], 53 cefuroxime (250 mg tablet) (8.2%) [25], 60 
levofloxacin (n=53 500 mg, n=7 250 mg tablet) (9.3%), 59 gentamicin (n=51 80 mg/2 ml 
ampoule, n=8 80 mg/2 ml vial) (9.1%) [57], 56 ciprofloxacin (500 mg tablets) (8.7%) 
[58], 57 fluconazole (n=5 150 mg, n=52 150 mg capsule) (8.8%), 9 nalidixic acid (n=3 
1000 mg, n=6 500 mg tablet) (1.4%), 57 ofloxacin (200 mg tablet) (8.8%), 56 
phenoxymethyl penicillin (n=13 250 mg, n=18 1000000 IU, n=6 400000 IU, n=19 
500000 IU tablet) (8.7%) and 57 roxithromycin (150 mg tablet) (8.8%) samples [59], 
from Battambang, Kandal, Kampong Speu, Takeo and Phnom Penh. In these surveys we 
collected 390 (60.3%) samples from urban areas and the rest (257, 39.7%) from rural 
areas. We found that 138 (21.3%) of 647 samples were domestically produced by 28 
(15.6%) manufacturers among the total of 179 manufacturers (Table 2.3).    
 
2.4.1 Drug outlets  
We collected 371 (57.3%) samples from pharmacies, 86 (13.3%) from Depot-A, 142 
(21.9%) from Depot-B, 45 (7%) from wholesalers and 3 (0.5%) from non-licensed drug 
outlets (Table 2.1). There was no significance association among of these outlets in the 





Table 2.2 Outline of samples collection in Cambodia  
        Urban area: The capital of Cambodia (Phnom Penh) 
        Rural area: Other provinces (Battambang, Kandal, Kampong Speu and Takeo) which are located outsides of capital city  
        Depot-A: Depot-A outlet by an assistant pharmacist (who received 3 years’ pharmacy training) 
        Depot-B: Depot-B outlet by a doctor or retired nurse 








Types of area  Type of drug outlet  
Price/unit ($) 
























2011 Clarithromycin 50 28 (56%) 22(44%)  26 (52%) 5 (10%) 17 (34%) 2 (4%) - 0.321 ± 0.198 
 Sulfamethoxazol
e/ Trimethoprim 
72 42 (58%) 30 (32%)  23 (32%) 15 (21%) 29 (40%) 4 (5%) 1 (2%) 0.039 ± 0.029 
2012 Ceftriaxone 61 32 (52%) 29 (48%)  26 (43%) 10 (16%) 19 (31%) 4 (7%) 2 (3%) 1.086 ± 1.386 
2013 Cefuroxime 53 37 (70%) 16 (30%)  34 (64%) 3 (6%) 10 (19%) 6 (11%) - 0.468 ± 0.198 
 Levofloxacin 60 35 (58%) 25 (32%)  30 (50%) 6 (10%) 18 (30%) 6 (10%) - 0.384 ± 0.294 
 Gentamicin 59 35 (59%) 24 (31%)  26 (44%) 11 (19%) 17 (29%) 5 (8%) - 0.069 ± 0.032 
2014 Ciprofloxacin 56 36 (64%) 20 (36%)  40 (71%) 7 (13%) 5 (9%) 4 (7%) - 0.075 ± 0.120 
 Fluconazole 57 35 (61%) 22 (29%)  36 (63%) 4 (7%) 9 (16%) 8 (14%) - 0.427 ± 0.312 
 Nalidixic Acid 9 6 (66%) 3 (34%)  6 (66%) 2 (22%) 1 (2%) - - 0.102 ± 0.072 
 Ofloxacin 57 33 (58%) 24 (32%)  41 (72%) 6 (10%) 9 (16%) 1 (2%) - 0.078 ± 0.039 
 Phenoxymethyl 
penicillin 
56 33 (59%) 23 (31%)  42 (75%) 8 (15%) 3 (5%) 3 (5%) - 0.063 ± 0.112 
 Roxithromycin 57 38 (66%) 19 (34%)  41 (72%) 9 (16%) 5 (9%) 2 (3%) - 0.091 ± 0.092 
 Total 647 (100%) 390 (60%) 257 (40%)  371 (57%) 86 (13%) 142 (22%) 45 (7%) 3 (1%)  
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Clarithromycin  14 2 36 8 
Sulfamethoxazole/ Trimethoprim 42 6 30 9 
Ceftriaxone 0 0 61 17 
Cefuroxime 0 0 53 15 
Levofloxacin 0 0 60 19 
Gentamicin 0 0 59 12 
Ciprofloxacin 18 5 38 15 
Fluconazole 10 1 47 16 
Nalidixic Acid 6 1 3 3 
Ofloxacin 14 6 43 15 
Phenoxymethyl penicillin 24 3 32 3 
Roxithromycin 10 4 47 19 










2.4.2 Observations  
During the collection of samples, we observed that 51 shops out of 353 were air-
conditioned. 85 (13.1%) samples lacked an insert, while insert information of one sample 
which was found in the package and package information about the medicine was not 
match during the observation. Five samples showed variations of package colour. Two 
lots of tablets and one ampoule showed different colours from others of the same brands. 
The blister which was picked from the package and it`s information did not match the 
package (which carry blister) information for one sample (Table 2.5). We collected 12 
(1.9%) samples that were not registered with the DDF (Table 2.6). We found one 
cefuroxime sample that was a physician sample (this was mentioned on the box) [25], and 









Quality test p (Fisher's 
exact test) Pass Fail 
Pharmacy 371 269 102 
 
 
n.s Depot-A 86 64 22 
Depot-B 142 94 48 
Wholesaler 45 36 9 
Non-licensed 3 2 1 * 
*Due to few samples not calculated in  statistically 
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Table 2.5 Number of abnormal samples were found during observation analysis. 
 
Table 2.6 Number of unregistered samples in DDF 
 
Name of medicine  Number of 
samples 
Samples were  
unregistered in DDF 




Ceftriaxone 61 2 
Cefuroxime 53 2 
Levofloxacin 60 0 
Gentamicin 59 2 
Ciprofloxacin 56 1 
Fluconazole 57 0 
Nalidixic Acid 9 3 




Roxithromycin 57 0 





























Clarithromycin  50 0 1 0 4 1 
Sulfamethoxazole/ 
Trimethoprim 
72 24 0 1 1 0 
Ceftriaxone 61 2 0 0 0 0 
Cefuroxime 53 2 0 0 0 0 
Levofloxacin 60 0 0 0 0 0 
Gentamicin 59 4 0 0 0 1 
Ciprofloxacin 56 4 0 0 0 0 
Fluconazole 57 4 0 0 0 0 
Nalidixic Acid 9 3 0 0 0 0 
Ofloxacin 57 8 0 0 0 0 
Phenoxymethyl 
penicillin 
56 32 0 0 0 0 
Roxithromycin 57 2 0 0 0 0 
Total 647 85 (13.1%) 1 (0.15%) 1 (0.15%) 5 (0.8%) 2 (0.30%) 
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2.4.3 Authenticity   
In 2011, 11 manufacturers replied about 60 samples; in 2012, 4 manufacturers replied 
about 17 samples; in 2013, 15 manufacturers replied about 51 samples, and in 2014, 13 
manufacturers replied about 26 samples, confirming that those samples were authentic. 
On the other hand, 18 MRAs out of 40 replied about manufacturer licenses and branded 
products (Table 2.7). The MRA in Germany replied that one manufacturer was not 
licensed.   
2.4.4 Quality investigation of samples 
The results of quality evaluation of collected samples are summarized in Table 2.8. In 
the quantity test, 533 (90.6%) out of 588 samples passed. Among 472 samples analyzed 
for content uniformity, 406 (86%) passed. In the dissolution test, 424 (80.4%) out of 527 
samples passed. Identification, microbial assay, sterility and endotoxin tests were 
satisfactory. In the content uniformity test, the average price of failed samples of 
cefuroxime was significantly cheaper than that of passed samples (Student's t-test, 
p<0.05). In the dissolution test, failed samples of roxithromycin were significantly 
cheaper than passed samples (Table 2.9) (Student's t-test, p<0.05). In the dissolution test, 
there was a significant difference between the pass and fail rates of Cambodian-produced 
samples and foreign-produced samples (Table 2.10) (Fisher's exact test, p<0.05).    
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Table 2.7 MRAs and manufacturers replied during the authenticity investigation  
 
  










confirmed all samples 
were genuine 
Austria 2013 & 2014 20013& 2014 2 17 Not replied  - 
 
Bangladesh 







2 Replied in 2013 
 
5 
Cambodia 2011, 2014 2011 & 2014 16 128 16 in 2011 128 
China 2013 2013 8 43 Not replied - 
 
Cyprus 2011, 2013 & 2014 2011 3 7 Not replied - 
France 2011 & 2014 2011 3 10 1 replied 2011 1 
Germany 2013 & 2014 2011 & 2014 2 10 1 in 2013 & 1 I 2014 1 
 
India 2011, 2012, 2013 & 
2014 





9 in 2013 
 
- 
Indonesia 2013 & 2014 - 4 5 1 in 2013 - 
Korea 2011, 2014 2011 13 36 1 in 2011 & 1 in 2014 7 
Malaysia 2011, 2013 & 2014 2011 3 10 1 in 2014 - 
 
Pakistan 
2011, 2012, 2013 & 
2014 








Singapore 2014 - 1 1 Not replied - 
Sweden 2012 2012 1 3 Replied 3 
Thailand 2011, 2013 & 2014 2011 7 33 2 in 2011 1 
United 
Kingdom  
2013 2013 1 10 Not replied - 
 
Vietnam 















 Dissolution  Content 
uniformity 
 Quantity  Identification  Sterility  Endotoxin  Microbial 
assay 
   Pass Fail  Pass Fail  Pass Fail  Pass Fail  Pass Fail  Pass Fail  Pass Fail 
Clarithromycin 50  36 14  43 7  49 1  50 0  - -  - -  - - 
Sulfamethoxazole/ 
Trimethoprim 
72  62 10  70 2  53 19  72 0  - -  - -  - - 
Ceftriaxone 61  - -  46 15  48 13  61 0  61 0  61 0  - - 
Cefuroxime 53  53 0  43 10  51 2  53 0  - -  - -  - - 
Levofloxacin 60  42 18  - -  57 3  60 0  - -  - -  - - 
Gentamicin 59  - -  - -  - -  59 0  59 0  59 0  59 0 
Ciprofloxacin 56  54 2  56 0  54 2  56 0  - -  - -  - - 
Fluconazole 57  29 28  40 17  54 3  57 0  - -  - -  - - 
Nalidixic Acid 9  3 6  9 0  9 0  9 0  - -  - -  - - 
Ofloxacin 57  49 8  44 13  46 11  57 0  - -  - -  - - 
Phenoxymethyl- 
penicillin 
56  56 0  - -  55 1  56 0  - -  - -  - - 
Roxithromycin 57  40 17  55 2  57 0  57 0  - -  - -  - - 




Table 2.9 Comparison between price and result of the quality test in samples  
 
  
Name of sample Test Result Number of 
samples 






































































































































































































































































































































Table 2.10 Factors associated with quality test found in roxithromycin samples which 





Test Result p (Fisher's 







Cambodia 18 18 0 - 
other 38 38 0 
Quantity 
Cambodia 18 18 0 - 
other 38 36 2 
Dissolution 
Cambodia 18 18 0 - 







Cambodia 10 7 3 n.s 
other 47 33 14 
Quantity 
Cambodia 10 10 0 - 
other 47 44 3 
Dissolution 
Cambodia 10 5 5 n.s 







Cambodia 6 6 0 - 
other 3 3 0 
Quantity 




other 3 3 0 
Dissolution 
Cambodia 6 1 5 







Cambodia 13 11 2 n.s 
other 42 33 9 
Quantity 
Cambodia 13 11 2 n.s 
other 42 35 7 
Dissolution 
Cambodia 13 12 1 n.s 





Cambodia 24 23 1 - 
 other 32 32 0 
Dissolution 
Cambodia 24 24 0 - 







Cambodia 10 10 0 - 
 other 45 45 0 
Quantity 
Cambodia 10 10 0 - 
 other 47 47 0 
Dissolution 
Cambodia 10 3 7 
 
p<0.05 







Cambodia 14 12 2  
other 36 31 5 
Quantity 
Cambodia 14 13 1 - 
 other 36 36 0 
Dissolution 
Cambodia 14 9 5 n.s 







Cambodia 42 40 2 - 
 other 30 30 0 
Quantity 
Cambodia 42 32 10 n.s 
other 30 21 9 
Dissolution 
Cambodia 42 36 6 n.s 





2.5 Discussion  
Falsified antibiotics have been found in previous surveys in Cambodia [43]. For 
this reason, our four-year survey covered a range of different regions in the country. 
Overall, we found that 424 (80.5%), 406 (86%), 533 (90.6%), 647 (100%), 120 (100%), 
120 (100%) and 59 (100%) samples passed the dissolution, content uniformity, quantity, 
identification, sterility, endotoxin, and microbial assay tests respectively (Table 2.8). 
Thus, poor-quality medicines were still available in Cambodia during the study period. 
Possible reasons include poor GMP implementation by manufacturers and inadequate 
storage conditions in outlets in Cambodia. Only 51 of 353 outlets were air-conditioned.  
Cambodia is situated in a tropical region, and the summer season is hot and humid. Our 
statistical investigation we did not get significance association, the effect of temperature 
on pass or fail samples of medicines compare with those outlets containing air-
conditioning. But it is well established that these conditions can markedly impair the 
quality of medicines [40-42]. In our investigation, failed samples were significantly 
cheaper than passed samples in the cases of cefuroxime and roxithromycin. Thus, it may 
be important to focus quality checks especially on cheaper medicines (Table 2.9). Foreign 
manufacturers not only supply poor quality medicines in the markets but also domestic 
manufactures were produced and supply this type of medicines to the markets. We found 
10 roxithromycin products which were produced domestically. Significance was 
associated in number of pass and fail samples which compared with the foreign products 
(Table 2.10). We also found one expired sample, and this could present a health hazard 
to patients. About medicine indication information get from insert which must 
compulsory inside of box or container. We found 13.1% samples did not contain insert. 
Unregistered samples which may causes to increase poor quality medicines in the markets. 
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We found 1.9% samples were not registered in DDF (Table 2.6). In our investigation 
maximum unregistered samples did not pass according to their pharmacopoeial test.    
 
Non-licenced drug outlets were found in Cambodia in previous studies [13, 16, 
43, 60], but have since been almost completely closed down, and only permitted clinics 
continue to sell medicines, thanks to the vigorous efforts of the Cambodian government 
to strengthen pharmaceutical control (Table 2.2). But, our statistical analysis among of 
these outlets did not get any significance (Table 2.4) 
More than 10% of the antibiotics sampled failed in various tests, except for 
levofloxacin, ciprofloxacin and phenoxymethyl penicillin (table 2.8). Among the failures, 
28% of clarithromycin and 49.1% of fluconazole samples failed only in the dissolution 
test. On the other hand, 20% of ofloxacin and 26.4% of sulfamethoxazole/trimethoprim 
samples failed in content uniformity and quality tests, respectively. These results are 
unsatisfactory from the viewpoint of public health, and are also likely to promote bacterial 
resistance to antibiotics [12]. This is a serious issue, because it has been reported that 60% 
and 18% of Klebsiella pneumonia and Neisseria gonorrhea, respectively, have developed 
resistance even to third-generation cephalosporin [44, 45]. In North Okkalapa General 
Hospital in Myanmar, 60% of Acinetobacter species, 60% of E. coli, 55% of Klebsiella, 
60% of Pseudomonas and 36% of Staphylococcus species were resistant to gentamicin 
[46]. In addition, resistance to old quinolones such as nalidixic acid, fluoroquinolones 
such as ciprofloxacin and ofloxacin, penicillins such as phenoxymethyl penicillin, 
macrolides such as roxithromycin and triazole antifungal drugs such as fluconazole has 
been documented globally. According to the 2014 WHO report, E. coli and Shigella 
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strains resistant to fluoroquinolones amounted to 31-32% and 11.8%, respectively, in 
Cambodia. Streptococcus pneumoniae resistant to penicillin has also been detected at a 
rate of 64% in Cambodia [45]. However, action against substandard or falsified medicines 
has improved the quality of medicines in recent years [13, 15,16]. In our four-year 
investigation we found poor-quality medicines, but we did not find any falsified 
medicines, which is consistent with the view that the quality of medicines in Cambodian 
markets has improved. The results of registration verification from DDF were also 
satisfactory.  
The prevalence of poor-quality medicines found in our investigation is broadly 
consistent with that in other lower-income countries [62]. But, although no falsified 
medicine has been identified among the collected samples, it has not been possible to 
confirm the authenticity of all the samples.  
2.6 Conclusion 
Poor-quality antibiotics remained prevalent in Cambodia during 2011 to 2014. 
Efforts are needed to encourage manufacturers to follow GMP, and to ensure proper 
handling of medicines throughout the supply chain. Also, continuous monitoring of 








                                                                                     Chapter three 





Poor quality medicines are a serious issue for public health; for example, 200 
children died in a Bangladesh hospital in 1990-93 after being given counterfeit 
paracetamol that had been substituted by diethylene glycol [17,19]. In 2016, the Supreme 
Court of Bangladesh ordered about twenty pharmaceutical companies identified as 
responsible for production of substandard drugs to cease operation [63]. Counterfeit 
medicines impact not only developing countries, but also high-income countries [64-68], 
although it has been estimated that 30% of counterfeit drugs are distributed in Africa, 
Asia, Middle East, compared with less than 1% in the USA and European countries [5, 
69-71]. In addition to counterfeit medicines, substandard medicines are also an important 
issue; for example, in 1999 more than 30 people died after being given substandard 
sulfadoxine-pyrimethamine as an anti-malarial [53].  
Since the 1990s, the Ministry of Health and law-enforcement agencies in 
Cambodia have been trying to identify and suppress the distribution of falsified 
medicines, in cooperation with various international organizations, including the World 
Health Organization (WHO), INTERPOL, USAID, US Pharmacopeial Convention 
(USP), and Japan Pharmaceutical Manufacturers Association (JPMA) [13, 60, 72-76]. 
Various surveys have found that the prevalence of counterfeit and substandard medicines 
in Cambodia ranged from 4% to 90% [13-16]. In a previous survey in 2010, we also found 
falsified and poor quality medicines in Cambodian markets [43, 62].  
As a part of Cambodia’s continuing efforts to eliminate falsified medicines, the 
Ministry of Health of Cambodia in collaboration with Kanazawa University carried out a 




3.2.1 Sample collection 
We decided to collect samples from regions of high population density, border 
regions and locations along national highways. In consultation with the Department of 
Drugs and Food (DDF), we selected Phnom Penh as an urban area, and Battambang, 
Kandal, Takeo, Kampong speu and Svay rieng as rural areas. A list of licensed drug 
outlets was obtained from DDF. The selected target drugs were cimetidine in 2011, 
amlodipine [77]; esomeprazole and rabeprazole [78] in 2012, glibenclamide [79] and 
metformin [80] in 2013. Samples were collected from four types of drug outlets: 
pharmacies, Depot-A, Depot-B and non-licensed drug outlets. Depot-A was defined as 
an outlet with a pharmacist who had at least 3 years’ pharmacy training, and Depot-B was 
defined as an outlet that contained a doctor or retired nurse [81]. Some samples were also 
collected from wholesalers. Each of the two sampling teams contained a research 
investigator, a local officer who had received training, and a sampling assistant. A 
sampling form was used to record information about each sample at the time of purchase, 
and samples were keep 20-25°C until analyzed. 
3.2.2 Observation  
The condition of each package, the colour of the box, the appearance of the 
medicines, and the insert in each package were carefully examined at Kanazawa 
University, and compared with those of other samples of the same brand, and the logo on 
the box was compared with that on the labeled supplier’s internet home page. The 
manufacturing date, expiry date, lot number, license number, and Cambodian registration 
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number were also recorded. Samples were photographed, and scans of the box and insert 
were made.  
3.2.3 Authenticity 
Authenticity investigation was conducted according to the recommendations of 
the World Health Organization (WHO) [16, 48]. Information on the label, photographs 
of samples, scans of the box and insert, and a short questionnaire were sent to 
manufacturers by E-mail, and manufacturers were also contacted by telephone using the 
number on their internet home page. We asked the responsible MRAs whether or not the 
manufacturers were registered. We also asked the DDF whether or not the collected 
medicines were registered in Cambodia.   
3.2.4 Quality analysis 
Sample quality was evaluated according to the Pharmacopeia stated on the label, 
using the USP 34, USP 35 and BP 2012 versions of the pharmacopeias [82-84].  Content 
uniformity tests were performed with 10 tablets/capsules of all samples. The HPLC 
columns and parameters used during the content uniformity tests are listed in Table 3.1. 
Quantity and dissolution tests followed the relevant pharmacopeial descriptions. 
Dissolution tests for all samples were performed with 6 tablets/capsules by using an NTR-
VS6P dissolution tester (Toyama, Osaka, Japan).  
3.2.5 Statistical analysis  
Data analysis was performed using SPSS release 19.0.0 (Chicago: SPSS Inc.). 
When appropriate, Fisher’s exact test was performed to identify significant relationships 






Table 3.1 HPLC conditions for pharmacopoeial tests  
 
Items 
Brand name of 
HPLC system 
 








Quantity %  
Q value for 30 
min. in dissolution 
Amlodipine Hitachi, Japan 4.6 mmX15 cm 237 nm 40˚C 15 90-110 ≥75% 
Cimetidine Shimadzu, Japan  4.6 mmX25 cm 220 nm 40˚C 15 90-110 ≥80% 
Esomeprazole Shimadzu, Japan  4.0 mmX10cm 302 nm 30˚C 15 90-110 ≥75% 
Glibenclamide Waters, USA 4.6 mmX15 cm 254 nm 25˚C 15 90-110 ≥70% 
Metformin Shimadzu, Japan  4.6 mmX25 cm 218 nm 30˚C 15 90-110 ≥70% 
Rabeprazole Waters, USA 4.6 mmX15 cm 290 nm 30˚C 15 90-110 ≥75% 




As summarized in Table 3.2, we collected 86 (25.1%) samples of cimetidine (40 
mg tablet), 79 (23.1%) amlodipine (n=3 10 mg capsule & n=76 5 mg tablet) [77], 54 
(15.8%) esomeprazole (20 mg n=14 capsule & n=12 tablets; 40 mg tablet n=16 & n=12 
capsule), 11 (3.2%) rabeprazole (10 mg n=1 capsule & 20 mg n=10 tablet) [78], 60 
(17.5%) metformin (500 mg tablet) [80] and 52 (15.2%) glibenclamide (5 mg tablet) [79]. 
Most of the samples (223, 65.2%) were collected from Phnom Penh, and the others (119, 
34.8%) were collected from rural areas.  
3.3.1 Drug Outlets 
We collected total 342 samples from 263 drug outlets in the investigated regions. 
We obtained 156 (45.6%) from pharmacies, 62 (18.1%) from Depot-A, 96 (28.1%) from 
Depot-B, and 30 (8.2%) from wholesalers (Table 3.2).  





 Area  Type of drug outlet 
 Urban Rural  Pharmacy Depot-A Depot-B Wholesaler 
2011          
Cimetidine 86  57 29  30 19 34 3 
2012          
Amlodipine 79  45 34  33 12 27 7 
Esomeprazole 54  38 16  28 4 13 9 
Rabeprazole 11  10 1  8 0 2 1 
2013          
Glibenclamide 52  33 19  25 14 10 3 
Metformin 60  40 20  32 13 10 5 






Among 263 outlets, only 18 were air-conditioned. The samples originated from 
78 manufacturers, and 38 (11.1%) were domestically produced. Three samples of 
cimetidine and one of amlodipine were in boxes or containers of nonstandard colour (Fig. 
1a, 1b). The colour of the tablets in two different samples did not match among the 
samples of cimetidine and amlodipine (Fig. 1c). The inserts in the two samples did not 
match those in other samples of the same brand. In addition, 32 (9.4%) samples had no 
insert.  
3.3.3 Authenticity 
  The DDF reported that 14 samples out of 342 were not registered (Table 3.3). 
Replies stating that products were authentic were received from 8 out of 27 manufacturers 
in 2011, 7 out of 35 manufacturers in 2012 and 6 out of 19 manufacturers in 2013. Thus, 
the response rate was quite poor. On the other hand, we received replies from 7 out of 12 
MRAs in 2011, 7 out of 13 MRAs in 2012 and 2 out of 10 MRAs in 2013, stating that 












 b: Different colour of the box of amlodipine sample 
 
  
Different boxes or containers of cimetidine  
Different boxes of amlodipine  
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     Different tablets of cimetidine  
 Different tablets of amlodipine  
    Items Unregistered  No insert in box 
Cimetidine 3 23 
Amlodipine 7 3 
Esomeprazole 1 2 
Rabeprazole 0 0 
Glibenclamide 1 1 
Metformin 2 3 
Total 14 32 
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3.3.4 Quality evaluation 
The test results for the 342 samples are summarized in Table 3.4. We found that 
38 (11.1%) samples failed the dissolution test, and 52 (15.2%) failed the content 
uniformity test. In addition, 48 (14%) samples out of 342 failed the quantity test. In the 
case of rabeprazole, 11 samples originated from Japan passed all the tests, whereas 16 
(42.1%) samples out of 38 produced domestically failed in one or more tests. Failure rates 
in quality tests were significantly associated with anomalies in visual observation of the 
samples (Fisher`s exact test, p<0.01 & p<0.05) (Table 3.5). 
 
Table 3.4 Summary of quality test of samples 
Sample name No. of 
samples 
 Dissolution  Content uniformity  Quantity 
 Pass Fail  Pass Fail  Pass Fail 
Cimetidine 86  79 7  65 21  71 15 
Amlodipine 79  77 2  73 6  78 1 
Esomeprazole 54*  31 22  32 22  33 21 
Rabeprazole 11  11 0  11 0  11 0 
Glibenclamide 52  47 5  49 3  46 6 
Metformin 60  58 2  60 0  55 5 
Total 342  303 38  290 52  294 48 















  Fisher's 
exact test 
 Pass Fail    
Domestic 19 8    




 Content uniformity    
 Pass Fail    
Phnom Penh 45 0   p<0.01 





   Price per unit ($)  
 
Dissolution Pass 31 0.32 ± 0.08 
 
p<0.05 
Fail 22 0.21 ± 0.11 
 
Quantity 








Factors  No. of 
samples 
        Pharmacist  




Absence 100 67 33 
 
p<0.05 
Presence 12 2 10 




Cambodia lies in a tropical region, and is very hot and humid in the summer 
season. These factors can seriously impact on the quality of improperly stored medicines 
[40-42]. Among the outlets from which samples were collected, we found that all the 
wholesalers were equipped with air-conditioning, but very few other outlets had air-
conditioning. There seems to be a clear need to improve the storage conditions in retail 
outlets in order to improve the quality of medicines.  
We observed some samples of boxes that had been imported, but showed a 
different colour compared with other samples of the same brand. The fact that these were 
on sale suggests that customers were not necessarily familiar with the authentic products. 
On the other hand, printing technology makes it quite easy to prepare packages for 
falsified medicines that resemble authentic products [47, 85]. In our investigation we also 
found two samples of tablets that had nonstandard colours. Among samples from both 
foreign and domestic manufacturers, we found that 32 (9.4%) lacked sample inserts in the 
box, although it was not clear whether inserts had been omitted by the manufacturers or 
removed by retailers. Among 14 samples that had been imported but not registered with 
the DDF (Table 3.3), 4 (28.6%) failed pharmacopoeial tests in Kanazawa University. A 
major issue in authenticity investigation was the poor response rate from manufacturers. 
We could not get any responses from 57 manufacturers, although 86 samples were 
confirmed to be genuine by 21 manufacturers.  
Among all the samples collected, 38, 52 and 48 samples failed in dissolution, 
content uniformity and/or quality tests at Kanazawa University. Most of the esomeprazole 
samples failed in all tests (Table 3.4). In the case of amlodipine, which is used to treat 
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hypertension and chest pain in adults or children, and we found that 6 samples failed the 
content uniformity test. It is noteworthy that 14 (42.1%) out of 38 samples of domestically 
produced rabeprazole were of poor quality. Thus, the manufacturers (Cambodian) which 
are produced poor quality medicines should avoid and imported good quality medicines 
from the manufacturers.   
Finally, it should be noted that our survey had a number of limitations. In 
particular, budgetary restrictions limited the number of samples that could be collected 
and the number of outlets that could be sampled. We did not visit all of the same sites in 
each of the 3 years. Nevertheless, our survey clearly shows that substandard and 
counterfeit medicines are widely available in Cambodia.  
3.6 Conclusion  
Poor-quality medicines were still prevalent in Cambodia during 2011-2013. It is 
desirable to conduct further surveys to continue monitoring the situation. Measures are 
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Comparative study between two-countries  
◆ According to pharmacopoeial analysis, from the investigation samples in Myanmar we 
found that 79.7%, 84.7%, 82%, 100%, 100%, 98.7%, and 94.8% samples were passed in 
assay, content uniformity, dissolution, endotoxin, sterility, identification and microbial 
assay test respectively (Table 1.5). In the case of antimicrobial samples from Cambodia 
we found that 90.6%, 86%, 80.4%, 100%, 100%, 100%, 100% samples were passed in 
assay, content uniformity, dissolution, endotoxin, sterility, identification and microbial 
assay test respectively (Table 2.8). While in the case in Cambodian lifesaving medicines 
we found that 86%, 84.8% and 88.9% samples were passed in assay, content uniformity 
and dissolution test respectively (Table3.4).  In Myanmar three GM samples which were 
failed in both identification and microbial assay test which were counterfeited. Myanmar 
government confirmed it and announced.   
◆ In our one-year investigation, we found counterfeit GM medicines which were sold in 
Yangon a commercial city in Myanmar. While in Cambodia we conducted above these 
surveys which included Phnom Penh the capital of Cambodia with five different 
provinces. In Cambodia we found only poor quality medicines but counterfeit medicines 
were not detected. It is our hypothesis regarding these surveys, since 1999 there were no 
systematic survey occurred in Myanmar. Manufacturers took this opportunity and to 
supply of these type of medicines in Myanmar. In the case in Cambodia regular survey 
monitoring was in there. We have been reporting each year to the Cambodian authority. 
Robust action from the Cambodian authority and comparatively better quality of 
medicines were found in Cambodian markets.  
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◆ Statistically we found that the average price of failed samples was significantly cheaper 
than that of passed samples in both of these countries. Manufacturers who did follow 
GMP might sell these products cheaper than those produced in comply with GMP.  
◆ Previously we stablished the evidences about the relationship between the quality of 
medicines and environmental conditions like as temperature and humidity. These 
conditions directly enhanced to decrease the quality of medicines. In our investigations, 
air-conditioning system of drug outlets in both countries were not satisfactory. Above 
evidences to obtain good quality medicines, it is highly necessary to improve air-
conditioning in any type of drug outlet.  
◆ We found some samples which were not registered in DDF, Cambodia and Myanmar 
FDA. But in the case of unregistered samples (all most) from Myanmar were 
counterfeited which were showing spelling errors on the package of the box. Unregister 
samples should not be allowed for use in future.   
◆ We had collected GM injection from both countries. In Cambodia we found all GM 
were ampoules. But in the case of Myanmar samples which were collected and some were 
ampoules and some were vials. We found counterfeit three gentamicin sample which were 
in ampoule. But, about the vial samples we observed that the samples colour were 
changed white to yellow before the expiration date. We also observed that the volume of 
samples were not equal (vial sample). In our laboratory investigation, we realized the 
samples which containing in to the vials were not properly shield. In this type of 
medicines should not be used to the patients.  
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◆ Investigations to Myanmar, we were collected samples from government hospital, 
privet hospital, community pharmacies, clinical pharmacies and wholesalers. We found 
counterfeit samples which were keep into only community pharmacies outlets. In this 
type of drug outlets must be needed special monitoring.  
Conclusion of these surveys: 
Our surveys were occurred in two low income countries. We found lot of foreign 
medicines from different manufacturers and countries. In these surveys we found lot of 
problems such as spelling error on the box, low volume, different package colour, insert 
messing in a sample box, insert information and package information not matching, loose 
samples, colour changed before the expiration, not registered samples and non-licenced 
samples were observed during the observation of samples. In authenticity investigation, 
from few manufacturers and MRAs replied to us. From both countries, we found huge 
amounts of poor quality or substandard medicines of samples those were produced in both 
foreign and domestically. It is our assumption that counterfeit medicine was not found in 
Cambodia because we have been investigating continuously in this country. But in the 
case of Myanmar we found counterfeit gentamicin (foreign manufacturers) from their 
markets and there was no survey occurred in Myanmar from the long time. We observed 
fail samples were cheaper in both countries than the pass samples.  
People not only in this two countries but also all developing countries can get 
good quality medicines in the future as well as remove counterfeit or poor quality 
medicines from their markets could be the following ways. If it will occur continuously 
monitoring (surveys for the evaluation of medicines) or manufacturers which are 
100 
 
producing cheaper medicines cordially must follow actual guideline as well as drug 
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Annex 1.2 Sampling form  
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Annex 1.3 Tool for Visual Inspection of Medicines 
  
Yes No Other Observations
1. PACKAGING
1.1 Container and Closure
Does the container and closure protect the
product from the outside environment; e.g.
is the container properly sealed?
Do they assure that the product will meet
the proper specifications throughout its
shelf life?
Are the container and the closure
appropriate for the product inside?
Is the container safely sealed?
1.2 Label
If there is a carton protecting the container,
does the label on the carton match the
label on the container?
Is all information on the label legible and 
indelble?
1.2.1 The trade (brand) name
Is the trade name spelled correctly?
Is the medicinal product (trade name) 
registered
in the country by the Drug Regulatory 
Authority) ?
Is the product legally sold in the coutry?
Does the symbol ® follow the trade name?
For blister or foil strip packed products, is the 
trade name indelibly impressed or imprinted 
onto
the strip?
1.2.2 The Active ingredient name
(scientific name/generic name)
Is the active ingredient name spelt correctly?
Do the trade name and the active ingredient 
names correspond to the registered product?
1.2.3 The manufacturer's name and logo
Are the manufacturer's name and logo legible 
and
correct?
Does the logo or hologram (if applicable) look 
authentic?
Does the logo or hologram (if applicable) 





1.2.4 The manufacturer's full address
Is the manufacturer's full address legible and
correct?
Has this company or its agent registered the 
product in the country?
1.2.5 The medicine strength (mg/unit)
Is the strength - the amount of active 
ingredient
per unit - clearly stated on the label?
For blister or foil strip packed products, is the
medicine strength indelibly impressed or 
imprinted
onto the strip?
1.2.6 The dosage form (e.g., tablet/capsule)
Is the dosage form clearly indicated on the
container label?
Does the dosage form stated on the label 
match
the actual dosage form of the medication?
Is the indicated madicine under this dosage 
form
registered and authorised for sale in the 
country?
1.2.7 The number of units per container
Does the number of dosage units listed on 
the 
label match the number of dosage units 
staated 
on the container?
1.2.8 Dosage statement (if appropriate)
Is the dosage clearly indicated on the label?
Is the dosage stated on the label appropriate 
for
the madicine in this form and strength?
Is the product registered and authorised for 
sale
in the country with this dosage?
1.2.9 The batch (or lot) number
Does the numbering system on the package
correspond to that of the producting 
company?
For blister or foil strip packed medicines, is 
the 
batch number indelibly impressed or 
imprinted onto
the strip?
1.2.10 The date of manufacture and the 
expiry date
Are the manufacture and expiry dates clearly 
indicated on the label?
For blister or foil strip packed products, is the 







Are the storage conditions indicated on the 
label?
Has the product been properly stored?
1.3 Leaflet or package insert
Is the package insert printed on the same
coloured or same quality paper as the original 
(If 
available to compare) or does it look 
familiar?
Is the ink on the package insert or packaging
smudge-proof?
Does the informationb on the package insert 
match the information on the product 
container?
2. PHYSICAL CHARACTERISTICS OF 
TABLETS/CAPSULES
2.1 Uniformity of Shape
Are the tablets/capsules uniform in shape?
2.2 Uniformity of Size
Are the tablets/capsules uniform in size?
2.3 Uniformity of Colour
Are the tablets/capsules uniform in colour?
2.4 Uniformity of Texture
Do the tablats have a uniform coating?
Is the base of the tablets fully covered?
Are the tablets unifomly polished, free of 
powder,
and non-sticking?
2.5 Markings (scoring, letters, etc)
Are markings uniform and identical?
Does the logo (if present) match that of the
manufacturing company?
2.6 Breaks, Cracks and Splits
Are the tablets/capsules free of breaks, 
cracks,
splits or pinholes?
2.7 Embedded surface spots or contamination
Are the tablets/capsules free of embedded 
surface spots and foreign particle 
contamination?
2.8 Presence of empty capsules in the case of 
asample of capsules
Is the sample examined free of empty 
capsules?
2.9 Smell
Does the medicine smell the same as the 
original
(If available)?
Does it smell peculiar?
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Annex 1.6 authenticity e-mail to MRAs  
 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Omeprazole Dissolution 1st Stage-BP  
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Result of dissolution test (DN) Result of quality test (DN) 
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Result of Microbial Assay [GM] 




CXM dissolution test 
 
ID Serial No . Sample Code
































Initial Judge New Judge 
3 A-005 A005/MM14/YG/01/HG/CXMSPIZEF Orchid HEALTHCARE India 101.01 96.57 95.96 96.92 99.78 95.69 97.65 2.2 2.26 Pass
4 A-006 A006/MM14/YG/01/HG/CXMZinnat GlaxoSmithKl ine UK 77.86 86.26 87.94 87.54 91.17 91.77 87.09 5.01 5.75 Pass
5 A-007 A007/MM14/YG/01/HG/CXMZIFTUM 250 Alkem Laboratories  LtdIndia 94.80 96.21 95.20 98.97 95.40 97.02 96.27 1.54 1.60 Pass
6 A-016 A016/MM14/YG/01/HG/CXMZiNNASAV-250 SAVIOUR PHARMACEUTICALSIndia 86.13 86.73 80.62 77.52 85.79 82.70 83.25 3.66 4.39 Pass
7 A-017 A017/MM14/YG/01/HG/CXMZIFATIL-250 Galpha Laboratories  LimitedIndia 108.91 95.81 110.33 106.09 107.70 113.48 107.05 6.06 5.66 Pass
8 A-018 A018/MM14/YG/01/HG/CXMCETIL LUPIN LTD. India 100.74 93.64 93.71 101.42 102.10 97.87 98.25 3.82 3.89 Pass
9 A-019 A019/MM14/YG/01/HG/CXMFUROCEF RENATA LIMITED Bangladesh 69.59 77.86 74.23 86.87 83.51 82.50 79.09 6.43 8.13 Pass
10 A-025 A025/MM14/YG/04/C/CXMSPIZEF Orchid HEALTHCARE India 84.11 96.75 94.19 78.87 95.81 91.57 90.22 7.18 7.96 Pass
11 A-030 A030/MM14/YG/02/C/CXMRUFEX-250 Global  Pharma Healthcare Pvt.Ltd,India 80.68 87.20 71.81 60.60 86.93 77.86 77.52 10.11 13.05 Fai l Pass
12 A-036 A036/MM14/YG/01/Ocl  /CXMZIFTUM 250 Alkem Laboratories  LtdIndia 100.40 94.87 87.70 95.28 92.61 92.96 93.97 4.15 4.41 Pass
13 A-037 A037/MM14/YG/01/Ocl/CXMCefusan 250 SRS pharmaceutica l  pvt l td.India 94.46 94.66 96.71 95.89 95.55 93.84 95.19 1.05 1.11 Pass
14 A-048 A048/MM14/YG/06/C/CXMRUFEX-250 Global  Pharma Healthcare Pvt.Ltd,India 66.77 63.95 65.56 66.37 66.57 68.99 66.37 1.65 2.48 Fai l Pass
15 A-052 A052/MM14/YG/02/HG/CXMZIFTUM 250 Alkem Laboratories  LtdIndia 96.81 97.35 98.50 97.22 100.85 101.05 98.63 1.88 1.91 Pass
16 A-054 A054/MM14/YG/02/C/CXMZIFTUM 250 Alkem Laboratories  LtdIndia 96.88 100.24 93.79 97.82 98.63 98.83 97.70 2.22 2.27 Pass
17 A-057 A057/MM14/YG/01/HP/CXMRUFEX-250 Global  Pharma Healthcare Pvt.Ltd,India 51.24 71.52 79.71 71.72 79.92 72.54 71.11 10.48 14.73 Fai l Pass
18 A-058 A058/MM14/YG/HP/CXMZinnat GlaxoSmithKl ine UK 94.19 91.57 91.17 88.14 96.81 93.39 92.55 2.96 3.20 Pass
19 A-063 A063/MM14/YG/01/Ocl/CXMZIFTUM 250 ALKEM LABORATORIES LTD.India 101.01 93.84 91.59 92.00 94.39 95.89 94.79 3.43 3.62 Pass
20 A-068 A068/MM14/YG/02/C/CXMRUFEX-250 Global  Pharma Healthcare Pvt.Ltd,India 78.46 80.68 70.40 63.34 69.59 71.61 72.35 6.32 8.74 Fai l Pass
21 A-071 A071/MM14/YG/01/HG/CXMZIFTUM 250 ALKEM LABORATORIES LTD.India 96.61 96.68 104.14 97.82 92.78 94.40 97.07 3.91 4.03 Pass
22 A-074 A074/MM14/YG/01/C/CXMZIFTUM 250 ALKEM LABORATORIES LTD.India 90.77 91.98 87.74 91.17 88.88 86.73 89.54 2.08 2.32 Pass
23 A-079 A079/MM14/YG/02/Ocl/CXMRUFEX-250 Global  Pharma Healthcare Pvt.Ltd,India 64.69 62.27 63.95 81.09 58.91 62.00 65.48 7.90 12.07 Fai l Pass
24 A-085 A085/MM14/YG/02/HP/CXMRUFEX-250 Global  Pharma Healthcare Pvt.Ltd,India 64.35 59.23 66.88 59.03 63.94 70.22 63.94 4.35 6.80 Fai l Pass
25 A-086 A086/MM14/YG/02/HP/CXMZinnat GlaxoSmithKl ine UK 82.97 81.89 85.32 89.62 85.12 87.94 85.48 2.92 3.41 Pass
26 A-089 A089/MM14/YG/01/W/CXMCefoti l SQUARE PHARMACEUTICALS LTD.Bangladesh BP ― ― ― ― ― ― ― ― ―
27 A-095 A095/MM14/YG/03/W/CXMKEFROX CCL Pharmaceutica ls (Pvt) Ltd.Pakis an BP ― ― ― ― ― ― ― ― ―
28 A-099 A099/MM14/YG/01/HG/CXMRUFEX-500 Global  Pharma Healthcare Pvt.Ltd,India 65.56 57.43 52.65 66.16 62.13 64.55 61.41 5.34 8.70 Fai l Pass
29 A-102 A102/MM14/YG/01/Ocl/CXMCETIL LUPIN LTD. India 73.42 72.28 70.60 76.05 70.80 69.66 72.14 2.33 3.24 Pass
30 A-104 A104/MM14/YG/02/HP/CXMZIFTUM 250 ALKEM LABORATORIES LTD.India 106.90 103.07 100.65 105.99 99.03 106.29 103.65 3.28 3.16 Pass
32 B-002 B-002/MM14/YG/01/HP/CXMZIFTUM 250 Alkem LaboratoriesIndia 126.66 131.50 131.09 122.42 131.30 136.54 129.92 4.83 3.71 Pass
33 B-003 B-003/MM14/YG/01/HP/CXMSPIZEF Orchid HEALTHCARE India 98.43 96.21 94.60 92.78 96.41 94.19 95.44 1.99 2.08 Pass
34 B-004 B-004/MM14/YG/01/HP/CXMETIL LUPIN LTD. India 73.42 74.84 73.89 75.31 80.48 74.23 75.36 2.60 3.44 Pass
35 B-023 B-023/MM14/YG/07/C/CXMRUFEX Global  Pharma Healthcare Pvt, Ltd.,India 62.33 64.15 62.13 65.36 65.09 63.34 63.73 1.37 2.14 Fai l Pass
36 B-027 B-027/MM14/YG/01/C/CXMZinnat GlaxoSmithKl ine UK 91.77 93.19 89.96 87.74 94.19 93.59 91.74 2.48 2.70 Pass
37 B-029 B-029/MM14/YG/02/C/CXMZIFTUM 250 Alkem LaboratoriesIndia 80.88 82.50 81.15 89.62 85.12 87.94 84.54 3.65 4.32 Pass
38 B-030 B-030/MM14/YG/08/C/CXMZinnat GlaxoSmithKl ine UK 89.54 79.58 89.54 84.29 86.06 82.99 85.33 3.89 4.56 Pass
39 B-031 B-031/MM14/YG/08/C/CXMZIFTUM 250 Alkem LaboratoriesIndia 98.83 97.02 97.42 97.22 101.25 96.41 98.02 1.77 1.81 Pass
40 B-034 B-034/MM14/YG/01/HP/CXMZIFTUM 250 Alkem LaboratoriesIndia 95.14 97.46 98.14 92.41 96.51 96.92 96.10 2.07 2.15 Pass
41 B-038 B-038/MM14/YG/01/HP/CXMZIFTUM 250 Alkem LaboratoriesIndia 127.26 122.02 127.47 124.04 122.09 123.84 124.45 2.41 1.94 Pass
42 B-042 B-042/MM14/YG/01/HG/CXMZIFATIL Galpha Laboratories  LimitedIndia 88.93 88.31 84.83 87.43 90.36 90.77 88.44 2.16 2.45 Pass
43 B-044 B-044/MM14/YG/01/HG/CXMZinmax DOMESCO MEDICAL IMPORT EXPORT JOINT-STOCK CORP.VietNam 90.77 91.17 92.38 88.55 89.15 89.56 90.26 1.43 1.58 Pass
44 B-047 B-047/MM14/YG/01/C/CXMRUFEX Global  Pharma Healthcare Pvt, Ltd.,India 60.52 59.51 59.71 62.94 60.52 60.32 60.59 1.23 2.03 Fai l Pass
45 B-052 B-052/MM14/YG/01/HP/CXMETIL LUPIN LTD. India 109.12 107.50 103.74 100.18 112.14 105.89 106.43 4.19 3.93 Pass
46 B-053 B-053/MM14/YG/01/HP/CXMZinnat GlaxoSmithKl ine UK 88.75 94.19 86.13 79.67 74.43 88.35 85.25 7.08 8.31 Pass
47 B-063 B-063/MM14/YG/01/O(c)/CXMZIFTUM 250 Alkem LaboratoriesIndia 93.43 88.93 105.52 98.14 93.23 103.13 97.06 6.38 6.57 Pass
48 B-066 B-066/MM14/YG/01/C/CXMZIFTUM 250 Alkem LaboratoriesIndia 91.59 87.90 96.92 95.69 94.25 100.60 94.49 4.39 4.65 Pass
49 B-067 B-067/MM14/YG/01/C/CXMRUFEX-250 Global  Pharma Healthcare Pvt, Ltd.,India 84.92 72.82 78.46 81.96 77.66 79.67 79.25 4.10 5.18 Pass
50 B-076 B-076/MM14/YG/01/HG/CXMZIFTUM 250 Alkem LaboratoriesIndia 99.23 92.98 93.99 95.60 94.19 96.21 95.37 2.22 2.33 Pass
51 B-079 B-079/MM14/YG/01/O(c)/CXMZIFTUM 250 Alkem LaboratoriesIndia 93.39 93.99 90.36 91.57 92.98 95.47 92.96 1.80 1.94 Pass
52 B-080 B-080/MM14/YG/01/O(c)/CXMZinnat GlaxoSmithKl ine UK 91.37 89.76 83.10 91.77 86.33 90.97 88.88 3.45 3.88 Pass
53 B-086 B-086/MM14/YG/03/C/CXMZinnat GlaxoSmithKl ine UK 77.26 88.61 85.19 80.88 82.50 81.15 82.60 3.91 4.73 Pass
54 B-089 B-089/MM14/YG/04/W/CXMZinnat GlaxoSmithKl ine UK 77.66 89.89 75.64 81.69 73.02 78.67 79.43 5.89 7.42 Pass
55 B-093 B-093/MM14/YG/01/C/CXMRUFEX Global  Pharma Healthcare Pvt, Ltd.,India 65.56 64.75 87.54 85.12 81.49 89.76 79.04 11.10 14.04 Fai l Pass
56 B-100 B-100/MM14/YG/04/C/CXMZIFTUM 250 Alkem LaboratoriesIndia 100.04 98.43 100.04 98.83 96.41 102.06 99.30 1.90 1.91 Pass
57 B-101 B-101/MM14/YG/05/C/CXMZinnat GlaxoSmithKl ine UK 89.15 85.52 92.51 88.35 89.15 91.17 89.31 2.41 2.70 Pass
58 B-102 B-102/MM14/YG/02/C/CXMZinnat GlaxoSmithKl ine UK 83.91 89.62 87.81 88.28 95.60 91.37 89.43 3.91 4.37 Pass
59 B-104 B104/MM14/YG/01/HG/CXMZIFTUM 250 Alkem LaboratoriesIndia 94.80 98.23 90.36 93.99 96.01 92.18 94.26 2.78 2.95 Pass
60 B-111 B111/MM14/YG/02/C/CXMRUFEX-250 Global  Pharma Healthcare Pvt, Ltd.,India 76.91 67.63 74.18 89.13 89.13 85.99 80.50 8.92 11.08 Pass
1 PA-001 PA001/MM14/YG/01/C/CXMZIFTUM 250 Alkem Laboratories  LtdIndia 158.05 134.52 153.14 152.94 136.54 146.22 146.90 9.60 6.53 Pass
2 PA-002 PA002/MM14/YG/01/C/CXMSPIZEF Orchid HEALTHCARE India 73.83 98.97 100.24 97.22 85.79 83.04 89.85 10.63 11.83 Pass
31 PB-001 PB-001/MM14/YG/01/O(c)/CXMZINNASAV-250 SAVIOUR PHARMACEUTICALSIndia 75.96 82.78 83.19 85.86 82.58 81.35 81.95 3.29 4.02 Pass
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104.92 104.54 100.00 102.70 95.88 99.40 94.86 105.87 101.22 96.94 100.6 3.9 3.9 9.372893126 Pass
104.21 103.39 98.63 97.51 93.65 103.10 106.08 98.50 95.83 102.27 100.3 4.1 4.0 9.731768808 Pass
102.27 103.86 100.48 102.58 98.18 97.12 100.36 100.98 97.48 92.73 99.6 3.3 3.3 7.89 Pass
92.41 93.57 91.85 95.51 95.75 90.01 89.77 84.34 88.41 101.55 92.3 4.7 5.1 17.48 Fai l Pass
84.42 99.25 100.84 85.26 90.85 90.97 97.08 91.92 93.14 92.91 92.7 5.4 5.8 18.72 Fai l Fa i l
85.61 97.53 104.85 104.61 90.77 107.86 98.31 94.87 97.54 98.02 98.0 6.7 6.8 16.58 Fai l Pass
99.58 97.87 93.20 95.87 93.71 103.43 100.62 95.39 98.09 95.14 97.3 3.2 3.3 9.00 Pass
94.08 101.01 89.89 94.86 93.99 95.64 99.03 101.53 94.92 92.86 95.8 3.7 3.8 11.55 Pass
92.98 91.66 89.14 90.87 92.74 88.74 88.45 86.30 82.74 82.84 88.6 3.7 4.2 18.76 Fai l Fa i l
104.08 102.32 92.47 95.41 111.73 93.88 93.39 101.14 92.26 94.69 98.1 6.4 6.6 15.45 Fai l Pass
91.27 93.27 96.13 88.28 98.09 91.63 91.59 94.10 87.74 79.11 91.1 5.3 5.8 20.06 Fai l Fa i l
95.65 100.96 82.79 86.92 84.50 92.64 87.53 87.83 84.09 83.79 88.7 5.9 6.7 24.08 Fai l Fa i l
92.28 99.85 94.71 96.54 95.82 98.57 99.74 103.67 107.73 105.66 99.5 5.0 5.0 11.90 Pass
101.48 100.22 91.88 103.28 95.38 105.52 97.11 98.08 92.65 95.07 98.1 4.5 4.6 11.28 Pass
87.87 87.87 87.65 82.96 87.90 82.50 85.36 79.08 77.86 80.46 84.0 3.9 4.7 23.95 Fai l Fa i l
95.38 104.18 100.01 98.10 103.39 99.45 93.58 100.25 90.67 91.76 97.7 4.7 4.8 12.04 Pass
99.58 95.59 96.90 102.68 100.60 103.08 94.12 99.93 98.40 95.48 98.6 3.1 3.1 7.38 Pass
85.13 80.97 74.62 ― ― ― ― ― ― ― 80.2 ― ― ― ―
107.29 97.04 100.25 99.21 101.42 104.80 95.76 99.53 94.60 89.71 99.0 5.1 5.1 12.13 Pass
105.17 99.99 101.85 103.65 98.37 100.92 98.68 93.11 93.86 98.67 99.4 3.8 3.9 9.21 Pass
86.23 86.08 82.00 86.17 84.76 88.14 83.31 89.02 81.19 82.07 84.9 2.7 3.2 20.05 Fai l Fa i l
98.68 88.40 99.10 101.87 98.65 93.01 98.22 95.66 96.45 97.29 96.7 3.7 3.9 10.77 Pass
94.85 92.47 90.91 95.96 99.71 94.09 96.69 97.74 93.76 94.46 95.1 2.6 2.7 9.60 Pass
97.95 97.60 93.43 92.10 101.08 87.19 96.73 96.72 93.55 94.45 95.1 3.8 4.0 12.63 Pass
89.41 99.51 95.97 94.42 103.65 96.10 90.11 97.75 94.44 90.99 95.2 4.4 4.6 13.88 Pass
79.62 80.37 82.34 80.60 76.43 78.62 81.50 79.29 78.70 75.53 79.3 2.1 2.7 24.28 Fai l Fa i l
98.44 99.04 95.46 93.58 98.00 95.74 100.25 97.12 98.56 87.30 96.3 3.7 3.9 11.12 Pass
103.02 98.07 99.18 103.84 101.83 103.11 94.54 97.96 102.81 97.01 100.1 3.2 3.2 7.67 Pass
96.55 104.47 106.58 100.60 100.41 102.25 90.34 103.61 96.69 99.31 100.1 4.7 4.7 11.27 Pass
94.9 96.3 96.4 94.2 99.8 100.9 95.0 95.7 91.2 103.1 96.7 3.5 3.6 10.22 Pass
98.99 100.25 99.81 95.66 94.94 97.36 89.83 90.59 94.11 93.58 95.5 3.6 3.8 11.71 Pass
86.47 88.94 86.99 95.59 93.94 92.55 73.24 90.08 89.30 82.01 87.9 6.5 7.4 26.13 Fai l Fa i l
96.26 93.06 95.03 91.98 95.18 90.38 93.66 86.06 98.76 92.34 93.3 3.5 3.7 13.57 Pass
98.08 99.17 97.64 88.44 89.52 93.13 83.94 84.61 78.65 95.15 90.8 6.9 7.6 24.34 Fai l Fa i l
97.84 98.27 109.33 101.97 98.36 104.72 97.52 111.74 108.12 93.15 102.1 6.1 6.0 15.27 Pass
96.67 101.02 94.08 96.38 93.86 95.06 93.75 96.25 96.24 97.52 96.1 2.2 2.3 7.63 Pass
101.07 100.73 104.94 106.81 101.49 97.11 102.96 106.33 102.82 102.79 102.7 2.9 2.8 8.11 Pass
105.30 92.74 104.55 105.08 97.92 98.05 98.24 100.54 98.83 98.10 99.9 4.0 4.0 9.59 Pass
83.66 84.52 86.32 91.22 84.44 85.86 91.58 84.65 93.10 80.82 86.6 4.0 4.6 21.48 Fai l Fa i l
102.47 102.35 102.44 104.48 103.97 103.72 102.78 98.97 97.20 96.30 101.5 2.9 2.9 6.98 Pass
71.12 69.88 88.62 76.65 74.10 77.86 88.15 85.61 73.36 74.00 77.9 7.0 9.0 37.37 Fai l Fa i l
91.71 97.36 88.44 93.86 88.52 96.88 92.86 90.31 92.94 92.51 92.5 3.0 3.3 13.24 Pass
104.46 85.18 85.58 83.73 90.96 104.88 89.09 90.42 102.98 103.08 94.0 8.8 9.3 25.50 Fai l Fa i l
98.72 91.94 97.51 92.91 97.18 91.92 109.19 92.38 98.29 102.77 97.3 5.5 5.7 14.50 Pass
97.47 99.41 97.77 99.32 92.59 92.40 94.94 95.56 96.13 101.41 96.7 2.9 3.0 8.88 Pass
97.63 100.15 107.00 101.46 107.64 106.13 101.37 101.88 100.85 101.86 102.6 3.2 3.2 8.89 Pass
97.22 96.14 92.13 89.04 90.90 91.00 95.82 93.73 84.56 92.74 92.3 3.8 4.1 15.21 Pass
101.08 94.44 98.21 99.11 103.97 102.67 97.27 97.77 97.49 97.75 99.0 2.8 2.9 6.80 Pass
97.64 99.42 97.71 100.36 97.58 96.02 98.42 96.52 96.50 96.74 97.7 1.4 1.4 4.12 Pass
92.29 98.58 98.56 91.81 102.01 90.37 90.05 93.33 92.23 94.00 94.3 4.0 4.3 13.81 Pass
109.93 105.57 104.26 115.00 103.68 107.96 107.55 110.73 101.57 102.22 106.8 4.2 4.0 15.48 Pass
88.76 91.12 80.84 80.41 75.56 87.75 83.93 82.01 89.50 86.58 84.6 4.9 5.8 25.68 Fai l Fa i l
93.01 94.13 107.34 91.54 94.24 102.22 93.05 92.89 89.85 90.01 94.8 5.6 5.9 17.08 Fai l Pass
101.68 103.63 103.61 99.44 102.50 115.40 101.56 97.35 95.65 98.59 101.9 5.4 5.3 13.47 Pass
94.09 96.03 98.31 97.15 93.26 92.67 95.69 99.97 95.30 96.11 95.9 2.2 2.3 8.01 Pass
99.74 105.46 105.23 100.22 101.84 95.14 97.11 101.63 90.14 102.08 99.9 4.7 4.7 11.22 Pass
77.76 80.96 83.08 77.55 76.53 76.92 78.97 79.20 74.70 77.48 78.3 2.4 3.0 25.88 Fai l Fa i l
93.01 94.13 101.56 91.54 94.24 102.22 93.05 92.89 89.85 90.01 94.3 4.3 4.6 14.57 Pass
103.65 100.90 102.00 99.25 97.83 96.97 102.27 102.52 93.13 99.91 99.8 3.2 3.2 7.64 Pass
88.20 90.25 93.58 92.14 90.62 79.25 94.40 95.94 85.54 88.40 89.83 4.87 5.42 20.36 Fai l Fa i l
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OM Dissolution test BP: 1st stage acid resistance stage 
 
































27 A-096 A096/MM14/YG/03/W/OMOmep-20 ARISTOPHARMA LTD. Bangladesh 22.3 10.4 8.9 11.6 9.6 10.2 12.2 5.0 41.4 Fai l Fa i l
189 B-065 B-065/MM14/YG/01/O(c)/OMOmep ARISTOPHARMA LTD. Bangladesh 11.1 11.3 10.9 11.0 11.2 10.9 11.1 0.2 1.7 Fai l Pass
23 A-076 A076/MM14/YG/01/C/OMASM ZOL-20 ASMOH LABORATORIES LTD. India 1.4 1.4 1.4 1.4 1.4 1.4 1.4 0.0 0.0 Pass
215 B-092 B-092/MM14/YG/01/C/OMOMEPREN BLUE CROSS LABORATORIES LTD. India 2.5 2.4 1.8 1.1 1.2 1.2 1.7 0.6 36.5 Pass
221 B-098 B-098/MM14/YG/01/HG/OMOMEPREN BLUE CROSS LABORATORIES LTD. India 2.4 2.3 2.5 2.4 2.2 2.4 2.3 0.1 4.6 Pass
129 B-005 B-005/MM14/YG/01/HP/OMOCID Cadi la  Health Limited India 6.0 3.6 3.6 3.9 5.8 4.1 4.5 1.1 24.6 Pass
135 B-011 B-011/MM14/YG/03/C/OMOCID Cadi la  Health Limited India 5.3 4.0 7.2 4.4 7.2 5.4 5.6 1.4 24.2 Pass
194 B-070 B-070/MM14/YG/01/C/OMOCID Cadi la  Health Limited India 3.7 3.9 3.8 2.5 3.1 2.5 3.3 0.6 19.7 Pass
213 B-090 B-090/MM14/YG/04/W/OMOCID Cadi la  Health Limited India 2.2 1.9 1.9 2.0 2.0 2.0 2.0 0.1 6.4 Pass
3 PA-006 PA006/MM14/YG/01/C/OMOCID Cadi la  Healthcare Limited India 5.4 4.0 7.2 4.4 7.2 5.5 5.6 1.4 24.2 Pass
5 A-002 A002/MM14/YG/01/HG/OMOCID Cadi la  Healthcare Limited India 3.0 2.7 2.6 2.6 2.5 4.0 2.9 0.6 19.1 Pass
10 A-026 A026/MM14/YG/04/C/OMOCID Cadi la  Healthcare Limited India 9.6 3.6 3.6 3.9 5.8 4.1 5.1 2.3 46.0 Pass
16 A-042 A042/MM14/YG/03/C/OMOCID Cadi la  Healthcare Limited India 5.6 5.0 3.6 3.8 5.0 5.4 4.7 0.8 17.2 Pass
18 A-060 A060/MM14/YG/01/HP/OMOCID Cadi la  Healthcare Limited India 2.4 2.5 4.4 2.9 2.9 2.6 2.9 0.7 24.9 Pass
25 A-084 A084/MM14/YG/02/HP/OMOCID Cadi la  Healthcare Limited India 9.9 9.5 7.3 9.6 9.7 10.0 9.3 1.0 10.8 Pass
12 A-034 A034/MM14/YG/01/Ocl/OMLOMAC-20 Cipla  Ltd. India 26.9 27.7 27.7 27.3 28.1 23.5 26.9 1.7 6.3 Fai l Fa i l
13 A-038 A038/MM14/YG/01/C/OMLOMAC-20 Cipla  Ltd. India 12.5 11.6 12.6 13.0 14.1 15.1 13.1 1.2 9.5 Fai l Fa i l
131 B-007 B-007/MM14/YG/01/HP/OMLOMAC Cipla  Ltd. India 39.9 38.1 42.5 40.3 39.5 42.3 40.4 1.7 4.2 Fai l Fa i l
233 B-110 B110/MM14/YG/01/C/OMLOMAC Cipla  Ltd. India 24.4 25.4 25.1 24.7 25.4 21.1 24.4 1.7 6.8 Fai l Fa i l
124 PB-003 PB-003/MM14/YG/01/O(c)/OMOMEZ Dr. REDDY'S LABORATORIES India 9.0 8.9 8.9 5.7 3.4 5.1 6.8 2.4 35.4 Pass
130 B-006 B-006/MM14/YG/01/HP/OMOMEZ Dr. REDDY'S LABORATORIES India 5.8 2.9 5.3 9.1 8.8 8.7 6.8 2.5 37.1 Pass
132 B-008 B-008/MM14/YG/01/HP/OMOMEZ Dr. REDDY'S LABORATORIES India 14.4 13.3 14.5 14.4 8.4 11.0 12.7 2.5 19.6 Fai l Fa i l
137 B-013 B-013/MM14/YG/03/C/OMOMEZ Dr. REDDY'S LABORATORIES India 16.5 15.9 8.5 15.0 10.6 15.9 13.7 3.4 24.4 Fai l Fa i l
160 B-036 B-036/MM14/YG/01/HP/OMOMEZ Dr. REDDY'S LABORATORIES India 8.8 7.6 1.0 1.2 0.9 8.0 4.6 3.9 85.4 Pass
178 B-054 B-054/MM14/YG/01/HP/OMOMEZ Dr. REDDY'S LABORATORIES India 22.8 26.4 28.2 24.0 25.3 27.4 25.7 2.1 8.0 Fai l Fa i l
229 B-106 B106/MM14/YG/01/HG/OMOMEZ Dr. REDDY'S LABORATORIES India 12.4 7.6 14.8 20.7 19.3 20.7 15.9 5.3 33.1 Fai l Fa i l
2 PA-005 PA005/MM14/YG/01/C/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 26.9 9.3 15.9 26.6 9.3 15.7 17.3 7.9 45.6 Fai l Fa i l
4 A-001 A001/MM14/YG/01/HG/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 9.8 5.9 7.5 9.3 6.9 7.4 7.8 1.5 19.1 Pass
8 A-015 A015/MM14/YG/01/HG/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 14.3 9.3 16.8 15.2 15.9 9.7 13.5 3.2 23.9 Fai l Fa i l
14 A-039 A039/MM14/YG/01/C/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 9.5 8.5 14.7 14.6 13.1 14.5 12.5 2.8 22.1 Fai l Fa i l
17 A-050 A050/MM14/YG/01/HG/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 10.5 9.2 20.2 17.3 17.9 24.3 16.6 5.8 34.9 Fai l Fa i l
19 A-061 A061/MM14/YG/01/HP/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 9.9 9.5 9.5 9.1 9.9 9.9 9.6 0.3 3.5 Pass
20 A-065 A065/MM14/YG/01/Ocl/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 9.2 9.2 9.1 9.8 7.0 7.4 8.6 1.1 13.3 Pass
29 A-101 A101/MM14/YG/01/HG/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 8.9 12.5 9.4 14.3 11.1 14.1 11.7 2.3 19.8 Fai l Pass
30 A-106 A106/MM14/YG/02/HP/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 1.9 1.9 1.9 1.9 1.9 1.9 1.9 0.0 0.0 Pass
31 A-107 A107/MM14/YG/01/C/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 4.8 4.7 4.6 4.5 4.6 4.4 4.6 0.1 3.3 Pass
33 A-114 A114/MM14/YG/01/C/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 1.9 1.9 1.9 1.9 1.9 1.9 1.9 0.0 0.0 Pass
7 A-012 A012/MM14/YG/01/HG/OMZosec Emcure PHARMACETICALS LTD. India 7.2 5.7 5.0 7.1 5.8 5.0 6.0 1.0 16.2 Pass
141 B-017 B-017/MM14/YG/04/C/OMZosec Emcure PHARMACEUTICAL LTD. India 2.6 2.4 1.8 1.3 1.2 1.0 1.7 0.6 37.4 Pass
161 B-037 B-037/MM14/YG/01/HP/OMOMFIL Fourrts  Laboratories  Pvt Ltd, India 3.5 7.1 5.1 4.2 6.8 5.0 5.3 1.4 26.7 Pass
11 A-033 A033/MM14/YG/01/Ocl/OMOMFIL 20 Fourrts  Laboratories  Pvt.Ltd. India 8.3 8.4 8.3 8.6 8.9 8.7 8.5 0.3 3.0 Pass
169 B-045 B-045/MM14/YG/01/C/OMOMPREZ Global  Pharma Healthcare Pvt, Ltd.,India 2.6 3.0 4.4 2.5 2.8 4.4 3.3 0.9 26.6 Pass
15 A-041 A041/MM14/YG/03/C/OMTRISEC GREAT HIMALAYAN PTE LTD. India 12.0 25.0 11.5 11.8 24.9 11.6 16.1 6.8 42.4 Fai l Fa i l
201 B-077 B-077/MM14/YG/01/HG/OMOmetab Intas  Pharmaceutica l  Ltd. India 1.4 1.4 1.4 1.4 1.4 1.4 1.4 0.0 0.0 Pass
231 B-108 B108/MM14/YG/02/HG/OMOmetab Intas  Pharmaceutica l  Ltd. India 3.5 7.2 4.9 4.2 6.9 4.9 5.3 1.5 28.3 Pass
123 PB-002 PB-002/MM14/YG/01/O(c)/OMOme-M Rainbow Li fe Sciences  Pvt. Ltd. India 11.0 18.1 11.0 17.7 18.2 11.2 14.5 3.8 26.1 Fai l Fa i l
24 A-078 A078/MM14/YG/02/C/OMReloc-20 Rhydburg Pharmaceutica ls  Ltd. India 23.0 34.4 17.1 23.3 33.1 16.6 24.6 7.6 31.1 Fai l Fa i l
6 A-011 A011/MM14/YG/01/HG/OMOmesec The United Drug (1996) Co,Ltd. Thai land 2.7 2.6 3.1 2.7 2.9 3.0 2.8 0.2 7.0 Pass
26 A-091 A091/MM14/YG/02/W/OMOmesec The United Drug (1996) Co,Ltd. Thai land 2.7 3.2 4.7 4.7 2.8 3.3 3.6 0.9 24.7 Pass
183 B-059 B-059/MM14/YG/01/HP/OMOmesec The United Drug(1996) Co., Ltd Thai land 2.3 2.2 2.7 2.3 2.5 2.6 2.4 0.2 8.2 Pass
28 A-097 A097/MM14/YG/03/W/OMOmesafe UNIVERSAL PHARMACEUTICALS LIMITEDIndia 2.8 2.7 6.7 2.6 2.7 3.6 3.5 1.6 46.1 Pass
173 B-049 B-049/MM14/YG/01/C/OMVirom Virchow Healthcare Drivate Limited.India 2.3 2.5 2.7 0.9 0.9 0.9 1.7 0.9 54.1 Pass
139 B-015 B-015/MM14/YG/04/C/OMHYCID XL LABORATORIES PVT. LTD. India 17.9 17.2 17.7 18.0 17.5 17.7 17.7 0.3 1.7 Fai l Fa i l
22 A-067 A067/MM14/YG/01/C/OMHY ID XL LABORATORIES PVT.LTD. India 3.3 9.0 9.0 8.0 5.1 9.1 7.3 2.5 33.8 Pass
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Disso New  
Final  
Judge
51.3 79.2 76.0 65.2 77.9 70.0 70.0 10.5 15.1 Fai l Fa i l Pass Fa i l
56.0 52.7 47.6 56.4 54.1 48.6 52.6 3.7 7.1 Fai l Fa i l Fa i l Fa i l
82.7 94.3 95.4 96.0 95.4 96.1 93.3 5.2 5.6 Pass Pass
92.8 95.2 98.8 97.5 97.3 94.7 96.0 2.2 2.3 Pass Pass
81.6 92.7 89.7 83.0 93.3 91.8 88.7 5.1 5.8 Pass Pass
96.0 92.6 95.2 91.6 94.0 95.8 94.2 1.8 1.9 Pass Pass
96.6 97.9 98.3 66.4 98.5 97.3 92.5 12.8 13.9 Pass Pass
82.7 94.3 93.5 94.2 95.4 95.7 92.7 4.9 5.3 Pass Pass
77.0 79.8 80.1 81.4 80.1 77.2 79.3 1.8 2.2 Pass Pass
83.1 84.9 82.2 82.7 83.6 82.1 83.1 1.0 1.2 Pass pass
96.9 99.5 98.2 96.1 96.4 98.4 97.6 1.3 1.4 Pass pass
86.9 72.9 75.2 76.9 75.4 86.8 79.0 6.2 7.9 Pass Pass
97.9 95.6 97.7 95.1 96.2 95.7 96.4 1.2 1.2 Pass Pass
99.3 98.1 98.6 95.4 99.0 98.0 98.1 1.4 1.4 Pass Pass
77.0 79.8 80.1 94.3 94.4 95.4 86.8 8.7 10.0 Pass Pass
52.1 53.8 47.6 51.8 50.9 48.5 50.8 2.3 4.6 Fai l Fa i l Fa i l Fa i l
85.4 84.1 83.3 81.7 85.2 83.6 83.9 1.3 1.6 Pass Fai l Fa i l
49.5 49.7 63.4 55.7 50.7 50.7 53.3 5.5 10.2 Fai l Fa i l Fa i l Fa i l
53.6 62.8 62.1 52.8 53.4 62.6 57.9 5.1 8.8 Fai l Fa i l Pass Fa i l
30.7 34.4 26.5 54.9 71.2 57.6 45.9 17.9 39.0 Fai l Fa i l Fa i l Fa i l
54.7 72.7 57.1 31.1 34.2 27.9 46.3 17.9 38.7 Fai l Fa i l Fa i l Fa i l
70.3 67.7 73.1 72.3 77.4 74.8 72.6 3.4 4.7 Fai l Fa i l Pass Fa i l
50.2 47.5 80.7 58.6 68.2 56.9 60.4 12.3 20.4 Fai l Fa i l Pass Fa i l
78.3 70.7 78.4 69.3 68.3 66.6 71.9 5.1 7.1 Fai l Fa i l Pass Fa i l
31.4 32.1 35.5 31.8 73.9 73.2 46.3 21.2 45.7 Fai l Fa i l Fa i l Fa i l
49.7 47.1 79.3 48.8 77.9 77.0 63.3 16.2 25.6 Fai l Fa i l Pass Fa i l
60.1 65.2 61.7 60.1 65.1 61.7 62.3 2.3 3.7 Fai l Fa i l Pass Fa i l
73.8 79.3 71.4 72.4 71.1 70.8 73.1 3.9 5.4 Pass pass
56.6 70.7 55.2 54.5 48.1 74.7 60.0 10.4 17.3 Fai l Fa i l Pass Fa i l
73.9 77.7 62.1 75.0 60.7 60.8 68.4 8.0 11.6 Fai l Fa i l Pass Fa i l
75.3 75.8 60.7 73.7 63.2 74.1 70.5 6.7 9.5 Fai l Fa i l Pass Fa i l
76.8 68.0 70.6 76.9 71.1 76.5 73.3 3.9 5.3 Fai l Fa i l Pass Pass
72.5 72.1 67.3 67.6 73.4 72.5 70.9 2.7 3.8 Fai l Fa i l Pass Pass
77.6 69.5 77.7 55.7 66.9 53.7 66.9 10.4 15.5 Fai l Fa i l Pass Pass
69.0 73.1 66.6 71.7 67.5 72.5 70.1 2.8 3.9 Fai l Fa i l Pass Pass
18.3 19.5 17.9 18.5 18.9 18.3 18.6 0.6 3.0 Fai l Fa i l Fa i l Fa i l
69.4 67.9 75.2 67.4 67.6 72.5 70.0 3.2 4.5 Fai l Fa i l Pass Pass
80.0 74.7 91.1 80.0 76.4 90.3 82.1 7.0 8.5 Pass pass
99.6 98.6 98.8 97.7 97.4 94.6 97.8 1.8 1.8 Pass Pass
92.2 86.9 87.1 91.1 88.9 92.9 89.9 2.6 2.9 Pass Pass
67.6 81.2 79.8 80.6 68.5 68.2 74.3 6.8 9.2 Fai l Fa i l Pass Pass
71.7 94.3 86.6 73.1 93.9 86.8 84.4 9.9 11.7 Pass Pass
59.7 98.8 61.0 59.7 98.7 61.4 73.2 19.8 27.1 Fai l Fa i l Pass Fa i l
87.1 86.9 87.2 86.4 88.0 87.9 87.2 0.6 0.7 Pass Pass
92.2 87.5 87.3 91.2 88.4 92.3 89.8 2.3 2.6 Pass Pass
51.5 60.6 59.9 50.7 51.3 60.4 55.7 5.0 9.0 Fai l Fa i l Fa i l Fa i l
49.4 43.5 50.8 49.9 44.1 50.9 48.1 3.4 7.1 Fai l Fa i l Fa i l Fa i l
93.5 91.0 92.9 89.3 92.8 94.3 92.3 1.8 2.0 Pass pass
89.9 93.5 95.8 99.9 95.9 98.2 95.5 3.5 3.7 Pass Pass
93.9 97.7 99.8 93.3 93.4 91.2 94.9 3.2 3.4 Pass Pass
94.6 95.2 78.9 96.5 80.6 82.9 88.1 8.1 9.2 Pass Pass
66.4 85.3 84.9 65.6 83.7 66.3 75.4 10.2 13.5 Fai l Fa i l Pass Fa i l
39.7 38.5 42.8 39.8 38.9 42.6 40.4 1.9 4.6 Fai l Fa i l Fa i l Fa i l
82.2 71.8 73.5 86.2 70.2 76.3 76.7 6.3 8.2 Pass Pass
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10.2 8.7 3.0 8.9 8.7 10.5 10.3 4.4 42.4 Pass
7.8 8.3 6.8 7.7 6.8 9.5 9.4 1.8 19.4 Pass
33.7 31.6 34.5 34.8 35.5 39.3 24.0 11.5 47.9 Fai l Fa i l
25.0 25.8 22.1 26.5 27.9 32.4 25.5 2.8 11.1 Fai l Fa i l
7.0 6.5 8.8 4.3 6.9 8.4 9.8 3.6 36.4 Pass
3.8 6.8 3.9 5.1 3.6 4.6 9.2 5.3 58.0 Pass
8.8 10.7 9.1 10.0 8.2 12.8 7.3 4.0 55.2 Pass
12.0 16.3 11.1 12.1 14.2 11.2 14.4 4.1 28.8 Fai l Fa i l
4.4 3.9 4.0 5.7 18.3 6.8 10.4 5.4 52.6 Pass
1.3 5.6 6.8 4.1 4.5 3.8 8.4 4.8 57.0 Pass
3.7 4.3 6.6 3.8 3.3 5.1 10.5 7.5 71.0 Fai l Pass
15.6 11.1 11.7 13.1 11.7 12.7 14.4 5.1 35.2 Fai l Fa i l
11.6 3.0 13.5 12.7 11.0 12.3 12.6 4.2 33.0 Fai l Fa i l









































63.5 71.2 102.5 64.7 76.4 46.9 70.4 14.3 20.3 Pass Pass
71.2 64.9 74.5 64.9 73.3 61.8 60.5 9.4 15.5 Fai l Fa i l Pass Pass
37.1 49.6 41.5 37.8 49.6 40.3 63.2 21.9 34.6 Fai l Fa i l Pass Fa i l
35.2 34.1 32.5 34.1 35.7 37.1 46.3 12.6 27.2 Fai l Fa i l Fa i l Fa i l
63.3 52.7 60.6 51.7 42.5 50.0 63.0 11.4 18.2 Fai l Fa i l Pass Pass
65.6 54.7 62.1 63.1 63.3 64.9 61.3 8.8 14.3 Fai l Fa i l Pass Pass
74.9 64.9 61.2 65.5 62.3 75.3 69.6 5.9 8.5 Pass Pass
34.0 27.7 31.1 32.4 28.6 26.2 46.6 20.7 44.3 Fai l Fa i l Fa i l Fa i l
58.8 81.4 72.6 67.6 73.9 64.5 64.9 10.2 15.7 Pass Pass
80.5 74.6 75.1 60.4 64.0 67.9 69.4 7.5 10.8 Pass Pass
67.2 52.1 62.3 79.2 65.7 76.5 68.8 8.2 12.0 Pass Fai l Pass
38.4 71.2 56.3 41.9 38.2 69.0 62.9 15.2 24.1 Fai l Fa i l Pass Pass
60.6 41.1 48.6 52.5 64.5 50.4 61.9 11.1 18.0 Fai l Fa i l Pass Pass
69.8 61.6 66.0 53.7 60.9 68.5 65.1 8.3 12.7 Pass Pass
39.2 67.8 56.7 43.5 41.6 69.6 61.6 12.9 20.9 Fai l Fa i l Pass Pass
53.0 69.8 66.7 60.4 61.1 66.8 66.5 5.9 8.9 Pass Pass
61.7 78.7 77.4 71.1 81.4 81.0 74.8 6.9 9.2 Pass Pass
24.3 18.1 29.6 19.4 22.9 18.6 47.7 30.0 62.9 Fai l Fa i l Fa i l Fa i l
61.8 90.6 60.5 64.9 57.5 53.4 60.2 10.7 17.7 Fai l Fa i l Pass Fa i l
65.6 72.1 81.4 78.6 78.2 80.4 75.7 8.0 10.5 Pass Pass
147 
 





















































98.4 103.4 96.8 103.9 100.1 99.0 94.2 99.7 98.1 95.7 98.9 3.1 3.1 7.4 Pass 98.9 Pass
90.5 91.9 91.6 95.1 95.2 96.6 91.0 90.8 91.1 96.5 93.0 2.5 2.7 11.5 Pass 93.0 Fai l Pass
88.2 87.8 86.7 97.1 83.7 84.2 88.3 93.3 85.2 105.7 90.0 6.9 7.6 25.0 Fai l Fa i l  90.0 Fai l Pass
99.9 103.1 98.4 102.9 105.9 94.3 102.8 101.5 98.1 103.8 101.1 3.4 3.4 8.2 Pass 101.1 Pass
97.5 95.4 81.2 90.8 100.2 98.4 100.1 94.5 93.9 101.2 95.3 6.0 6.2 17.5 Fai l Pass 95.3 Pass
99.1 108.0 100.1 99.8 99.6 106.5 103.0 100.4 104.1 107.9 102.9 3.6 3.5 7.2 Pass 102.9 Pass
102.7 102.6 105.7 101.5 96.8 106.0 106.1 105.5 101.0 106.7 103.5 3.1 3.0 5.6 Pass 103.5 Pass
95.9 94.0 97.5 91.8 91.4 90.8 99.0 100.9 96.1 104.8 96.2 4.5 4.7 13.0 Pass 96.2 Pass
97.1 94.1 95.2 100.0 99.5 100.9 92.6 105.0 97.8 102.7 98.5 3.9 4.0 9.4 Pass 98.5 Pass
107.7 105.9 104.9 101.8 99.9 104.6 103.2 104.3 107.8 105.1 104.5 2.4 2.3 2.8 Pass 104.5 Pass
101.6 106.5 107.0 106.7 106.5 105.2 106.5 104.5 109.7 109.8 106.4 2.4 2.2 0.8 Pass 106.4 Fai l Pass
101.4 106.5 106.8 106.7 106.5 105.1 107.9 107.4 109.2 109.7 106.7 2.3 2.2 0.3 Pass 106.7 Fai l Pass
99.5 107.6 104.4 106.9 104.4 109.8 107.9 109.4 108.3 105.4 106.4 3.1 2.9 2.5 Pass 106.4 Fai l Pass
99.6 108.0 99.8 98.9 106.3 105.3 104.0 99.5 100.2 102.9 102.4 3.3 3.2 7.0 Pass 102.4 Pass
99.8 107.9 104.5 107.2 104.5 109.8 107.8 109.6 108.4 105.8 106.5 3.0 2.8 2.2 Pass 106.5 Fai l Pass
91.1 91.6 92.7 97.9 99.0 97.1 94.9 96.7 93.7 93.8 94.9 2.7 2.9 10.2 Pass 94.9 Pass
89.8 92.1 89.0 88.8 90.8 93.0 92.2 93.5 90.0 84.7 90.4 2.6 2.9 14.3 Pass 90.4 Fai l Pass
89.8 92.1 89.1 88.9 91.0 93.0 92.3 93.5 89.9 84.8 90.4 2.6 2.9 14.2 Pass 90.4 Fai l Pass
87.9 89.2 89.3 87.9 90.6 87.9 88.6 85.5 91.0 93.8 89.2 2.2 2.5 5.4 Pass 89.2 Fai l Pass
92.1 96.0 90.3 91.2 92.0 95.0 94.2 93.6 95.9 96.5 93.7 2.2 2.3 10.1 Pass 93.7 Fai l Pass
96.4 94.7 95.8 91.6 97.6 92.5 97.6 96.6 98.5 98.0 95.9 2.3 2.4 8.2 Pass 95.9 Pass
102.0 95.8 110.0 107.2 107.8 108.5 106.7 98.2 105.6 105.3 104.7 4.6 4.4 7.9 Pass 104.7 Pass
90.7 95.5 93.6 91.0 99.3 90.8 96.0 91.3 98.0 91.7 93.8 3.2 3.4 12.4 Pass 93.8 Fai l Pass
96.2 97.8 99.7 95.8 98.9 94.6 93.0 93.6 98.6 90.6 95.9 2.9 3.1 9.7 Pass 95.9 Pass
93.5 94.2 102.0 93.3 96.1 93.1 98.5 100.9 92.9 93.8 95.8 3.4 3.6 10.9 Pass 95.8 Pass
98.9 93.0 95.9 96.4 100.3 99.5 92.0 96.3 100.5 103.6 97.6 3.6 3.7 9.5 Pass 97.6 Pass
96.3 101.6 92.5 98.5 99.4 96.6 97.9 96.6 100.0 98.2 97.8 2.5 2.5 6.7 Pass 97.8 Pass
101.2 94.0 105.6 98.6 101.9 98.5 95.0 95.6 102.6 102.7 99.6 3.8 3.9 8.2 Pass 99.6 Pass
90.0 90.9 92.3 92.2 95.9 95.4 92.5 94.4 93.4 92.2 92.9 1.9 2.0 10.1 Pass 92.9 Fai l Pass
93.2 98.1 96.6 99.7 95.5 94.3 97.0 97.2 96.9 101.7 97.0 2.5 2.5 7.4 Pass 97.0 Pass
90.1 95.5 92.5 95.0 96.7 103.7 98.3 90.8 95.4 97.0 95.5 3.9 4.1 12.4 Pass 95.5 Pass
92.1 102.4 99.3 96.7 92.8 98.1 95.1 100.4 98.0 98.5 97.3 3.3 3.4 9.0 Pass 97.3 Pass
92.3 94.7 98.9 100.1 99.6 95.7 93.9 95.3 92.7 97.2 96.0 2.8 2.9 9.1 Pass 96.0 Pass
95.2 90.3 96.8 103.7 95.0 92.6 98.2 90.7 95.9 97.1 95.5 3.9 4.1 12.4 Pass 95.5 Pass
92.5 92.6 96.1 92.2 92.3 90.0 91.1 93.6 94.5 95.4 93.0 1.9 2.0 10.0 Pass 93.0 Fai l Pass
94.8 92.6 97.8 98.2 97.0 92.0 98.3 96.7 99.3 96.0 96.3 2.5 2.6 8.2 Pass 96.3 Pass
97.1 93.7 96.7 97.7 94.0 93.4 94.0 96.9 91.6 93.9 94.9 2.0 2.1 8.5 Pass 94.9 Pass
56.5 47.1 95.7 99.2 77.9 47.6 83.0 72.5 85.2 99.6 76.4 20.1 26.4 70.4 Fai l Fa i l  76.4 Fai l Pass
89.0 91.5 96.7 95.8 98.8 100.1 88.1 90.3 93.3 92.7 93.6 4.1 4.4 14.7 Pass 93.6 Fai l Pass
92.4 93.0 94.0 99.5 100.6 98.6 96.3 98.2 94.8 95.2 96.3 2.8 3.0 9.1 Pass 96.3 Pass
75.6 84.7 81.9 86.5 101.0 80.1 99.1 100.1 95.9 91.3 89.6 9.1 10.2 30.8 Fai l Fa i l  89.6 Fai l Pass
93.0 78.3 77.4 76.2 89.1 94.1 91.4 97.8 82.9 87.6 86.8 7.7 8.8 30.1 Fai l Fa i l  86.8 Fai l Pass
109.2 107.2 107.9 106.3 102.1 105.1 104.5 105.3 106.4 100.3 105.4 2.7 2.5 2.4 Pass 105.4 Pass
86.1 91.8 87.7 83.8 90.4 86.5 88.2 89.4 84.2 90.7 87.9 2.7 3.1 17.2 Fai l Pass 87.9 Fai l Pass
101.2 101.4 98.2 99.3 96.9 96.9 98.6 96.0 99.1 101.5 98.9 2.0 2.0 4.7 Pass 98.9 Pass
90.9 81.7 99.9 92.7 93.5 85.0 85.6 87.3 85.5 86.5 88.8 5.4 6.0 22.5 Fai l Fa i l  88.8 Fai l Pass
99.8 94.0 62.2 62.5 76.6 45.5 73.8 90.3 76.0 78.7 75.9 16.4 21.5 61.8 Fai l Fa i l  75.9 Fai l Fa i l
100.0 93.9 99.7 95.4 96.7 97.9 98.4 98.9 104.0 103.3 98.8 3.2 3.2 7.6 Pass 98.8 Pass
93.3 94.5 96.5 91.2 96.4 95.7 93.8 92.6 98.3 98.7 95.1 2.4 2.6 9.3 Pass 95.1 Pass
98.3 90.0 97.8 90.3 99.0 101.3 101.6 104.2 103.4 103.3 98.9 5.1 5.2 12.2 Pass 98.9 Pass
94.1 103.4 99.3 101.9 96.4 104.2 97.3 103.5 98.6 104.0 100.3 3.6 3.6 8.7 Pass 100.3 Pass
80.6 69.2 77.8 80.0 89.5 78.4 85.0 85.6 82.6 83.4 81.2 5.5 6.8 30.5 Fai l Fa i l  81.2 Fai l Pass
98.6 113.1 90.3 98.3 116.2 96.6 100.7 108.9 113.3 113.5 104.9 9.1 8.6 18.3 Fai l Fa i l  104.9 Pass
88.1 99.5 100.1 94.7 95.0 89.9 98.0 87.3 90.8 91.6 93.5 4.7 5.0 16.2 Fai l Pass 93.5 Fai l Pass
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70.4 Fai l Fa i l
14.7 Pass
9.1 Pass
109.2 95.3 93.1 91.4 97.5 98.6 109.9 98.7 94.3 89.2 92.7 103.1 95.8 90.7 90.1 88.0 99.3 88.9 85.3 96.8 93.5 7.9 8.4 98.5 20.8 Fai l Fa i l
79.9 91.1 90.9 95.6 95.4 104.3 102.6 104.3 87.3 91.6 91.8 93.4 96.9 89.8 93.8 94.0 85.5 95.2 95.5 97.6 91.5 7.3 7.9 98.5 21.6 Fai l Fa i l
2.4 Pass
90.0 90.2 87.1 93.9 90.6 92.2 92.3 94.5 92.4 93.0 93.9 94.0 90.7 95.6 91.5 94.3 92.0 93.7 92.7 93.5 90.9 3.1 3.4 98.5 13.8 Pass
4.7 Pass
98.8 102.9 93.9 89.2 88.4 92.5 93.6 100.4 90.5 96.6 102.7 94.0 95.9 100.6 98.1 92.9 104.4 92.8 96.9 100.1 93.8 6.0 6.4 98.5 16.7 Fai l Pass





30.5 Fai l Fa i l
106.1 96.1 109.7 111.1 98.0 101.1 106.5 92.3 97.5 108.2 107.4 108.5 108.7 107.6 107.5 98.5 110.9 99.6 108.6 107.2 104.7 6.8 6.5 101.5 10.4 Pass
90.3 96.0 102.0 98.0 101.1 93.0 92.4 101.6 104.0 95.1 98.0 103.5 93.5 96.2 97.9 87.3 88.3 92.0 97.4 87.7 95.0 5.0 5.3 98.5 13.6 Pass
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Annex 1.9 To observed unacceptable samples with new (considered) judge 
    
Cefuroxime tablets Myanmar project 2014
ID Serial No . Sample Code
































Initial Judge New Judge 
3 A-005 A005/MM14/YG/01/HG/CXMSPIZEF Orchid HEALTHCARE India 101.01 96.57 95.96 96.92 99.78 95.69 97.65 2.2 2.26 Pass
4 A-006 A006/MM14/YG/01/HG/CXMZinnat GlaxoSmithKl ine UK 77.86 86.26 87.94 87.54 91.17 91.77 87.09 5.01 5.75 Pass
5 A-007 A007/MM14/YG/01/HG/CXMZIFTUM 250 Alkem Laboratories  LtdIndia 94.80 96.21 95.20 98.97 95.40 97.02 96.27 1.54 1.60 Pass
6 A-016 A016/MM14/YG/01/HG/CXMZiNNASAV-250 SAVIOUR PHARMACEUTICALSIndia 86.13 86.73 80.62 77.52 85.79 82.70 83.25 3.66 4.39 Pass
7 A-017 A017/MM14/YG/01/HG/CXMZIFATIL-250 Galpha Laboratories  LimitedIndia 108.91 95.81 110.33 106.09 107.70 113.48 107.05 6.06 5.66 Pass
8 A-018 A018/MM14/YG/01/HG/CXMCETIL LUPIN LTD. India 100.74 93.64 93.71 101.42 102.10 97.87 98.25 3.82 3.89 Pass
9 A-019 A019/MM14/YG/01/HG/CXMFUROCEF RENATA LIMITED Bangladesh 69.59 77.86 74.23 86.87 83.51 82.50 79.09 6.43 8.13 Pass
10 A-025 A025/MM14/YG/04/C/CXMSPIZEF Orchid HEALTHCARE India 84.11 96.75 94.19 78.87 95.81 91.57 90.22 7.18 7.96 Pass
11 A-030 A030/MM14/YG/02/C/CXMRUFEX-250 Global  Pharma Healthcare Pvt.Ltd,India 80.68 87.20 71.81 60.60 86.93 77.86 77.52 10.11 13.05 Fai l Pass
12 A-036 A036/MM14/YG/01/Ocl  /CXMZIFTUM 250 Alkem Laboratories  LtdIndia 100.40 94.87 87.70 95.28 92.61 92.96 93.97 4.15 4.41 Pass
13 A-037 A037/MM14/YG/01/Ocl/CXMCefusan 250 SRS pharmaceutica l  pvt l td.India 94.46 94.66 96.71 95.89 95.55 93.84 95.19 1.05 1.11 Pass
14 A-048 A048/MM14/YG/06/C/CXMRUFEX-250 Global  Pharma Healthcare Pvt.Ltd,India 66.77 63.95 65.56 66.37 66.57 68.99 66.37 1.65 2.48 Fai l Pass
15 A-052 A052/MM14/YG/02/HG/CXMZIFTUM 250 Alkem Laboratories  LtdIndia 96.81 97.35 98.50 97.22 100.85 101.05 98.63 1.88 1.91 Pass
16 A-054 A054/MM14/YG/02/C/CXMZIFTUM 250 Alkem Laboratories  LtdIndia 96.88 100.24 93.79 97.82 98.63 98.83 97.70 2.22 2.27 Pass
17 A-057 A057/MM14/YG/01/HP/CXMRUFEX-250 Global  Pharma Healthcare Pvt.Ltd,India 51.24 71.52 79.71 71.72 79.92 72.54 71.11 10.48 14.73 Fai l Pass
18 A-058 A058/MM14/YG/HP/CXMZinnat GlaxoSmithKl ine UK 94.19 91.57 91.17 88.14 96.81 93.39 92.55 2.96 3.20 Pass
19 A-063 A063/MM14/YG/01/Ocl/CXMZIFTUM 250 ALKEM LABORATORIES LTD.India 101.01 93.84 91.59 92.00 94.39 95.89 94.79 3.43 3.62 Pass
20 A-068 A068/MM14/YG/02/C/CXMRUFEX-250 Global  Pharma Healthcare Pvt.Ltd,India 78.46 80.68 70.40 63.34 69.59 71.61 72.35 6.32 8.74 Fai l Pass
21 A-071 A071/MM14/YG/01/HG/CXMZIFTUM 250 ALKEM LABORATORIES LTD.India 96.61 96.68 104.14 97.82 92.78 94.40 97.07 3.91 4.03 Pass
22 A-074 A074/MM14/YG/01/C/CXMZIFTUM 250 ALKEM LABORATORIES LTD.India 90.77 91.98 87.74 91.17 88.88 86.73 89.54 2.08 2.32 Pass
23 A-079 A079/MM14/YG/02/Ocl/CXMRUFEX-250 Global  Pharma Healthcare Pvt.Ltd,India 64.69 62.27 63.95 81.09 58.91 62.00 65.48 7.90 12.07 Fai l Pass
24 A-085 A085/MM14/YG/02/HP/CXMRUFEX-250 Global  Pharma Healthcare Pvt.Ltd,India 64.35 59.23 66.88 59.03 63.94 70.22 63.94 4.35 6.80 Fai l Pass
25 A-086 A086/MM14/YG/02/HP/CXMZinnat GlaxoSmithKl ine UK 82.97 81.89 85.32 89.62 85.12 87.94 85.48 2.92 3.41 Pass
26 A-089 A089/MM14/YG/01/W/CXMCefoti l SQUARE PHARMACEUTICALS LTD.Bangladesh BP ― ― ― ― ― ― ― ― ―
27 A-095 A095/MM14/YG/03/W/CXMKEFROX CCL Pharmaceutica ls (Pvt) Ltd.Pakis an BP ― ― ― ― ― ― ― ― ―
28 A-099 A099/MM14/YG/01/HG/CXMRUFEX-500 Global  Pharma Healthcare Pvt.Ltd,India 65.56 57.43 52.65 66.16 62.13 64.55 61.41 5.34 8.70 Fai l Pass
29 A-102 A102/MM14/YG/01/Ocl/CXMCETIL LUPIN LTD. India 73.42 72.28 70.60 76.05 70.80 69.66 72.14 2.33 3.24 Pass
30 A-104 A104/MM14/YG/02/HP/CXMZIFTUM 250 ALKEM LABORATORIES LTD.India 106.90 103.07 100.65 105.99 99.03 106.29 103.65 3.28 3.16 Pass
32 B-002 B-002/MM14/YG/01/HP/CXMZIFTUM 250 Alkem LaboratoriesIndia 126.66 131.50 131.09 122.42 131.30 136.54 129.92 4.83 3.71 Pass
33 B-003 B-003/MM14/YG/01/HP/CXMSPIZEF Orchid HEALTHCARE India 98.43 96.21 94.60 92.78 96.41 94.19 95.44 1.99 2.08 Pass
34 B-004 B-004/MM14/YG/01/HP/CXMETIL LUPIN LTD. India 73.42 74.84 73.89 75.31 80.48 74.23 75.36 2.60 3.44 Pass
35 B-023 B-023/MM14/YG/07/C/CXMRUFEX Global  Pharma Healthcare Pvt, Ltd.,India 62.33 64.15 62.13 65.36 65.09 63.34 63.73 1.37 2.14 Fai l Pass
36 B-027 B-027/MM14/YG/01/C/CXMZinnat GlaxoSmithKl ine UK 91.77 93.19 89.96 87.74 94.19 93.59 91.74 2.48 2.70 Pass
37 B-029 B-029/MM14/YG/02/C/CXMZIFTUM 250 Alkem LaboratoriesIndia 80.88 82.50 81.15 89.62 85.12 87.94 84.54 3.65 4.32 Pass
38 B-030 B-030/MM14/YG/08/C/CXMZinnat GlaxoSmithKl ine UK 89.54 79.58 89.54 84.29 86.06 82.99 85.33 3.89 4.56 Pass
39 B-031 B-031/MM14/YG/08/C/CXMZIFTUM 250 Alkem LaboratoriesIndia 98.83 97.02 97.42 97.22 101.25 96.41 98.02 1.77 1.81 Pass
40 B-034 B-034/MM14/YG/01/HP/CXMZIFTUM 250 Alkem LaboratoriesIndia 95.14 97.46 98.14 92.41 96.51 96.92 96.10 2.07 2.15 Pass
41 B-038 B-038/MM14/YG/01/HP/CXMZIFTUM 250 Alkem LaboratoriesIndia 127.26 122.02 127.47 124.04 122.09 123.84 124.45 2.41 1.94 Pass
42 B-042 B-042/MM14/YG/01/HG/CXMZIFATIL Galpha Laboratories  LimitedIndia 88.93 88.31 84.83 87.43 90.36 90.77 88.44 2.16 2.45 Pass
43 B-044 B-044/MM14/YG/01/HG/CXMZinmax DOMESCO MEDICAL IMPORT EXPORT JOINT-STOCK CORP.VietNam 90.77 91.17 92.38 88.55 89.15 89.56 90.26 1.43 1.58 Pass
44 B-047 B-047/MM14/YG/01/C/CXMRUFEX Global  Pharma Healthcare Pvt, Ltd.,India 60.52 59.51 59.71 62.94 60.52 60.32 60.59 1.23 2.03 Fai l Pass
45 B-052 B-052/MM14/YG/01/HP/CXMETIL LUPIN LTD. India 109.12 107.50 103.74 100.18 112.14 105.89 106.43 4.19 3.93 Pass
46 B-053 B-053/MM14/YG/01/HP/CXMZinnat GlaxoSmithKl ine UK 88.75 94.19 86.13 79.67 74.43 88.35 85.25 7.08 8.31 Pass
47 B-063 B-063/MM14/YG/01/O(c)/CXMZIFTUM 250 Alkem LaboratoriesIndia 93.43 88.93 105.52 98.14 93.23 103.13 97.06 6.38 6.57 Pass
48 B-066 B-066/MM14/YG/01/C/CXMZIFTUM 250 Alkem LaboratoriesIndia 91.59 87.90 96.92 95.69 94.25 100.60 94.49 4.39 4.65 Pass
49 B-067 B-067/MM14/YG/01/C/CXMRUFEX-250 Global  Pharma Healthcare Pvt, Ltd.,India 84.92 72.82 78.46 81.96 77.66 79.67 79.25 4.10 5.18 Pass
50 B-076 B-076/MM14/YG/01/HG/CXMZIFTUM 250 Alkem LaboratoriesIndia 99.23 92.98 93.99 95.60 94.19 96.21 95.37 2.22 2.33 Pass
51 B-079 B-079/MM14/YG/01/O(c)/CXMZIFTUM 250 Alkem LaboratoriesIndia 93.39 93.99 90.36 91.57 92.98 95.47 92.96 1.80 1.94 Pass
52 B-080 B-080/MM14/YG/01/O(c)/CXMZinnat GlaxoSmithKl ine UK 91.37 89.76 83.10 91.77 86.33 90.97 88.88 3.45 3.88 Pass
53 B-086 B-086/MM14/YG/03/C/CXMZinnat GlaxoSmithKl ine UK 77.26 88.61 85.19 80.88 82.50 81.15 82.60 3.91 4.73 Pass
54 B-089 B-089/MM14/YG/04/W/CXMZinnat GlaxoSmithKl ine UK 77.66 89.89 75.64 81.69 73.02 78.67 79.43 5.89 7.42 Pass
55 B-093 B-093/MM14/YG/01/C/CXMRUFEX Global  Pharma Healthcare Pvt, Ltd.,India 65.56 64.75 87.54 85.12 81.49 89.76 79.04 11.10 14.04 Fai l Pass
56 B-100 B-100/MM14/YG/04/C/CXMZIFTUM 250 Alkem LaboratoriesIndia 100.04 98.43 100.04 98.83 96.41 102.06 99.30 1.90 1.91 Pass
57 B-101 B-101/MM14/YG/05/C/CXMZinnat GlaxoSmithKl ine UK 89.15 85.52 92.51 88.35 89.15 91.17 89.31 2.41 2.70 Pass
58 B-102 B-102/MM14/YG/02/C/CXMZinnat GlaxoSmithKl ine UK 83.91 89.62 87.81 88.28 95.60 91.37 89.43 3.91 4.37 Pass
59 B-104 B104/MM14/YG/01/HG/CXMZIFTUM 250 Alkem LaboratoriesIndia 94.80 98.23 90.36 93.99 96.01 92.18 94.26 2.78 2.95 Pass
60 B-111 B111/MM14/YG/02/C/CXMRUFEX-250 Global  Pharma Healthcare Pvt, Ltd.,India 76.91 67.63 74.18 89.13 89.13 85.99 80.50 8.92 11.08 Pass
1 PA-001 PA001/MM14/YG/01/C/CXMZIFTUM 250 Alkem Laboratories  LtdIndia 158.05 134.52 153.14 152.94 136.54 146.22 146.90 9.60 6.53 Pass
2 PA-002 PA002/MM14/YG/01/C/CXMSPIZEF Orchid HEALTHCARE India 73.83 98.97 100.24 97.22 85.79 83.04 89.85 10.63 11.83 Pass
31 PB-001 PB-001/MM14/YG/01/O(c)/CXMZINNASAV-250 SAVIOUR PHARMACEUTICALSIndia 75.96 82.78 83.19 85.86 82.58 81.35 81.95 3.29 4.02 Pass
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97.95 96.71 96.10 96.71 99.30 95.48 97.04 1.38 1.42 Pass Pass
94.60 103.07 95.00 96.41 100.44 100.65 98.36 3.49 3.55 Pass Pass
99.23 107.50 106.29 107.91 104.68 105.28 105.15 3.15 3.00 Pass Pass
94.40 95.20 88.14 85.52 95.20 87.14 90.93 4.47 4.92 Pass Pass
116.37 109.32 111.27 108.17 112.27 115.97 112.23 3.38 3.01 Pass Pass
108.38 100.40 100.19 104.49 101.83 102.04 102.89 3.10 3.01 Pass Pass
80.88 86.53 87.54 100.51 100.85 92.58 91.48 8.04 8.78 Pass Pass
97.55 100.85 92.98 81.29 97.82 96.01 94.42 6.92 7.33 Pass Pass
91.57 91.57 76.25 93.05 90.97 93.79 89.53 6.59 7.36 Pass Fail Pass
106.13 101.56 94.05 102.24 103.26 101.22 101.41 4.02 3.96 Pass Pass
96.92 100.26 97.94 98.76 104.70 97.80 99.40 2.83 2.85 Pass Pass
85.93 87.54 85.72 85.93 88.14 88.82 87.01 1.33 1.53 Pass Fail Pass
102.86 101.65 107.77 101.92 107.17 103.13 104.09 2.69 2.58 Pass Pass
105.28 106.90 101.86 105.69 103.67 104.48 104.65 1.75 1.67 Pass Pass
79.03 83.19 81.56 85.65 90.91 84.01 84.06 4.04 4.81 Fai l Pass Fail Pass
101.25 101.65 98.43 98.02 102.06 100.04 100.24 1.71 1.70 Pass Pass
109.41 100.33 99.17 97.53 106.13 102.24 102.47 4.51 4.40 Pass Pass
86.06 85.93 75.44 89.35 91.57 91.37 86.62 6.01 6.93 Fai l Pass Fail Pass
102.86 101.86 92.51 103.67 97.82 102.86 100.27 4.33 4.32 Pass Pass
99.84 100.04 90.77 95.81 96.21 93.79 96.08 3.56 3.71 Pass Pass
77.05 83.44 73.29 86.73 69.79 75.64 77.66 6.34 8.17 Fai l Pass Fail Pass
86.47 78.89 91.18 79.23 84.22 90.57 85.09 5.34 6.27 Fai l Pass Fail Pass
96.21 96.81 99.84 99.71 98.02 96.28 97.81 1.65 1.69 Pass Pass
90.56 93.19 91.57 94.80 96.41 95.81 93.72 2.35 2.51 Pass Pass
97.29 98.36 100.04 100.31 91.17 93.39 96.76 3.71 3.84 Pass Pass
84.72 83.91 84.51 86.93 82.09 86.26 84.74 1.72 2.04 Pass Fail Pass
99.44 93.39 98.23 99.44 94.80 96.41 96.95 2.51 2.59 Pass Pass
107.70 105.82 106.70 118.19 102.66 110.80 108.64 5.37 4.94 Pass Pass
117.58 121.01 117.18 119.40 115.16 118.93 118.21 2.03 1.71 Pass Pass
101.45 97.02 95.20 99.84 97.62 100.24 98.56 2.34 2.37 Pass Pass
98.56 93.79 87.94 95.00 99.44 97.02 95.29 4.18 4.38 Pass Pass
82.90 84.31 81.49 81.29 84.31 89.56 83.98 3.03 3.61 Pass Fail Pass
100.24 104.95 98.83 97.96 100.65 100.44 100.51 2.41 2.40 Pass Pass
104.88 97.82 104.28 103.87 104.88 102.33 103.01 2.71 2.63 Pass Pass
97.32 96.92 97.73 96.10 95.48 95.28 96.47 1.01 1.04 Pass Pass
104.48 125.11 103.47 107.91 125.45 103.67 111.68 10.66 9.54 Pass Pass
100.40 105.31 105.31 99.10 98.28 101.01 101.57 3.05 3.01 Pass Pass
119.20 123.03 124.24 116.58 119.00 112.54 119.10 4.27 3.59 Pass Pass
92.00 97.53 92.41 93.16 92.82 99.37 94.55 3.10 3.28 Pass Pass
102.06 105.08 99.84 101.52 100.78 100.38 101.61 1.88 1.85 Pass Pass
83.04 80.48 85.93 83.71 81.02 81.89 82.68 2.00 2.41 Pass Fail Pass
108.31 105.89 102.06 107.30 106.16 100.85 105.09 2.97 2.83 Pass Pass
102.66 106.09 95.00 95.00 91.44 96.21 97.73 5.50 5.62 Pass Pass
101.83 95.28 112.89 103.06 116.58 110.57 106.70 7.98 7.48 Pass Pass
96.30 96.44 107.22 103.06 105.52 108.73 102.88 5.38 5.23 Pass Pass
97.15 90.77 94.60 96.01 93.99 96.81 94.89 2.37 2.49 Pass Pass
108.51 103.67 105.69 108.11 83.10 104.81 102.32 9.60 9.38 Pass Pass
105.89 102.66 100.04 101.25 102.86 104.68 102.90 2.15 2.09 Pass Pass
101.18 98.23 95.00 108.17 96.41 100.65 99.94 4.68 4.69 Pass Pass
90.97 98.02 99.37 94.40 88.75 97.29 94.80 4.22 4.45 Pass Pass
93.79 101.25 97.89 100.04 94.40 97.62 97.50 2.97 3.05 Pass Pass
71.47 72.62 94.73 91.50 87.34 91.57 84.87 10.22 12.04 Fai l Pass Fail Pass
104.28 100.04 103.13 103.27 103.67 108.11 103.75 2.59 2.50 Pass Pass
102.53 97.82 97.82 99.30 82.50 100.11 96.68 7.16 7.41 Pass Pass
97.02 102.60 99.44 99.03 85.12 98.02 96.87 6.06 6.25 Pass Pass
103.81 108.71 101.45 102.26 107.30 97.62 103.53 4.05 3.91 Pass Pass
90.84 86.06 85.86 90.16 91.80 91.39 89.35 2.68 3.00 Pass Pass
125.25 126.12 123.63 124.24 117.18 120.61 122.84 3.35 2.73 Pass Pass
79.81 100.23 100.71 99.97 87.07 85.32 92.19 9.21 10.00 Fail Pass Fai l Pass
79.44 91.18 90.57 89.95 86.47 90.02 87.94 4.48 5.09 Fail Pass Fai l Pass
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104.92 104.54 100.00 102.70 95.88 99.40 94.86 105.87 101.22 96.94 100.6 3.9 3.9 9.372893126 Pass
104.21 103.39 98.63 97.51 93.65 103.10 106.08 98.50 95.83 102.27 100.3 4.1 4.0 9.731768808 Pass
102.27 103.86 100.48 102.58 98.18 97.12 100.36 100.98 97.48 92.73 99.6 3.3 3.3 7.89 Pass
92.41 93.57 91.85 95.51 95.75 90.01 89.77 84.34 88.41 101.55 92.3 4.7 5.1 17.48 Fai l Pass
84.42 99.25 100.84 85.26 90.85 90.97 97.08 91.92 93.14 92.91 92.7 5.4 5.8 18.72 Fai l Fa i l
85.61 97.53 104.85 104.61 90.77 107.86 98.31 94.87 97.54 98.02 98.0 6.7 6.8 16.58 Fai l Pass
99.58 97.87 93.20 95.87 93.71 103.43 100.62 95.39 98.09 95.14 97.3 3.2 3.3 9.00 Pass
94.08 101.01 89.89 94.86 93.99 95.64 99.03 101.53 94.92 92.86 95.8 3.7 3.8 11.55 Pass
92.98 91.66 89.14 90.87 92.74 88.74 88.45 86.30 82.74 82.84 88.6 3.7 4.2 18.76 Fai l Fa i l
104.08 102.32 92.47 95.41 111.73 93.88 93.39 101.14 92.26 94.69 98.1 6.4 6.6 15.45 Fai l Pass
91.27 93.27 96.13 88.28 98.09 91.63 91.59 94.10 87.74 79.11 91.1 5.3 5.8 20.06 Fai l Fa i l
95.65 100.96 82.79 86.92 84.50 92.64 87.53 87.83 84.09 83.79 88.7 5.9 6.7 24.08 Fai l Fa i l
92.28 99.85 94.71 96.54 95.82 98.57 99.74 103.67 107.73 105.66 99.5 5.0 5.0 11.90 Pass
101.48 100.22 91.88 103.28 95.38 105.52 97.11 98.08 92.65 95.07 98.1 4.5 4.6 11.28 Pass
87.87 87.87 87.65 82.96 87.90 82.50 85.36 79.08 77.86 80.46 84.0 3.9 4.7 23.95 Fai l Fa i l
95.38 104.18 100.01 98.10 103.39 99.45 93.58 100.25 90.67 91.76 97.7 4.7 4.8 12.04 Pass
99.58 95.59 96.90 102.68 100.60 103.08 94.12 99.93 98.40 95.48 98.6 3.1 3.1 7.38 Pass
85.13 80.97 74.62 ― ― ― ― ― ― ― 80.2 ― ― ― ―
107.29 97.04 100.25 99.21 101.42 104.80 95.76 99.53 94.60 89.71 99.0 5.1 5.1 12.13 Pass
105.17 99.99 101.85 103.65 98.37 100.92 98.68 93.11 93.86 98.67 99.4 3.8 3.9 9.21 Pass
86.23 86.08 82.00 86.17 84.76 88.14 83.31 89.02 81.19 82.07 84.9 2.7 3.2 20.05 Fai l Fa i l
98.68 88.40 99.10 101.87 98.65 93.01 98.22 95.66 96.45 97.29 96.7 3.7 3.9 10.77 Pass
94.85 92.47 90.91 95.96 99.71 94.09 96.69 97.74 93.76 94.46 95.1 2.6 2.7 9.60 Pass
97.95 97.60 93.43 92.10 101.08 87.19 96.73 96.72 93.55 94.45 95.1 3.8 4.0 12.63 Pass
89.41 99.51 95.97 94.42 103.65 96.10 90.11 97.75 94.44 90.99 95.2 4.4 4.6 13.88 Pass
79.62 80.37 82.34 80.60 76.43 78.62 81.50 79.29 78.70 75.53 79.3 2.1 2.7 24.28 Fai l Fa i l
98.44 99.04 95.46 93.58 98.00 95.74 100.25 97.12 98.56 87.30 96.3 3.7 3.9 11.12 Pass
103.02 98.07 99.18 103.84 101.83 103.11 94.54 97.96 102.81 97.01 100.1 3.2 3.2 7.67 Pass
96.55 104.47 106.58 100.60 100.41 102.25 90.34 103.61 96.69 99.31 100.1 4.7 4.7 11.27 Pass
94.9 96.3 96.4 94.2 99.8 100.9 95.0 95.7 91.2 103.1 96.7 3.5 3.6 10.22 Pass
98.99 100.25 99.81 95.66 94.94 97.36 89.83 90.59 94.11 93.58 95.5 3.6 3.8 11.71 Pass
86.47 88.94 86.99 95.59 93.94 92.55 73.24 90.08 89.30 82.01 87.9 6.5 7.4 26.13 Fai l Fa i l
96.26 93.06 95.03 91.98 95.18 90.38 93.66 86.06 98.76 92.34 93.3 3.5 3.7 13.57 Pass
98.08 99.17 97.64 88.44 89.52 93.13 83.94 84.61 78.65 95.15 90.8 6.9 7.6 24.34 Fai l Fa i l
97.84 98.27 109.33 101.97 98.36 104.72 97.52 111.74 108.12 93.15 102.1 6.1 6.0 15.27 Pass
96.67 101.02 94.08 96.38 93.86 95.06 93.75 96.25 96.24 97.52 96.1 2.2 2.3 7.63 Pass
101.07 100.73 104.94 106.81 101.49 97.11 102.96 106.33 102.82 102.79 102.7 2.9 2.8 8.11 Pass
105.30 92.74 104.55 105.08 97.92 98.05 98.24 100.54 98.83 98.10 99.9 4.0 4.0 9.59 Pass
83.66 84.52 86.32 91.22 84.44 85.86 91.58 84.65 93.10 80.82 86.6 4.0 4.6 21.48 Fai l Fa i l
102.47 102.35 102.44 104.48 103.97 103.72 102.78 98.97 97.20 96.30 101.5 2.9 2.9 6.98 Pass
71.12 69.88 88.62 76.65 74.10 77.86 88.15 85.61 73.36 74.00 77.9 7.0 9.0 37.37 Fai l Fa i l
91.71 97.36 88.44 93.86 88.52 96.88 92.86 90.31 92.94 92.51 92.5 3.0 3.3 13.24 Pass
104.46 85.18 85.58 83.73 90.96 104.88 89.09 90.42 102.98 103.08 94.0 8.8 9.3 25.50 Fai l Fa i l
98.72 91.94 97.51 92.91 97.18 91.92 109.19 92.38 98.29 102.77 97.3 5.5 5.7 14.50 Pass
97.47 99.41 97.77 99.32 92.59 92.40 94.94 95.56 96.13 101.41 96.7 2.9 3.0 8.88 Pass
97.63 100.15 107.00 101.46 107.64 106.13 101.37 101.88 100.85 101.86 102.6 3.2 3.2 8.89 Pass
97.22 96.14 92.13 89.04 90.90 91.00 95.82 93.73 84.56 92.74 92.3 3.8 4.1 15.21 Pass
101.08 94.44 98.21 99.11 103.97 102.67 97.27 97.77 97.49 97.75 99.0 2.8 2.9 6.80 Pass
97.64 99.42 97.71 100.36 97.58 96.02 98.42 96.52 96.50 96.74 97.7 1.4 1.4 4.12 Pass
92.29 98.58 98.56 91.81 102.01 90.37 90.05 93.33 92.23 94.00 94.3 4.0 4.3 13.81 Pass
109.93 105.57 104.26 115.00 103.68 107.96 107.55 110.73 101.57 102.22 106.8 4.2 4.0 15.48 Pass
88.76 91.12 80.84 80.41 75.56 87.75 83.93 82.01 89.50 86.58 84.6 4.9 5.8 25.68 Fai l Fa i l
93.01 94.13 107.34 91.54 94.24 102.22 93.05 92.89 89.85 90.01 94.8 5.6 5.9 17.08 Fai l Pass
101.68 103.63 103.61 99.44 102.50 115.40 101.56 97.35 95.65 98.59 101.9 5.4 5.3 13.47 Pass
94.09 96.03 98.31 97.15 93.26 92.67 95.69 99.97 95.30 96.11 95.9 2.2 2.3 8.01 Pass
99.74 105.46 105.23 100.22 101.84 95.14 97.11 101.63 90.14 102.08 99.9 4.7 4.7 11.22 Pass
77.76 80.96 83.08 77.55 76.53 76.92 78.97 79.20 74.70 77.48 78.3 2.4 3.0 25.88 Fai l Fa i l
93.01 94.13 101.56 91.54 94.24 102.22 93.05 92.89 89.85 90.01 94.3 4.3 4.6 14.57 Pass
103.65 100.90 102.00 99.25 97.83 96.97 102.27 102.52 93.13 99.91 99.8 3.2 3.2 7.64 Pass






















































































- - - - - - - - - - - - - - - - - - - - - - - - Fa i l Fa i l
- - - - - - - - - - - - - - - - - - - - - - - - Pass
Pass
Pass
92.27 92.42 92.10 92.27 92.68 91.66 88.43 90.69 83.91 80.84 91.06 90.78 85.74 85.97 87.09 82.13 85.49 81.53 83.53 89.05 88.51 3.94 4.46 17.88 Fai l Pass
Pass
103.74 97.31 100.95 96.99 97.34 94.32 93.53 99.38 94.32 100.71 97.08 90.13 99.63 93.98 97.15 83.28 93.22 92.56 90.18 97.62 94.15 5.19 5.51 14.72 Pass
106.26 97.80 101.48 92.52 100.54 104.06 101.64 85.36 104.57 99.83 88.92 94.43 94.28 95.97 91.60 94.93 95.01 93.71 104.98 91.35 94.22 6.92 7.34 18.11 Fai l Fa i l
Pass
Pass

















Fai l Fa i l
Pass





- - - - - - - - - - - - - - - - - - - - - - - - Fa i l Fa i l
Pass
Fa i l Fa i l
Pass









92.16 91.21 87.91 88.03 88.11 86.34 86.50 83.10 88.83 91.62 84.15 84.91 76.84 79.15 85.28 78.81 85.54 81.09 78.94 82.78 85.26 4.52 5.31 22.29 Fai l Fa i l




93.21 89.27 87.18 90.76 86.50 86.94 88.76 92.50 88.72 82.25 85.54 83.32 82.14 75.51 85.60 78.09 77.83 79.58 81.52 83.49 82.84 5.17 6.25 26.01 Fai l Fa i l
Pass
Pass
85.84 88.33 107.07 89.15 94.20 89.80 87.21 89.31 87.72 84.92 90.39 84.84 89.89 95.62 94.75 99.33 94.43 79.50 89.28 96.57 90.56 5.58 6.16 19.11 Fai l Fa i l
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New 
Aｌｌ
100.63 Pass - Pass Pass
100.32 Pass - Pass Pass
99.60 Pass - Pass Pass
92.32 Pass 88.96 Fai l Pass Fa i l Pass
92.66 Pass - Pass Fa i l Fa i l
98.00 Pass - Pass Fa i l Pass
97.29 Pass - Pass Pass
95.78 Pass - Pass Pass
88.65 Fai l Pass 88.51 Fai l Pass Fa i l Pass
98.14 Pass 101.90 Pass Pass
91.12 Pass 94.15 Pass Pass
88.67 Fai l Pass 94.22 Pass Fai l Fa i l
99.46 Pass - Pass Pass
98.07 Pass - Pass Pass
83.95 Fai l Pass 82.88 Fai l Pass Fa i l Fa i l
97.68 Pass - Pass Pass
98.64 Pass - Pass Pass
80.24 Fai l Pass - Fa i l Pass Fa i l Pass
98.96 Pass - Pass Pass
99.43 Pass - Pass Pass
84.90 Fai l Pass 85.72 Fai l Pass Fa i l Fa i l
96.73 Pass - Pass Pass
95.06 Pass - Pass Pass
95.08 Pass - Pass Pass
95.24 Pass - Pass Pass
79.30 Fai l Pass 79.30 Fai l Pass Fa i l Fa i l
96.35 Pass - Pass Pass
100.14 Pass - Pass Pass
100.08 Pass - Pass Pass
96.72 Pass - Pass Pass
95.51 Pass - Pass Pass
87.91 Fai l Pass 87.91 Fai l Pass Fa i l Fa i l
93.27 Pass - Pass Pass
90.84 Pass 98.84 Pass Pass
102.10 Pass - Pass Pass
96.08 Pass - Pass Pass
102.71 Pass - Pass Pass
99.93 Pass - Pass Pass
86.61 Fai l Pass 86.61 Fai l Pass Fa i l Fa i l
101.47 Pass - Pass Pass
77.93 Fai l Pass 77.93 Fai l Pass Fa i l Fa i l
92.54 Pass - Pass Pass
94.04 Pass 95.20 Pass Pass
97.28 Pass - Pass Pass
96.70 Pass - Pass Pass
102.60 Pass - Pass Pass
92.33 Pass - Pass Pass
98.98 Pass - Pass Pass
97.69 Pass - Pass Pass
94.32 Pass - Pass Pass
106.85 Pass - Pass Pass
84.65 Fai l Pass 85.26 Fai l Pass Fa i l Fa i l
94.83 Pass - Pass Fa i l Pass
101.94 Pass - Pass Pass
95.14 Pass - Pass Pass
99.86 Pass - Pass Pass
78.32 Fai l Pass 82.84 Fai l Pass Fa i l Fa i l
94.25 Pass - Pass Pass
99.84 Pass - Pass Pass




   
































A-096 A096/MM14/YG/03/W/OMOmep-20 ARISTOPHARMA LTD. Bangladesh 22.3 10.4 8.9 11.6 9.6 10.2 12.2 5.0 41.4 Fai l Fa i l
B-065 B-065/MM14/YG/01/O(c)/OMOmep ARISTOPHARMA LTD. Bangladesh 11.1 11.3 10.9 11.0 11.2 10.9 11.1 0.2 1.7 Fai l Pass
A-076 A076/MM14/YG/01/C/OMASM ZOL-20 ASMOH LABORATORIES LTD. India 1.4 1.4 1.4 1.4 1.4 1.4 1.4 0.0 0.0 Pass
B-092 B-092/MM14/YG/01/C/OMOMEPREN BLUE CROSS LABORATORIES LTD. India 2.5 2.4 1.8 1.1 1.2 1.2 1.7 0.6 36.5 Pass
B-098 B-098/MM14/YG/01/HG/OMOMEPREN BLUE CROSS LABORATORIES LTD. India 2.4 2.3 2.5 2.4 2.2 2.4 2.3 0.1 4.6 Pass
B-005 B-005/MM14/YG/01/HP/OMOCID Cadi la  Health Limited India 6.0 3.6 3.6 3.9 5.8 4.1 4.5 1.1 24.6 Pass
B-011 B-011/MM14/YG/03/C/OMOCID Cadi la  Health Limited India 5.3 4.0 7.2 4.4 7.2 5.4 5.6 1.4 24.2 Pass
B-070 B-070/MM14/YG/01/C/OMOCID Cadi la  Health Limited India 3.7 3.9 3.8 2.5 3.1 2.5 3.3 0.6 19.7 Pass
B-090 B-090/MM14/YG/04/W/OMOCID Cadi la  Health Limited India 2.2 1.9 1.9 2.0 2.0 2.0 2.0 0.1 6.4 Pass
PA-006 PA006/MM14/YG/01/C/OMOCID Cadi la  Healthcare Limited India 5.4 4.0 7.2 4.4 7.2 5.5 5.6 1.4 24.2 Pass
A-002 A002/MM14/YG/01/HG/OMOCID Cadi la  Healthcare Limited India 3.0 2.7 2.6 2.6 2.5 4.0 2.9 0.6 19.1 Pass
A-026 A026/MM14/YG/04/C/OMOCID Cadi la  Healthcare Limited India 9.6 3.6 3.6 3.9 5.8 4.1 5.1 2.3 46.0 Pass
A-042 A042/MM14/YG/03/C/OMOCID Cadi la  Healthcare Limited India 5.6 5.0 3.6 3.8 5.0 5.4 4.7 0.8 17.2 Pass
A-060 A060/MM14/YG/01/HP/OMOCID Cadi la  Healthcare Limited India 2.4 2.5 4.4 2.9 2.9 2.6 2.9 0.7 24.9 Pass
A-084 A084/MM14/YG/02/HP/OMOCID Cadi la  Healthcare Limited India 9.9 9.5 7.3 9.6 9.7 10.0 9.3 1.0 10.8 Pass
A-034 A034/MM14/YG/01/Ocl/OMLOMAC-20 Cipla  Ltd. India 26.9 27.7 27.7 27.3 28.1 23.5 26.9 1.7 6.3 Fai l Fa i l
A-038 A038/MM14/YG/01/C/OMLOMAC-20 Cipla  Ltd. India 12.5 11.6 12.6 13.0 14.1 15.1 13.1 1.2 9.5 Fai l Fa i l
B-007 B-007/MM14/YG/01/HP/OMLOMAC Cipla  Ltd. India 39.9 38.1 42.5 40.3 39.5 42.3 40.4 1.7 4.2 Fai l Fa i l
B-110 B110/MM14/YG/01/C/OMLOMAC Cipla  Ltd. India 24.4 25.4 25.1 24.7 25.4 21.1 24.4 1.7 6.8 Fai l Fa i l
PB-003 PB-003/MM14/YG/01/O(c)/OMOMEZ Dr. REDDY'S LABORATORIES India 9.0 8.9 8.9 5.7 3.4 5.1 6.8 2.4 35.4 Pass
B-006 B-006/MM14/YG/01/HP/OMOMEZ Dr. REDDY'S LABORATORIES India 5.8 2.9 5.3 9.1 8.8 8.7 6.8 2.5 37.1 Pass
B-008 B-008/MM14/YG/01/HP/OMOMEZ Dr. REDDY'S LABORATORIES India 14.4 13.3 14.5 14.4 8.4 11.0 12.7 2.5 19.6 Fai l Fa i l
B-013 B-013/MM14/YG/03/C/OMOMEZ Dr. REDDY'S LABORATORIES India 16.5 15.9 8.5 15.0 10.6 15.9 13.7 3.4 24.4 Fai l Fa i l
B-036 B-036/MM14/YG/01/HP/OMOMEZ Dr. REDDY'S LABORATORIES India 8.8 7.6 1.0 1.2 0.9 8.0 4.6 3.9 85.4 Pass
B-054 B-054/MM14/YG/01/HP/OMOMEZ Dr. REDDY'S LABORATORIES India 22.8 26.4 28.2 24.0 25.3 27.4 25.7 2.1 8.0 Fai l Fa i l
B-106 B106/MM14/YG/01/HG/OMOMEZ Dr. REDDY'S LABORATORIES India 12.4 7.6 14.8 20.7 19.3 20.7 15.9 5.3 33.1 Fai l Fa i l
PA-005 PA005/MM14/YG/01/C/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 26.9 9.3 15.9 26.6 9.3 15.7 17.3 7.9 45.6 Fai l Fa i l
A-001 A001/MM14/YG/01/HG/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 9.8 5.9 7.5 9.3 6.9 7.4 7.8 1.5 19.1 Pass
A-015 A015/MM14/YG/01/HG/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 14.3 9.3 16.8 15.2 15.9 9.7 13.5 3.2 23.9 Fai l Fa i l
A-039 A039/MM14/YG/01/C/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 9.5 8.5 14.7 14.6 13.1 14.5 12.5 2.8 22.1 Fai l Fa i l
A-050 A050/MM14/YG/01/HG/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 10.5 9.2 20.2 17.3 17.9 24.3 16.6 5.8 34.9 Fai l Fa i l
A-061 A061/MM14/YG/01/HP/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 9.9 9.5 9.5 9.1 9.9 9.9 9.6 0.3 3.5 Pass
A-065 A065/MM14/YG/01/Ocl/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 9.2 9.2 9.1 9.8 7.0 7.4 8.6 1.1 13.3 Pass
A-101 A101/MM14/YG/01/HG/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 8.9 12.5 9.4 14.3 11.1 14.1 11.7 2.3 19.8 Fai l Pass
A-106 A106/MM14/YG/02/HP/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 1.9 1.9 1.9 1.9 1.9 1.9 1.9 0.0 0.0 Pass
A-107 A107/MM14/YG/01/C/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 4.8 4.7 4.6 4.5 4.6 4.4 4.6 0.1 3.3 Pass
A-114 A114/MM14/YG/01/C/OMOMEZ Dr.REDDY'S LABORATORIES LTD. India 1.9 1.9 1.9 1.9 1.9 1.9 1.9 0.0 0.0 Pass
A-012 A012/MM14/YG/01/HG/OMZosec Emcure PHARMACETICALS LTD. India 7.2 5.7 5.0 7.1 5.8 5.0 6.0 1.0 16.2 Pass
B-017 B-017/MM14/YG/04/C/OMZosec Emcure PHARMACEUTICAL LTD. India 2.6 2.4 1.8 1.3 1.2 1.0 1.7 0.6 37.4 Pass
B-037 B-037/MM14/YG/01/HP/OMOMFIL Fourrts  Laboratories  Pvt Ltd, India 3.5 7.1 5.1 4.2 6.8 5.0 5.3 1.4 26.7 Pass
A-033 A033/MM14/YG/01/Ocl/OMOMFIL 20 Fourrts  Laboratories  Pvt.Ltd. India 8.3 8.4 8.3 8.6 8.9 8.7 8.5 0.3 3.0 Pass
B-045 B-045/MM14/YG/01/C/OMOMPREZ Global  Pharma Healthcare Pvt, Ltd.,India 2.6 3.0 4.4 2.5 2.8 4.4 3.3 0.9 26.6 Pass
A-041 A041/MM14/YG/03/C/OMTRISEC GREAT HIMALAYAN PTE LTD. India 12.0 25.0 11.5 11.8 24.9 11.6 16.1 6.8 42.4 Fai l Fa i l
B-077 B-077/MM14/YG/01/HG/OMOmetab Intas  Pharmaceutica l  Ltd. India 1.4 1.4 1.4 1.4 1.4 1.4 1.4 0.0 0.0 Pass
B-108 B108/MM14/YG/02/HG/OMOmetab Intas  Pharmaceutica l  Ltd. India 3.5 7.2 4.9 4.2 6.9 4.9 5.3 1.5 28.3 Pass
PB-002 PB-002/MM14/YG/01/O(c)/OMOme-M Rainbow Li fe Sciences  Pvt. Ltd. India 11.0 18.1 11.0 17.7 18.2 11.2 14.5 3.8 26.1 Fai l Fa i l
A-078 A078/MM14/YG/02/C/OMReloc-20 Rhydburg Pharmaceutica ls  Ltd. India 23.0 34.4 17.1 23.3 33.1 16.6 24.6 7.6 31.1 Fai l Fa i l
A-011 A011/MM14/YG/01/HG/OMOmesec The United Drug (1996) Co,Ltd. Thai land 2.7 2.6 3.1 2.7 2.9 3.0 2.8 0.2 7.0 Pass
A-091 A091/MM14/YG/02/W/OMOmesec The United Drug (1996) Co,Ltd. Thai land 2.7 3.2 4.7 4.7 2.8 3.3 3.6 0.9 24.7 Pass
B-059 B-059/MM14/YG/01/HP/OMOmesec The United Drug(1996) Co., Ltd Thai land 2.3 2.2 2.7 2.3 2.5 2.6 2.4 0.2 8.2 Pass
A-097 A097/MM14/YG/03/W/OMOmesafe UNIVERSAL PHARMACEUTICALS LIMITEDIndia 2.8 2.7 6.7 2.6 2.7 3.6 3.5 1.6 46.1 Pass
B-049 B-049/MM14/YG/01/C/OMVirom Virchow Healthcare Drivate Limited.India 2.3 2.5 2.7 0.9 0.9 0.9 1.7 0.9 54.1 Pass
B-015 B-015/MM14/YG/04/C/OMHYCID XL LABORATORIES PVT. LTD. India 17.9 17.2 17.7 18.0 17.5 17.7 17.7 0.3 1.7 Fai l Fa i l
A-067 A067/MM14/YG/01/C/OMHY ID XL LABORATORIES PVT.LTD. India 3.3 9.0 9.0 8.0 5.1 9.1 7.3 2.5 33.8 Pass
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51.3 79.2 76.0 65.2 77.9 70.0 70.0 10.5 15.1 Fai l Fa i l Pass Fa i l
56.0 52.7 47.6 56.4 54.1 48.6 52.6 3.7 7.1 Fai l Fa i l Fa i l Fa i l
82.7 94.3 95.4 96.0 95.4 96.1 93.3 5.2 5.6 Pass Pass
92.8 95.2 98.8 97.5 97.3 94.7 96.0 2.2 2.3 Pass Pass
81.6 92.7 89.7 83.0 93.3 91.8 88.7 5.1 5.8 Pass Pass
96.0 92.6 95.2 91.6 94.0 95.8 94.2 1.8 1.9 Pass Pass
96.6 97.9 98.3 66.4 98.5 97.3 92.5 12.8 13.9 Pass Pass
82.7 94.3 93.5 94.2 95.4 95.7 92.7 4.9 5.3 Pass Pass
77.0 79.8 80.1 81.4 80.1 77.2 79.3 1.8 2.2 Pass Pass
83.1 84.9 82.2 82.7 83.6 82.1 83.1 1.0 1.2 Pass pass
96.9 99.5 98.2 96.1 96.4 98.4 97.6 1.3 1.4 Pass pass
86.9 72.9 75.2 76.9 75.4 86.8 79.0 6.2 7.9 Pass Pass
97.9 95.6 97.7 95.1 96.2 95.7 96.4 1.2 1.2 Pass Pass
99.3 98.1 98.6 95.4 99.0 98.0 98.1 1.4 1.4 Pass Pass
77.0 79.8 80.1 94.3 94.4 95.4 86.8 8.7 10.0 Pass Pass
52.1 53.8 47.6 51.8 50.9 48.5 50.8 2.3 4.6 Fai l Fa i l Fa i l Fa i l
85.4 84.1 83.3 81.7 85.2 83.6 83.9 1.3 1.6 Pass Fai l Fa i l
49.5 49.7 63.4 55.7 50.7 50.7 53.3 5.5 10.2 Fai l Fa i l Fa i l Fa i l
53.6 62.8 62.1 52.8 53.4 62.6 57.9 5.1 8.8 Fai l Fa i l Pass Fa i l
30.7 34.4 26.5 54.9 71.2 57.6 45.9 17.9 39.0 Fai l Fa i l Fa i l Fa i l
54.7 72.7 57.1 31.1 34.2 27.9 46.3 17.9 38.7 Fai l Fa i l Fa i l Fa i l
70.3 67.7 73.1 72.3 77.4 74.8 72.6 3.4 4.7 Fai l Fa i l Pass Fa i l
50.2 47.5 80.7 58.6 68.2 56.9 60.4 12.3 20.4 Fai l Fa i l Pass Fa i l
78.3 70.7 78.4 69.3 68.3 66.6 71.9 5.1 7.1 Fai l Fa i l Pass Fa i l
31.4 32.1 35.5 31.8 73.9 73.2 46.3 21.2 45.7 Fai l Fa i l Fa i l Fa i l
49.7 47.1 79.3 48.8 77.9 77.0 63.3 16.2 25.6 Fai l Fa i l Pass Fa i l
60.1 65.2 61.7 60.1 65.1 61.7 62.3 2.3 3.7 Fai l Fa i l Pass Fa i l
73.8 79.3 71.4 72.4 71.1 70.8 73.1 3.9 5.4 Pass pass
56.6 70.7 55.2 54.5 48.1 74.7 60.0 10.4 17.3 Fai l Fa i l Pass Fa i l
73.9 77.7 62.1 75.0 60.7 60.8 68.4 8.0 11.6 Fai l Fa i l Pass Fa i l
75.3 75.8 60.7 73.7 63.2 74.1 70.5 6.7 9.5 Fai l Fa i l Pass Fa i l
76.8 68.0 70.6 76.9 71.1 76.5 73.3 3.9 5.3 Fai l Fa i l Pass Pass
72.5 72.1 67.3 67.6 73.4 72.5 70.9 2.7 3.8 Fai l Fa i l Pass Pass
77.6 69.5 77.7 55.7 66.9 53.7 66.9 10.4 15.5 Fai l Fa i l Pass Pass
69.0 73.1 66.6 71.7 67.5 72.5 70.1 2.8 3.9 Fai l Fa i l Pass Pass
18.3 19.5 17.9 18.5 18.9 18.3 18.6 0.6 3.0 Fai l Fa i l Fa i l Fa i l
69.4 67.9 75.2 67.4 67.6 72.5 70.0 3.2 4.5 Fai l Fa i l Pass Pass
80.0 74.7 91.1 80.0 76.4 90.3 82.1 7.0 8.5 Pass pass
99.6 98.6 98.8 97.7 97.4 94.6 97.8 1.8 1.8 Pass Pass
92.2 86.9 87.1 91.1 88.9 92.9 89.9 2.6 2.9 Pass Pass
67.6 81.2 79.8 80.6 68.5 68.2 74.3 6.8 9.2 Fai l Fa i l Pass Pass
71.7 94.3 86.6 73.1 93.9 86.8 84.4 9.9 11.7 Pass Pass
59.7 98.8 61.0 59.7 98.7 61.4 73.2 19.8 27.1 Fai l Fa i l Pass Fa i l
87.1 86.9 87.2 86.4 88.0 87.9 87.2 0.6 0.7 Pass Pass
92.2 87.5 87.3 91.2 88.4 92.3 89.8 2.3 2.6 Pass Pass
51.5 60.6 59.9 50.7 51.3 60.4 55.7 5.0 9.0 Fai l Fa i l Fa i l Fa i l
49.4 43.5 50.8 49.9 44.1 50.9 48.1 3.4 7.1 Fai l Fa i l Fa i l Fa i l
93.5 91.0 92.9 89.3 92.8 94.3 92.3 1.8 2.0 Pass pass
89.9 93.5 95.8 99.9 95.9 98.2 95.5 3.5 3.7 Pass Pass
93.9 97.7 99.8 93.3 93.4 91.2 94.9 3.2 3.4 Pass Pass
94.6 95.2 78.9 96.5 80.6 82.9 88.1 8.1 9.2 Pass Pass
66.4 85.3 84.9 65.6 83.7 66.3 75.4 10.2 13.5 Fai l Fa i l Pass Fa i l
39.7 38.5 42.8 39.8 38.9 42.6 40.4 1.9 4.6 Fai l Fa i l Fa i l Fa i l



































10.2 8.7 3.0 8.9 8.7 10.5 10.3 4.4 42.4 Pass
7.8 8.3 6.8 7.7 6.8 9.5 9.4 1.8 19.4 Pass
33.7 31.6 34.5 34.8 35.5 39.3 24.0 11.5 47.9 Fai l Fa i l
25.0 25.8 22.1 26.5 27.9 32.4 25.5 2.8 11.1 Fai l Fa i l
7.0 6.5 8.8 4.3 6.9 8.4 9.8 3.6 36.4 Pass
3.8 6.8 3.9 5.1 3.6 4.6 9.2 5.3 58.0 Pass
8.8 10.7 9.1 10.0 8.2 12.8 7.3 4.0 55.2 Pass
12.0 16.3 11.1 12.1 14.2 11.2 14.4 4.1 28.8 Fai l Fa i l
4.4 3.9 4.0 5.7 18.3 6.8 10.4 5.4 52.6 Pass
1.3 5.6 6.8 4.1 4.5 3.8 8.4 4.8 57.0 Pass
3.7 4.3 6.6 3.8 3.3 5.1 10.5 7.5 71.0 Fai l Pass
15.6 11.1 11.7 13.1 11.7 12.7 14.4 5.1 35.2 Fai l Fa i l
11.6 3.0 13.5 12.7 11.0 12.3 12.6 4.2 33.0 Fai l Fa i l
8.0 7.5 6.8 6.7 6.4 7.8 4.4 3.0 67.2 Pass
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63.5 71.2 102.5 64.7 76.4 46.9 70.4 14.3 20.3 Pass Pass
71.2 64.9 74.5 64.9 73.3 61.8 60.5 9.4 15.5 Fai l Fa i l Pass Pass
37.1 49.6 41.5 37.8 49.6 40.3 63.2 21.9 34.6 Fai l Fa i l Pass Fa i l
35.2 34.1 32.5 34.1 35.7 37.1 46.3 12.6 27.2 Fai l Fa i l Fa i l Fa i l
63.3 52.7 60.6 51.7 42.5 50.0 63.0 11.4 18.2 Fai l Fa i l Pass Pass
65.6 54.7 62.1 63.1 63.3 64.9 61.3 8.8 14.3 Fai l Fa i l Pass Pass
74.9 64.9 61.2 65.5 62.3 75.3 69.6 5.9 8.5 Pass Pass
34.0 27.7 31.1 32.4 28.6 26.2 46.6 20.7 44.3 Fai l Fa i l Fa i l Fa i l
58.8 81.4 72.6 67.6 73.9 64.5 64.9 10.2 15.7 Pass Pass
80.5 74.6 75.1 60.4 64.0 67.9 69.4 7.5 10.8 Pass Pass
67.2 52.1 62.3 79.2 65.7 76.5 68.8 8.2 12.0 Pass Fai l Pass
38.4 71.2 56.3 41.9 38.2 69.0 62.9 15.2 24.1 Fai l Fa i l Pass Pass
60.6 41.1 48.6 52.5 64.5 50.4 61.9 11.1 18.0 Fai l Fa i l Pass Pass
69.8 61.6 66.0 53.7 60.9 68.5 65.1 8.3 12.7 Pass Pass
39.2 67.8 56.7 43.5 41.6 69.6 61.6 12.9 20.9 Fai l Fa i l Pass Pass
53.0 69.8 66.7 60.4 61.1 66.8 66.5 5.9 8.9 Pass Pass
61.7 78.7 77.4 71.1 81.4 81.0 74.8 6.9 9.2 Pass Pass
24.3 18.1 29.6 19.4 22.9 18.6 47.7 30.0 62.9 Fai l Fa i l Fa i l Fa i l
61.8 90.6 60.5 64.9 57.5 53.4 60.2 10.7 17.7 Fai l Fa i l Pass Fa i l
65.6 72.1 81.4 78.6 78.2 80.4 75.7 8.0 10.5 Pass Pass
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98.4 103.4 96.8 103.9 100.1 99.0 94.2 99.7 98.1 95.7 98.9 3.1 3.1 7.4 Pass 98.9 Pass
90.5 91.9 91.6 95.1 95.2 96.6 91.0 90.8 91.1 96.5 93.0 2.5 2.7 11.5 Pass 93.0 Fai l Pass
88.2 87.8 86.7 97.1 83.7 84.2 88.3 93.3 85.2 105.7 90.0 6.9 7.6 25.0 Fai l Fa i l  90.0 Fai l Pass
99.9 103.1 98.4 102.9 105.9 94.3 102.8 101.5 98.1 103.8 101.1 3.4 3.4 8.2 Pass 101.1 Pass
97.5 95.4 81.2 90.8 100.2 98.4 100.1 94.5 93.9 101.2 95.3 6.0 6.2 17.5 Fai l Pass 95.3 Pass
99.1 108.0 100.1 99.8 99.6 106.5 103.0 100.4 104.1 107.9 102.9 3.6 3.5 7.2 Pass 102.9 Pass
102.7 102.6 105.7 101.5 96.8 106.0 106.1 105.5 101.0 106.7 103.5 3.1 3.0 5.6 Pass 103.5 Pass
95.9 94.0 97.5 91.8 91.4 90.8 99.0 100.9 96.1 104.8 96.2 4.5 4.7 13.0 Pass 96.2 Pass
97.1 94.1 95.2 100.0 99.5 100.9 92.6 105.0 97.8 102.7 98.5 3.9 4.0 9.4 Pass 98.5 Pass
107.7 105.9 104.9 101.8 99.9 104.6 103.2 104.3 107.8 105.1 104.5 2.4 2.3 2.8 Pass 104.5 Pass
101.6 106.5 107.0 106.7 106.5 105.2 106.5 104.5 109.7 109.8 106.4 2.4 2.2 0.8 Pass 106.4 Fai l Pass
101.4 106.5 106.8 106.7 106.5 105.1 107.9 107.4 109.2 109.7 106.7 2.3 2.2 0.3 Pass 106.7 Fai l Pass
99.5 107.6 104.4 106.9 104.4 109.8 107.9 109.4 108.3 105.4 106.4 3.1 2.9 2.5 Pass 106.4 Fai l Pass
99.6 108.0 99.8 98.9 106.3 105.3 104.0 99.5 100.2 102.9 102.4 3.3 3.2 7.0 Pass 102.4 Pass
99.8 107.9 104.5 107.2 104.5 109.8 107.8 109.6 108.4 105.8 106.5 3.0 2.8 2.2 Pass 106.5 Fai l Pass
91.1 91.6 92.7 97.9 99.0 97.1 94.9 96.7 93.7 93.8 94.9 2.7 2.9 10.2 Pass 94.9 Pass
89.8 92.1 89.0 88.8 90.8 93.0 92.2 93.5 90.0 84.7 90.4 2.6 2.9 14.3 Pass 90.4 Fai l Pass
89.8 92.1 89.1 88.9 91.0 93.0 92.3 93.5 89.9 84.8 90.4 2.6 2.9 14.2 Pass 90.4 Fai l Pass
87.9 89.2 89.3 87.9 90.6 87.9 88.6 85.5 91.0 93.8 89.2 2.2 2.5 5.4 Pass 89.2 Fai l Pass
92.1 96.0 90.3 91.2 92.0 95.0 94.2 93.6 95.9 96.5 93.7 2.2 2.3 10.1 Pass 93.7 Fai l Pass
96.4 94.7 95.8 91.6 97.6 92.5 97.6 96.6 98.5 98.0 95.9 2.3 2.4 8.2 Pass 95.9 Pass
102.0 95.8 110.0 107.2 107.8 108.5 106.7 98.2 105.6 105.3 104.7 4.6 4.4 7.9 Pass 104.7 Pass
90.7 95.5 93.6 91.0 99.3 90.8 96.0 91.3 98.0 91.7 93.8 3.2 3.4 12.4 Pass 93.8 Fai l Pass
96.2 97.8 99.7 95.8 98.9 94.6 93.0 93.6 98.6 90.6 95.9 2.9 3.1 9.7 Pass 95.9 Pass
93.5 94.2 102.0 93.3 96.1 93.1 98.5 100.9 92.9 93.8 95.8 3.4 3.6 10.9 Pass 95.8 Pass
98.9 93.0 95.9 96.4 100.3 99.5 92.0 96.3 100.5 103.6 97.6 3.6 3.7 9.5 Pass 97.6 Pass
96.3 101.6 92.5 98.5 99.4 96.6 97.9 96.6 100.0 98.2 97.8 2.5 2.5 6.7 Pass 97.8 Pass
101.2 94.0 105.6 98.6 101.9 98.5 95.0 95.6 102.6 102.7 99.6 3.8 3.9 8.2 Pass 99.6 Pass
90.0 90.9 92.3 92.2 95.9 95.4 92.5 94.4 93.4 92.2 92.9 1.9 2.0 10.1 Pass 92.9 Fai l Pass
93.2 98.1 96.6 99.7 95.5 94.3 97.0 97.2 96.9 101.7 97.0 2.5 2.5 7.4 Pass 97.0 Pass
90.1 95.5 92.5 95.0 96.7 103.7 98.3 90.8 95.4 97.0 95.5 3.9 4.1 12.4 Pass 95.5 Pass
92.1 102.4 99.3 96.7 92.8 98.1 95.1 100.4 98.0 98.5 97.3 3.3 3.4 9.0 Pass 97.3 Pass
92.3 94.7 98.9 100.1 99.6 95.7 93.9 95.3 92.7 97.2 96.0 2.8 2.9 9.1 Pass 96.0 Pass
95.2 90.3 96.8 103.7 95.0 92.6 98.2 90.7 95.9 97.1 95.5 3.9 4.1 12.4 Pass 95.5 Pass
92.5 92.6 96.1 92.2 92.3 90.0 91.1 93.6 94.5 95.4 93.0 1.9 2.0 10.0 Pass 93.0 Fai l Pass
94.8 92.6 97.8 98.2 97.0 92.0 98.3 96.7 99.3 96.0 96.3 2.5 2.6 8.2 Pass 96.3 Pass
97.1 93.7 96.7 97.7 94.0 93.4 94.0 96.9 91.6 93.9 94.9 2.0 2.1 8.5 Pass 94.9 Pass
56.5 47.1 95.7 99.2 77.9 47.6 83.0 72.5 85.2 99.6 76.4 20.1 26.4 70.4 Fai l Fa i l  76.4 Fai l Pass
89.0 91.5 96.7 95.8 98.8 100.1 88.1 90.3 93.3 92.7 93.6 4.1 4.4 14.7 Pass 93.6 Fai l Pass
92.4 93.0 94.0 99.5 100.6 98.6 96.3 98.2 94.8 95.2 96.3 2.8 3.0 9.1 Pass 96.3 Pass
75.6 84.7 81.9 86.5 101.0 80.1 99.1 100.1 95.9 91.3 89.6 9.1 10.2 30.8 Fai l Fa i l  89.6 Fai l Pass
93.0 78.3 77.4 76.2 89.1 94.1 91.4 97.8 82.9 87.6 86.8 7.7 8.8 30.1 Fai l Fa i l  86.8 Fai l Pass
109.2 107.2 107.9 106.3 102.1 105.1 104.5 105.3 106.4 100.3 105.4 2.7 2.5 2.4 Pass 105.4 Pass
86.1 91.8 87.7 83.8 90.4 86.5 88.2 89.4 84.2 90.7 87.9 2.7 3.1 17.2 Fai l Pass 87.9 Fai l Pass
101.2 101.4 98.2 99.3 96.9 96.9 98.6 96.0 99.1 101.5 98.9 2.0 2.0 4.7 Pass 98.9 Pass
90.9 81.7 99.9 92.7 93.5 85.0 85.6 87.3 85.5 86.5 88.8 5.4 6.0 22.5 Fai l Fa i l  88.8 Fai l Pass
99.8 94.0 62.2 62.5 76.6 45.5 73.8 90.3 76.0 78.7 75.9 16.4 21.5 61.8 Fai l Fa i l  75.9 Fai l Fa i l
100.0 93.9 99.7 95.4 96.7 97.9 98.4 98.9 104.0 103.3 98.8 3.2 3.2 7.6 Pass 98.8 Pass
93.3 94.5 96.5 91.2 96.4 95.7 93.8 92.6 98.3 98.7 95.1 2.4 2.6 9.3 Pass 95.1 Pass
98.3 90.0 97.8 90.3 99.0 101.3 101.6 104.2 103.4 103.3 98.9 5.1 5.2 12.2 Pass 98.9 Pass
94.1 103.4 99.3 101.9 96.4 104.2 97.3 103.5 98.6 104.0 100.3 3.6 3.6 8.7 Pass 100.3 Pass
80.6 69.2 77.8 80.0 89.5 78.4 85.0 85.6 82.6 83.4 81.2 5.5 6.8 30.5 Fai l Fa i l  81.2 Fai l Pass
98.6 113.1 90.3 98.3 116.2 96.6 100.7 108.9 113.3 113.5 104.9 9.1 8.6 18.3 Fai l Fa i l  104.9 Pass
88.1 99.5 100.1 94.7 95.0 89.9 98.0 87.3 90.8 91.6 93.5 4.7 5.0 16.2 Fai l Pass 93.5 Fai l Pass
164 
 
























7.4 Pass 98.9 Pass Pass Pass
11.5 Pass 93.0 Fai l Pass Fa i l Pass Fail Fail
19.9 Fai l Fa i l 90.0 Fai l Pass Pass Fail Fail
8.2 Pass 101.1 Pass Pass Pass
17.5 Pass 95.3 Pass Pass Pass
7.2 Pass 102.9 Pass Pass Pass
5.6 Pass 103.5 Pass Pass Pass
13.0 Pass 96.2 Pass Pass Pass
9.4 Pass 98.5 Pass Pass Pass
2.8 Pass 104.5 Pass Pass Pass
0.8 Pass 106.4 Fai l Pass Pass Fail Pass
0.3 Pass 106.7 Fai l Pass Pass Fail Pass
2.5 Pass 106.4 Fai l Pass Pass Fail Pass
7.0 Pass 102.4 Pass Pass Pass
2.2 Pass 106.5 Fai l Pass Pass Fail Pass
10.2 Pass 94.9 Pass Fai l Fa i l Fail Fai l
14.3 Pass 90.4 Fai l Pass Fa i l Fa i l Fail Fai l
14.2 Pass 90.4 Fai l Pass Fa i l Fa i l Fail Fai l
5.4 Pass 89.2 Fai l Pass Fa i l Fa i l Fail Fai l
10.1 Pass 93.7 Fai l Pass Fa i l Fa i l Fail Fai l
8.2 Pass 95.9 Pass Fai l Fa i l Fail Fai l
7.9 Pass 104.7 Pass Pass Pass
12.4 Pass 93.8 Fai l Pass Pass Fail Pass
9.7 Pass 95.9 Pass Pass Pass
10.9 Pass 95.8 Pass Fai l Fa i l Fail Fai l
9.5 Pass 97.6 Pass Fai l Fa i l Fail Fai l
6.7 Pass 97.8 Pass Fai l Fa i l Fail Fai l
8.2 Pass 99.6 Pass Pass Pass
10.1 Pass 92.9 Fai l Pass Pass Fail Pass
7.4 Pass 97.0 Pass Pass Pass
12.4 Pass 95.5 Pass Pass Pass
9.0 Pass 97.3 Pass Fai l Pass Fail Pass
9.1 Pass 96.0 Pass Pass Pass
12.4 Pass 95.5 Pass Pass Pass
10.0 Pass 93.0 Fai l Pass Fa i l Pass Fail Pass
8.2 Pass 96.3 Pass Fai l Fa i l Fail Fai l
8.5 Pass 94.9 Pass Pass Pass
70.4 Fai l Fa i l 76.4 Fai l Pass Pass Fail Pass
14.7 Pass 93.6 Fai l Pass Pass Fail Pass
9.1 Pass 96.3 Pass Pass Pass
20.8 Fai l Fa i l 89.6 Fai l Pass Pass Fail Fai l
21.6 Fai l Fa i l 86.8 Fai l Pass Pass Fail Fai l
2.4 Pass 105.4 Pass Fai l Fa i l Fail Fai l
13.8 Pass 87.9 Fai l Pass Pass Fail Pass
4.7 Pass 98.9 Pass Pass Pass
16.7 Fai l Pass 88.8 Fai l Pass Fa i l Fa i l Fail Fai l
61.8 Fai l Fa i l 75.9 Fai l Fa i l Fa i l Fa i l Fail Fai l
7.6 Pass 98.8 Pass Pass Pass
9.3 Pass 95.1 Pass Pass Pass
12.2 Pass 98.9 Pass Pass Pass
8.7 Pass 100.3 Pass Pass Pass
30.5 Fai l Fa i l 81.2 Fai l Pass Pass Fail Fai l
10.4 Pass 104.9 Pass Fai l Fa i l Fail Fai l
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A-010 A010/MM14/YG/01/HG/CTRXBECEF Nectar Li fesciences  Ltd.India 124.43 122.277 117.405 111.121 122.58 119.109 115.877 111.927 119.555 112.343 117.7 4.7631335 4.0481356 Fai l Pass
A-028 A028/MM14/YG/04/C/CTRXTEFAXONE Sta l l ion LABORATORIES PVT.LTD.India 102.6 102.6 103.4 105.3 104.2 104.1 101.2 103.0 103.5 103.0 103.3 1.1204033 1.0847109 Pass
A-047 A047/MM14/YG/05/C/CTRXTRA ONE Korea Pharma Co .Ltd.K rea 107.8 108.2 109.4 107.9 105.1 108.6 106.3 108.6 109.0 108.6 108.0 1.301357 1.2052883 Pass
A-062 A062/MM14/YG/01/Ocl/CTRXLYFAXONE LYKA LABS LIMITEDIndia 111.0 110.2 112.2 113.9 115.4 111.1 115.0 110.3 111.4 110.3 112.1 1.9964575 1.7812202 Pass
A-087 A087/MM14/YG/01/W/CTRXCeftron SQUARE PHARMACEUTICALS LTD.Bangladesh 106.5 104.4 106.2 108.2 105.9 109.3 107.5 109.5 105.8 109.5 107.3 1.7882748 1.6670657 Pass
A-093 A093/MM14/YG/03/W/CTRXDALITRIXON SHENZHEN ZHIJUN PHARMACEUTICAL CO .,LTD.China 107.8 108 6 108.8 108.2 110.6 110.6 110.3 105.4 109.5 105.4 108.5 1.9207722 1.7702399 Pass
A-094 A094/MM14/YG/03/W/CTRXTRAXEF CCL Pharmaceutica ls (Pvt) Ltd.Pakis tan 108.8 108.3 108.7 108.9 108.3 107.7 107.8 108.8 110.9 108.8 108.7 0.8792508 0.8088747 Pass
B-014 B-014/MM14/YG/04/C/CTRXC- ri Emcure PHARMACEUTICAL LTD.India 108.6 109.9 108.3 109.1 107.7 107.4 109.1 107.7 108.6 107.7 108.4 0.8211277 0.7574986 Pass
B-020 B-020/MM14/YG/05/C/CTRXU IXONE UMEDICA LABORATORIES PVT LTD.India 106 5 105.2 106.2 103.7 104.6 106.2 109.2 109.8 107.0 109.8 106.8 2.1423105 2.0056308 Pass
B-041 B-041/MM14/YG/01/HG/CTRXPOWERCEF WOCKHARDT LIMITEDIndia 105.7 106.0 109.9 106.6 103.9 105.9 103.7 107.6 105.2 107.6 106.2 1.8691588 1.7599819 Pass
B-082 B-082/MM14/YG/01/O(c)/CTRXZEFONE Cadi la  Health LimitedInd a 109.2 108.5 109.4 108.2 109.1 105.6 106.0 107.7 108.5 107.7 108.0 1.2988663 1.2027108 Pass
PA-007 PA007/MM14/YG/01/C/CTRXOframax RANBAXY LABORATORIES LIMITEDIndia 108.7 109.0 108.3 108.2 108.5 108.9 107.7 108.0 110.3 108.0 108.5 0.7328835 0.675193 Pass
A-031 A031/MM14/YG/01/Ocl/CTRXPARCEF Jayson Pharmaceutica ls  Ltd.Bangl desh 89.34 139.89 135..054 124.33 117.37 121.08 107.18 122.08 124.42 121.78 118.6 13.860013 11.685618 Fai l Pass
A-098 A098/MM14/YG/01/HG/CTRXCEFTRIAXONE MJM.J.BIOPHARM PRIVATE LIMITEDIndia 106.39 113.20 109.84 114.41 112.13 111.64 110.36 108.79 109.40 110.76 110.7 2.3030828 2.0806339 Pass
B-021 B-021/MM14/YG/05/C/CTRXCEFDEC BELCO PHARMAIndia 106.65 110.03 111.10 106.70 107.92 108.31 105.68 107.16 105.24 107.51 107.6 1.8231694 1.6939404 Pass
B-025 B-025/MM14/YG/06/C/CTRXCeftriaxone InjectionMyanma Pharmaceutica l  Factory,Myanmar 106.55 105.70 109.19 105.16 104.43 109.46 113.24 113.02 103.04 102.31 107.2 3.875495 3.6148768 Pass
B-033 B-033/MM14/YG/01/HP/CTRXRocephin F.Hoffmann-LaRoche Ltd.Switzland 111.40 109.24 112.44 111.26 110.71 114.94 111.58 115.00 109.41 109.91 111.6 2.0431297 1.8309534 Pass
A-055 A055/MM14/YG/01/HP/CTRXOframax RANBAXY LABORATORIES LIMITEDIndia 114.68 103.49 104.38 103.70 104.15 104.08 103.53 105.26 107.14 105.26 105.6 3.3886221 3.2099285 Pass
B-097 B-097/MM14/YG/02/C/CTRXBECEF Nectar Li fesciences  Ltd.India 113.50 113.38 113.42 114.97 115.92 114.78 115.17 113.23 113.86 113.23 114.1 0.9770122 0.8559388 Pass
A-027 A027/MM14/YG/04/C/CTRXBECEF Nectar Li fesciences  Ltd.India 106.35 109.31 104.98 102.93 105.69 108.25 106.14 108.87 104.40 104.51 106.1 2.0958745 1.9746004 Pass
A-029 A029/MM14/YG/04/C/CTRXLYFAXONE LYKA LABS LIMITEDIndia 108.98 103.90 107.80 101.91 102.47 109.30 105.43 107.81 105.95 101.11 105.5 3.0044357 2.8487271 Pass
A-051 A051/MM14/YG/01/HG/CTRXOframax RANBAXY LABORATORIES LIMITEDIndia 111.91 105.87 104.91 104.09 105.81 105.61 103.08 110.40 107.50 108.68 106.8 2.8104251 2.6318637 Pass
A-110 A110/MM14/YG/01/C/CTRXTrixone TOQURE Pharmaceutica ls  Pvt Ltd.India 104 25 97.81 101.04 99.92 106.75 101.00 103.82 101.96 105.13 103.37 102.5 2.6651732 2.6000647 Pass
B-010 B-010/MM14/YG/02/O(c)/CTRXCefaxone LUPIN LTD. India 109.63 104.08 103.56 106.66 109.69 104.92 103.62 104.70 106.78 104.55 105.8 2.3035502 2.1768777 Pass
A-008 A008/MM14/YG/01/HG/CTRXOframax RANBAXY LABORATORIES LIMITEDIndia 110.31 107.77 108.26 107.07 108.79 107.31 108.13 108.93 107.37 110.81 108.5 1.2629433 1.1642606 Pass
A-009 A009/MM14/YG/01/HG/CTRXCEFTRIAXONE MJM.J.BIOPHARM PRIVATE LIMITEDIndia 105.85 107.98 105.72 108.70 102.81 101.20 104.49 106.38 102.49 104.89 105.1 2.3905065 2.2755675 Pass
A-032 A032/MM14/YG/03/C/CTRXUTRIXONE UMEDICA LABORATORIES PVT.LTD.India 108 28 111.14 105.56 108.08 108.21 109.42 105.26 104.61 105.13 103.78 106.9 2.4015438 2.2455772 Pass
A-045 A045/MM14/YG/04/C/CTRXeftriaxone InjectionMyanmar Pharmaceutica l  factoryMyanm r 96.26 96.03 105.16 101.32 101.42 99.78 99.51 105.68 103.21 101.37 101.0 3.2557728 3.2243808 Pass
A-046 A046/MM14/YG/05/C/CTRX-Tri Emcure PHARMACETICALS LTD.India 110.51 111.25 113.27 114.43 110.83 110.24 113.82 112.08 111.77 109.20 111.7 1.6766657 1.5005156 Pass
A-056 A056/MM14/YG/01/HP/CTRXBECEF Nectar Li fesciences  Ltd.India 108.18 112.41 108.56 110.26 109.53 110.00 111.65 110.55 110.44 111.12 110.3 1.2998492 1.178793 Pass
A-073 B-073/MM14/YG/01/HG/CTRXPOWERCEF WOCKHARDT LIMITEDIndia 107.90 109.01 108.50 111.99 111.01 110.76 110.67 107.67 107.91 109.79 109.5 1.5341904 1.4008147 Pass
A-081 A081/MM14/YG/02/HP/CTRXLYFAXONE LYKA LABS LIMITEDIndia 106.00 102.23 104.36 109.30 106.48 110.40 108.38 105.97 104.48 105.96 106.4 2.4501827 2.3037993 Pass
A-082 A082/MM14/YG/02/HP/CTRXOframax RANBAXY LABORATORIES LIMITEDIndia 103.21 107.15 111.10 106.50 108.35 105.71 103.68 112.17 106.11 111.17 107.5 3.1308773 2.9120295 Pass
A-103 A103/MM14/YG/02/HP/CTRXBECEF Nectar Li fesciences  Ltd.India 108.10 105.28 110.35 104.52 110.46 105.80 106.02 106.84 106.12 107.00 107.0 2.0181697 1.8853136 Pass
A-109 A109/MM14/YG/01/C/CTRXBECEF Nectar Li fesciences  Ltd.India 111.31 113.98 112.48 113.15 112.38 109.38 109.94 109.62 108.23 110.86 111.1 1.8530369 1.6674377 Pass
A-013 A013/MM14/YG/01/HG/CTRXLYFAXONE LYKA LABS LIMITEDIndia 94.63 102.90 96.61 98.98 97.82 103.60 92.65 96.80 100.11 95.75 98.0 3.4824192 3.5541425 Pass
B-024 B-024/MM14/YG/06/C/CTRXCeftriaxone InjectionMyanma Pharmaceutica l  Factory,Myanmar 102.71 98.63 104.18 103.42 102.42 103.75 105.73 102.97 102.37 112.55 103.9 3.5430774 3.4109775 Pass
B-032 B-032/MM14/YG/01/HP/CTRXOframax RANBAXY LABARATORIES LIMITEDIndia 110.28 104.87 106.17 106.59 105.97 106.34 108.70 107.96 105.27 107.96 107.0 1.6789096 1.568919 Pass
B-039 B-039/MM14/YG/01/HP/CTRXOframax RANBAXY LABARATORIES LIMITEDIndia 106.22 109.23 110.80 106.04 107.99 105.95 106.38 109.92 104.93 105.62 107.3 2.0330108 1.8945442 Pass
B-055 B-055/MM14/YG/01/HP/CTRXBE EF Nectar Li fesciences  Ltd.India 101.25 101.43 100.30 100.81 105.88 99.54 99.47 102.22 102.02 106.88 102.0 2.507431 2.4587205 Pass
B-056 B-056/MM14/YG/01/HP/CTRXOframax RANBAXY LABARATORIES LIMITEDIndia 110.41 110.13 111.47 105.49 105.83 107.83 105.51 109.49 106.90 108.44 108.1 2.18673 2.0219736 Pass
B-057 B-057/MM14/YG/01/HP/CTRXZEFONE Cadi la  Health LimitedIndia 111.36 106.88 107.80 109.84 104.50 108.12 106.75 106.56 108.64 115.63 108.6 3.106839 2.8605828 Pass
B-061 B-061/MM14/YG/01/O(c)/CTRXLYFAXONE LYKA LABS LIMITEDIndia 106.00 105.14 105.92 107.70 105.27 107.78 107.32 105.02 105.71 106.73 106.3 1.0525429 0.9905438 Pass
B-062 B-062/MM14/YG/01/O(c)/CTRXOframax RANBAXY LABARATORIES LIMITEDIndia 106.32 107.39 108.88 104.83 108.49 108.77 109.36 107.41 103.07 106.87 107.1 1.9777604 1.8459934 Pass
B-073 B-073/MM14/YG/01/HG/CTRXPOWERCEF WOCKHARDT LIMITEDIndia 101.75 100.85 100.83 100.81 99.60 98.52 96.52 101.97 97.38 99.22 99.7 1.8352227 1.839889 Pass
B-083 B-083/MM14/YG/01/O(c)/CTRXBECEF Nectar Li fesciences  Ltd.India 107.99 107.29 104.44 103.85 108.00 105.91 108.69 104.77 105.71 108.60 106.5 1.8121895 1.7011966 Pass
B-087 B-087/MM14/YG/04/W/CTRXTRAXONE Korea Pharma Co .Ltd.K rea 98.19 97.05 98.98 100.26 103.23 99.78 100.37 104.65 102.74 104.84 101.0 2.7091045 2.6820334 Pass
B-103 B-103/MM14/YG/01/HG/CTRXOframax RANBAXY LABARATORIES LIMITEDIndia 107.53 106.38 108.51 109.16 109.26 109.78 111.26 109.71 110.73 6.75 98.9 32.412876 32.770953 Pass
B-112 B-112/MM14/YG/05/C/CTRXOframax RANBAXY LABARATORIES LIMITEDIndia 99.98 99.91 105.18 101.63 95.14 103.85 102.05 98.52 102.12 99.73 100.8 2.8335197 2.8107222 Pass






















27.63 Fai l Fa i l 27.63 Fai l Fa i l 117.66 Fai l Pass Fa i l
4.49 Pass 4.49 Pass 103.29 Pass
9.62 Pass 9.62 Pass 107.97 Pass
15.00 Pass 15.00 Pass 112.08 Pass
10.10 Pass 10.10 Pass 107.27 Pass
11.61 Pass 11.61 Pass 108.50 Pass
9.31 Pass 9.31 Pass 108.70 Pass
8.87 Pass 8.87 Pass 108.40 Pass
10.34 Pass 10.34 Pass 106.81 Pass
10.19 Pass 10.19 Pass 106.20 Pass
9.62 Pass 9.62 Pass 107.99 Pass
8.75 Pass 8.75 Pass 108.54 Pass
50.36 Fai l Fa i l 50.36 Fai l Fa i l 118.61 Fai l Pass Fa i l
14.72 Pass 14.72 Pass 110.69 Pass
10.46 Pass 10.46 Pass 107.63 Pass
15.00 Pass 15.00 Pass 107.21 Pass
15.00 Pass 15.00 Pass 111.59 Pass
12.23 Pass 12.23 Pass 105.57 Pass
14.95 Pass 14.95 Pass 114.15 Pass
9.64 Pass 9.64 Pass 106.14 Pass
11.10 Pass 11.10 Pass 105.47 Pass
12.53 Pass 12.53 Pass 106.78 Pass
7.41 Pass 7.41 Pass 102.50 Pass
9.82 Pass 9.82 Pass 105.82 Pass
10.02 Pass 10.02 Pass 108.48 Pass
9.34 Pass 9.34 Pass 105.05 Pass
11.06 Pass 11.06 Pass 106.95 Pass
6.16 Pass 6.16 Pass 100.97 Pass
14.23 Pass 14.23 Pass 111.74 Pass
11.92 Pass 11.92 Pass 110.27 Pass
11.96 Pass 11.96 Pass 109.52 Pass
10.78 Pass 10.78 Pass 106.35 Pass
12.41 Pass 12.41 Pass 107.52 Pass
10.34 Pass 10.34 Pass 107.05 Pass
14.04 Pass 14.04 Pass 111.13 Pass
8.85 Pass 8.85 Pass 97.98 Pass
10.90 Pass 10.90 Pass 103.87 Pass
9.53 Pass 9.53 Pass 107.01 Pass
10.37 Pass 10.37 Pass 107.31 Pass
6.52 Pass 6.52 Pass 101.98 Pass
11.14 Pass 11.14 Pass 108.15 Pass
14.55 Pass 14.55 Pass 108.61 Pass
7.76 Pass 7.76 Pass 106.26 Pass
10.25 Pass 10.25 Pass 107.14 Pass
5.44 Pass 5.44 Pass 99.75 Pass
9.35 Pass 9.35 Pass 106.52 Pass
6.50 Pass 6.50 Pass 101.01 Pass
77.79 Fai l Fa i l 77.79 Fai l Fa i l 98.91 Pass Fai l
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